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Abstract 
The epidermal growth factor receptor (EGFR) is overexpressed in many cancers including lung, 
breast, head and neck and brain. Furthermore, mutations of this receptor have been shown to play 
crucial roles in response to EGFR-targeted therapies in non small cell lung carcinoma (NSCLC) 
patients. Imaging EGFR or its function using positron emission tomography (PET) could aid in 
selection and monitoring patient’s therapeutic response to small molecule tyrosine kinase inhibitors 
(TKIs) including gefitinib.  
The aims of this project are first to further investigate the use of a series of cyanoquinoline tracers 
for imaging the EGFR and second to assess the role of PET imaging to predict early response to EGFR 
directed therapy such as gefitinib.  
First, the uptake of a representative cyanoquinoline radiotracer, [18F](2E)-N-{4-[(3-chloro-4-
fluorophenyl)amino]-3-cyano-7-ethoxyquinolin-6-yl}}4-({[1-(2-fluoroethyl)-1H-1,2,3-triazol-4-
yl]methyl*amino)but-2-enamide ([18F]FED6), was examined in cell lines harbouring mutant forms of 
EGFR. In vitro assays, evaluating the affinity of cyanoquinoline compounds for different mutant EGFR 
and in vivo PET imaging in NSCLC xenograft models expressing mutant or wild type (WT) EGFR were 
carried out. The lack of specificity for mutant vs WT EGFR and overall low tumour uptake led us to 
investigate the potential interaction of the radiotracer with members of the ABC transporters. In 
vitro experiments of radiolabelled [18F] showed substrate specificity of the cyanoquinoline tracer for 
at least two ABC transporters, ABCG2 and ABCB1. This was confirmed by inhibiting the activity of the 
transporters through drug and siRNA treatment. To overcome the transporter substrate specificity of 
FED6, investigations into a novel radiotracer, (2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-3-cyano-7-
ethoxyquinolin-6-yl}-4-[({1-[(2R,5S)-3-fluoro-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]-1H-1,2,3-
triazol-4-yl}methyl)amino]but-2-enamide (FED20), designed so as to limit the affinity for the ABC 
transporters were carried out. These studies showed that FED20 lacked the substrate specificity for 
both ABCB1 and ABCG2, and maintained a strong affinity for EGFR. 
Second, the role of choline kinase as a biomarker of response to gefitinib treatment in sensitive vs 
resistant NSCLC cell lines was investigated. In vitro western blots, Q-PCR, cell viability and cell cycle 
analysis assays were undertaken. In vitro cell uptake experiments using tritiated choline were 
compared with uptake of [18F]3’ deoxy-3’ Fluorothymidine (FLT) and [18F]Fluoro-D glucose (FDG). 
Higher levels of choline uptake were found in the sensitive compared to the resistant cell line 
whereas both [18F]FLT and [18F]FDG showed higher accumulation in the resistant versus sensitive cell 
line. These experiments confirmed that differential responses of the sensitive and the resistant cell 
lines to gefitinib treatment were detectable by tracer pulse-chase. In vivo PET imaging of NSCLC 
   
 6 
xenografts using [18F]FLT, [18F]FDG and [18F]D4Choline showed that gefitinib treatment was 
associated with a decrease in the fractional retention of all three tracers in the sensitive but not 
resistant NSCLC xenografts. 
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MAPK: Mitogen activated protein kinase 
MDR: Multi drug resistance 
MEK: MAP/extracellular signalling 
MET: Hepatocyte growth factor receptor 
MRS: Magnetic resonance spectroscopy 
m-TOR: mammalian target of rapamycin 
NSCLC: Non small cell lung carcinoma 
ORR: Objective response rate 
OS: Overall survival 
 PBS: Phosphate buffer saline 
PET: Positron Emission Tomography 
PFS: Progression free survival 
Pgp: Permeability glycoprotein 
PI: Propidium iodide 
PIP2: Phosphatidylinositol 4,5-bisphosphate 
PIP3 :Phosphatidylinositol (3,4,5)-triphosphate 
PI3K: Phosphatidylinositol-3-kinase 
PSA: Polar surface area 
PTEN: Phosphatase and tensin homolog 
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PTK: Protein tyrosine kinase 
RD: Refractory disease 
RECIST: Response evaluation criteria in solid tumours 
SRB: Sulforhodamine B  
SRC: Sarcoma 
STAT: Signal transducer and activator of transcription 
TAC: Time activity curve 
TBST: Tris-buffered saline and tween 20  
TGFα: Transforming growth factor alpha 
TK1: Thymidine kinase 
TKI: Tyrosine kinase inhibitor 
WT: Wild type 
  




























1.1 Epidermal growth factor receptor 
1.1.1. Member of the human epidermal growth factor receptor (HER) family. 
The epidermal growth factor receptor (EGFR) is a 170 kDA transmembrane tyrosine kinase receptor. 
It is a member of the HER family; also referred to as ERbB family of receptors, which includes HER2 
(ERbB2), HER3 (ERbB3) and HER4 (ERbB4) (Yarden and Sliwkowski, 2001). EGFR is formed of several 
domains, which are depicted in Figure 1. The ligand binding occurs between domains I and III. 
Domains II and IV are cysteine rich and domain II plays an important role in the dimerisation of the 
EGFR. Indeed, a loop from domain II interacts with domain II of the dimerising receptor (Ogiso et al., 
2002). 
The kinase domain, which contains the ATP binding pocket, shares a strong sequence similarity with 
other members of the tyrosine kinase receptor family. Finally, the C-terminal domain is rich in 
tyrosine residues which become phosphorylated upon activation of the receptor and direct the 
signal transduction of the EGFR (Jorissen et al., 2003). 
  













Figure 1: EGFR schematic structure. 
Adapted from (Jorissen et al., 2003)AA: Amino acid I: Ligand binding domain 1, II: Cysteine rich domain 1, III: Ligand binding 
domain 2, IV: Cysteine rich domain 2, TM: Transmembrane domain, JM Juxtamembrane domain, c-term: Carboxy terminal 
domain. 
1.1.2. EGFR activation and signal transduction 
Ligands for the epidermal growth factor receptor contain an EGF-like domain along with three 
intramolecular disulphide bonds. These ligands are found as precursor proteins within the cell 
membrane and are converted to their active forms through proteolysis. Ligands include EGF, 
epiregulin, neuregulin, transforming growth factor α (TGFα) and betacellulin (Prenzel et al., 2001). 
Following ligand binding the receptor undergoes a conformational change and homo-or hetero-
dimerises with another receptor from the ERB family of receptors. HER1-HER2 heterodimers are 
favourable and lead to the strongest biological signals. The receptor dimerisation leads to 
autophosphorylation at specific tyrosine residues within the intracellular region of EGFR (Yarden and 
Sliwkowski, 2001). A given adapter protein will bind to a specific phosphorylated tyrosine residue 
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(Y1068) is the docking site for the adaptor protein Grb2 (Sebastian et al., 2006). The docking of Grb2 
forms the beginning of the mitogen-activated protein kinase (MAPK) intracellular signal transduction 
pathway. A series of phosphorylation’s leads to the activation of extracellular signal-regulated kinase 
(ERK) protein, which in turn activates transcription factor ELK and c-fos. These transcription factors 
regulate the expression of genes involved in cell proliferation, including cyclin D cell cycle protein. 
Thus, the activation of the MAPK pathway through EGFR leads to an increase in mitosis (Yarden and 
Sliwkowski, 2001). 
Activated EGFR initiates many signal transduction pathways, (including: Janus kinase (JAK)/ Signal 
transducer and activator of transcription (STAT), Phosphatidylinositide 3-kinases (PI3K)/ protein 
kinase B (AKT)), which are involved in several aspects of cellular function including: proliferation, 
angiogenesis, cell adhesion and migration (Burgess, 2008). More recently it has been shown that 
EGFR dimerisation with HER3 also plays an important role in the regulation of cell proliferation by 
activating MAPK and PI3K/AKT pathways (Choi et al., 2012). 
The complexity of the EGFR signalling network is accentuated further by the tight link and 
modulation of this network by other signalling pathways within the cell, for example, via active G-
protein coupled receptors (Yarden and Sliwkowski, 2001). 
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Figure 2: EGFR phosphorylation and signal transduction. 
Following EGFR activation, several tyrosine residues can become phosphorylated. Secondary messengers including Grb2, 
Src binds to these phosphorylated residues and will initiate the intracellular signal transduction resulting in changes to 
proliferation, apoptosis and cell cycle progression (Sebastian et al., 2006, Felip and Rosell, 2006). 
 
1.2 EGFR and cancer 
The complex network of signal transduction pathways, which are affected by EGFR, explain the 
involvement of this tyrosine kinase receptor in different mechanisms of cancer. Indeed, modification 
to this receptor leads to not only an increase in proliferation but also a decrease in apoptosis and an 
increase in angiogenesis (Hynes and Lane, 2005, Sharma et al., 2007). 
The involvement of EGFR in the development of cancer was first made from the study of viral 
oncogenes. It was found that EGFR is a homolog of the avian erythroblastosis virus (v-erb) oncogene 
(Downward et al., 1984b) and it was later demonstrated that cells in culture in which EGFR was 
overexpressed underwent malignant transformation (Di Fiore et al., 1987). 
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1.2.1 EGFR’s involvement in many types of cancer 
Since the first link between EGFR and cancer development was made, this receptor has been shown 
to be involved in a multitude of cancers. The involvement of EGFR in cancer development and or 
progression can be the result of different factors including; gene amplification leading to 
overexpression of EGFR and increased activation of EGFR caused by activating mutations (Sebastian 
et al., 2006). However, it is the overexpression of EGFR, which has been the most reported. In a 
pathological setting, the number of EGFR molecules expressed per cell can increase to over a million 
from twenty to two hundred thousand in a physiological setting (Rowinsky, 2004). Abnormal 
expression of EGFR has been observed in head and neck, breast, uterus, oesophageal, pancreatic, 
non small cell lung carcinoma (NSCLC), prostate, colon, ovarian, bladder, brain and gastric cancer 
(Salomon et al., 1995). The percentage of tumours that overexpress EGFR differs greatly from cancer 
to cancer. For example, between 90 and 95 % of head and neck tumours overexpress EGFR, whereas 
changes in EGFR expression are only seen in 4 to 33 % of gastric tumours (Sebastian et al., 2006). 
EGFR overexpression has been shown to be linked to tumour initiation in glioma (Mazzoleni et al., 
2010). Nicholson et al carried out a meta-analysis study in which they looked into over 200 studies 
and investigated the correlation between EGFR and cancer prognosis. They found that EGFR 
overexpression leads to increased aggressiveness of disease in head and neck, ovarian, cervical, 
bladder and oesophageal cancer (Nicholson et al., 2001). In contrast to this, they found a modest 
correlation between EGFR overexpression and disease outcome prediction in gastric, breast and 
colorectal cancer. Finally, in NSCLC only 3 out of the 10 studies they reviewed showed a relationship 
between EGFR overexpression and patient outcome prediction (Nicholson et al., 2001). Despite 
these differences of prevalence of EGFR overexpression in different cancers, overall, there was a 
strong correlation between high levels of EGFR expression and metastasis potential and later stage 
disease diagnosis (Sebastian et al., 2006). 
1.2.2 EGFR gene amplification 
Amplification of the gene coding for EGFR is one of the main events that leads to overexpression of 
EGFR. EGFR gene amplification is found in NSCLC, glioma, colorectal and bladder cancer (Rowinsky, 
2004). It is also interesting to note that a correlation between EGFR gene copy number and tumour 
grade has been observed in cancers such as colorectal and bladder, while in other cancers including 
NSCLC no link between EGFR copy number and severity of disease have been found (Rowinsky, 
2004). 
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1.2.3 EGFR Mutations  
In addition to looking at changes in the expression of EGFR, investigation into EGFR mutations in 
human cancers has been carried out. EGFR mutations are highly prevalent in glioblastoma where 
EGFR gene rearrangement, which leads to mutant EGFR, is present in 63 to 75 % of patients. These 
gene rearrangements result in deletions of large sections of the EGFR gene. The most prevalent 
deletion mutation in glioblastoma involves the loss of exons 2 to 7 of the EGFR gene, which encode 
for the extracellular ligand binding domain of the receptor. The EGFRvIII mutant, which results from 
this in frame deletion, is constitutively active and no longer requires ligand binding for its activation 
(Gan et al., 2009). 
Another mutation seen in glioblastoma, involves the deletion of the exons that encode the carboxyl 
terminal domain of EGFR, resulting in the EGFRIV mutant. A recent study has brought clarity to the 
mechanism of tumourgenicity of this mutant including the importance of the intrinsic tyrosine kinase 
activity and a role for the HSP90 chaperone (Pines et al., 2010). 
The other cancer in which EGFR mutations have been extensively investigated is lung cancer, and will 
be reviewed below.  
 Mutations involved in NSCLC 
There are two forms of lung cancer, small cell lung carcinoma (SCLC) and NSCLC. NSCLC represents 
over 85 % of cases of lung cancer. NSCLC is characterised by modifications to a number of genes 
including, p53 mutation, kirsten rat sarcoma viral oncogene (KRAS) mutation, HER2 mutation,  
hepatocyte growth factor receptor (MET) mutation and amplification, anaplastic lymphoma kinase-
echinoderm microtubule- associated protein 4 (ALK-EML4) fusion, as well as EGFR mutation, the 
latter will be discussed in the following paragraph (Herbst et al., 2008). 
The mutational status of EGFR has been extensively studied in NSCLC and this mainly came from a 
surge in translational research in this field from 2004, in a bid to increase the efficacy of TKI therapy 
by selecting a responding group of patients. A number of different mutations in the EGFR gene have 
been recorded from studies involving NSCLC patients. The majority of these mutations affect regions 
of the gene, which encode for the tyrosine kinase domain (exons 18 to 21) (Gazdar, 2009). These 
mutations can be divided into different classes: single nucleotide substitutions, in frame deletions 
and insertions, as depicted in Figure 3. 
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Figure 3: Summary of mutations of EGFR in NSCLC. 
Mutations to the tyrosine kinase coding domain of EGFR can be classed as activating (indicated in green) or resistant 
(indicated in red) mutations. Adapted from (Mishani et al., 2008) 
The frequency of mutations in the EGFR recorded in NSCLC patients has been found to range 
between 10 to 33 % (Pao and Miller, 2005, Dahabreh et al., 2010, Riely et al., 2006). In certain 
subtypes of NSCLC this value can be much higher with EGFR mutations identified in up to 44 % of 
adenocarcinoma patients, and the highest frequency of these somatic mutations are recorded in 
female patients that have no previous history of smoking and patients of Asian origin (Kosaka et al., 
2004, Pao and Miller, 2005, Tanaka et al., 2010). The most frequent mutation, recorded in over 44 % 
of cases of EGFR mutations, involves an in frame deletion in exon 19, these deletions can vary in 
location and length but in the majority of cases result in the deletion of the tripeptide leucine 747, 
arginine 748 and glutamic acid 749 (Gazdar, 2009). The second most frequent mutation, occurring in 
over 40 % of cases, is the single nucleotide substitution which results in the leucine at position 858 
being replaced by an arginine amino acid (L858R) (Sharma et al., 2007). 
The mutations mentioned above, which occur within the tyrosine kinase domain of EGFR are classed 
as activating mutations. They have been shown to lead to an increased kinase activity of the 
receptor. EGFR molecules that contain an activating mutation, notably the leucine 858 to arginine 
mutation, showed a reduced affinity for ATP as measured by a higher Km value for ATP (Carey et al., 
2006, Yun et al., 2007). 
The characteristics of mutant EGFR molecules have further been investigated using X ray 
crystallography data of both WT and mutant EGFR. The increase in activity of mutant EGFR is 
thought to originate from changes to the homeostasis between the inactive and active form of the 
receptor. The leucine residue 858 of EGFR lies within the P activation loop, and forms part of a 
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hydrophobic cluster of amino acids, which are involved in stabilising the molecule in an inactive 
conformation, by blocking the interaction with the activating part of the C helix (Yun et al., 2007). 
The X ray crystallography structure of the L858R mutant shows that the arginine residue causes a 
destabilisation of this “auto-inhibited” inactive conformation, leading to a constitutively active EGFR 
(Kumar et al., 2008). 
Alongside the two most frequent mutations mentioned above, there are other rare mutations, 
which occur in under 1 % of NSCLC cases. These include point mutations in exon 20 of the EGFR 
gene. (Gazdar, 2009). The identification of mutant EGFR is very important as the different properties 
of these molecules often translate into differences in targeted drug response.  
1.3 EGFR targeted cancer therapies 
The involvement of EGFR in a broad range of cancers along with the central role it plays in many 
pathways of cell activity (Figure 2), including promoting proliferation, and inhibiting apoptosis, 
makes it an important target for cancer therapy. Two different approaches have been taken. The 
first involves inhibiting the binding of ligands to EGFR at the extracellular level, while the second 
approach consists of targeting the intracellular tyrosine kinase domain of EGFR.  
1.3.1 Antibody based compounds 
The first method for targeting EGFR involves the inhibition of ligand binding to EGFR by targeting the 
receptor with monoclonal antibodies (mAb). Cetuximab (Merck), a chimeric mouse-human 
monoclonal antibody was approved in 2004 by the food and drug administration (FDA) for use in 
treatment of colorectal cancer and in 2006 received approval for head and neck cancer (Mendelsohn 
and Baselga, 2006). Another mAb targeting EGFR is panitumumab. It was approved by the FDA in 
2006, for metastatic colorectal cancer, following a successful clinical trial that showed progression 
free survival (PFS) of 96 days in patients receiving panitumumab compared to 60 days in patients 
receiving best standard of care. (Van Cutsem et al., 2007). A host of antibody fragments have also 
been developed and tested in animal models but have yet to make it to the clinic (Lammerts van 
Bueren et al., 2008, Friedman et al., 2008). 
1.3.2 Small molecular TKIs: first generation, erlotinib and gefitinib 
The second approach for targeting EGFR involves the use of small molecular TKIs. The first 
generation of these drugs include two molecules that are currently in clinical use in NSCLC, these are 
gefitinib and erlotinib. Both these compounds are defined as reversible TKIs due to the non-covalent 
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nature of their binding to EGFR. They showed good in vitro profiles with high selectivity and affinity 
for EGFR (Barker et al., 2001, Moyer et al., 1997). Phase I clinical trials demonstrated good 
tolerability of both drugs and phase II trials showed activity of the inhibitors as measured by 
objective response or disease control compared to chemotherapy which was given as standard of 
care (Swaisland et al., 2001, Fukuoka et al., 2003). This lead to further investigation in phase III trials. 
However, several Phase III trials did not meet their outcomes with any improvement in overall 
survival compared to standard of care (Giaccone et al., 2004, Thatcher et al., 2005). This low level of 
response, to TKI treatment, in the majority of patients was contrasted by a strong and rapid 
response of a subgroup of patients (Lynch et al., 2004). Through translational work and retrospective 
studies, profiling the EGFR status of responders versus non-responders, it was established that 
patients who had active mutant forms of EGFR showed significantly higher response rates to 
gefitinib or erlotinib (Paez et al., 2004). In later clinical trials, in which patient selection was 
undertaken, response rates were greatly increased (Kris et al., 2003). The break through trial in 
regards to EGFR mutational status and response to gefitinib was the iressa pan-Asia-study (IPASS), 
which compared gefitinib to carboplatin + paclitaxel in a first line treatment setting in NSCLC Asian 
patients (Mok et al., 2009). The primary end point of this trial was progression free survival. The 
authors showed that patients with EGFR activation mutations had a significantly higher PFS in the 
gefitinib arm compared to carboplatin + paclitaxel, while patients who were EGFR mutant negative 
showed lower PFS compared to carboplatin + paclitaxel. Furthermore, patients harbouring EGFR 
activation mutations had an objective response of 71.2 % in the gefitinib arm compared to 47.3 % in 
the carboplatin-paclitaxel arm. This was one of the first indications for the superiority of gefitinib 
treatment vs classical chemotherapeutics in adenocarcinoma patients, who possess mutant EGFR 
(Mok et al., 2009).  
Since then, several randomised phase III trials have been carried out, comparing EGFR-TKI and 
chemotherapy in NSCLC patients that express active mutant EGFR. The results of these trials are 
summarised in Table 1. A common feature of all these trials was a higher objective response rate 
and higher PFS in the gefitinib treated arms compared to the chemotherapy arms. In addition, the 
overall survival was not improved in the TKI treated groups (Mok et al., 2009, Mitsudomi et al., 2010, 
A. Inoue, 2012, Rosell et al., 2012, Han et al., 2012). One explanation for this is the confounding 
effect of subsequent therapies once the studies had finished. Indeed, a large proportion of patients 
in the chemotherapy arm subsequently went on to receive TKI treatment. This proportion ranged 
from 59.3 % in the WJTOG3405 trial (Tetsuya Mitsudomi, 2012), to 96 % in the NEJ002 trial (A. Inoue, 
2012). 
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Both gefitinib and erlotinib are currently approved for treatment of advanced NSCLC. In the UK, the 
national institute for health and care excellence (NICE) approved gefitinib for first line treatment in 
advanced or metastatic NSCLC in patients harbouring activation mutation in EGFR since July 2010. In 
addition to this, the FDA approved erlotinib in May 2013 for first line treatment of NSCLC harbouring 
activation mutant EGFR. Activation mutations have been shown to have both strong sensitivity and 
specificity as predictive biomarkers of response to TKI treatment. It has also been shown that EGFR 
mutations are a better predictor of TKI response compared to EGFR expression levels as assessed by 
methods such as immunohistochemsitry and fluorescence in situ hybridization (Sholl et al., 2010). 
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Table 1: Summary of the outcome of first line TKI vs chemotherapy phase III clinical trials in patients expressing active mutant EGFR advanced NSCLC  
clinical trial Author TKI and chemotherapy Patient population ORR(%) PFS(months) OS(months) 
IPASS (Mok et al., 2009) Gefitinib Asian patients with 
adenocarcinoma (Pan Asia) 
71.2 9.6 21.6 
Carboplatin+ paclitaxel 47.3 6.3 21.9 
WJTOG3405 
 
(Mitsudomi et al., 2010, Tetsuya 
Mitsudomi, 2012) 
Gefitinib  EGFR mutation positive Japanese  62.1 9.6 35.5 
Cisplatin+docetaxel 32.1 6.6 38.8 
 
NEJ002 
(Maemondo et al., 2010, A. Inoue, 
2012) 
Gefitinib EGFR mutation positive japanese 73.7 10.8 27.7 
Carboplatin+Paclitaxel 30.7 5.4 26.6 
OPTIMAL (Zhou et al., 2011a) Erlotinib Chinese patients with EGFR 
activating mutations in Advanced 
NSCLC  
83 13.7 22.69 
Carboplatin+gemcitabine 36 4.6 19.3 
EURTAC (Rosell et al., 2012) Erlotinib European NSCLC patients with 
active mutant EGFR. 
58 9.7 19.3 
Platinum based doublets 15 5.2 19.5 
SIGNAL (Han et al., 2012) Gefitinib Korean never smokers with NSCL 
adenocarcinoma 
84.6 8 27.2 
Cisplatin + gemcitabine 37.5 6.3 25.6 
ORR: Objective response rate OS: overall survival PFS: progression free survival. Adapted from (Rossi et al., 2013) 
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1.3.3 Resistance to TKI treatment 
There are two forms of resistance: Intrinsic resistance also called primary resistance, where 
resistance to the TKI is present in the patient before the start of TKI therapy, and acquired 
resistance, which arises following treatment. 
1.3.3.1 Intrinsic resistance 
In NSCLC exon 20 insertion EGFR mutants confer intrinsic resistance to TKI therapy. Patients 
harbouring EGFR with D770 (NPG) N771 insertion mutation do not respond to gefitinib treatment 
(Gazdar, 2009). Other forms of intrinsic resistance result from mutations to genes encoding other 
proteins within the major signalling pathways occurring in up to 50 % of NSCLC patients. These 
include KRAS, EML-ALK fusion, HER2 and PIK3CA (Pao and Hutchinson, 2012). 
1.3.3.2 Acquired resistance 
 T790M EGFR mutation 
In 50 % of cases of acquired resistance, a single nucleotide substitution in exon 20 is detected which 
leads to the exchange of threonine at position 790 of the EGFR to a methionine amino acid (Gazdar, 
2009). Two hypotheses as to how this mutation causes resistance to gefitinib treatment have been 
proposed. The first results from the location of amino acid 790 at the back of the ATP binding pocket 
of EGFR. This residue is called a “gate keeper residue”. The bulkier nature of methionine compared 
to threonine was hypothesized by several researchers to cause a steric hindrance blocking the access 
of gefitinib or erlotinib to the binding site (Pao and Miller, 2005, Kobayashi et al., 2005). However, X-
ray crystallography structures of T790M mutant EGFR in lattice with erlotinib, have shown binding to 
the ATP pocket of the mutant EGFR despite the bulky methionine, suggesting that steric hindrance 
may not be an explanation for the developed resistance (Yun et al., 2008). 
The second hypothesis attributes changes to the affinity of ATP, for the mutated EGFR, for the lack 
of response to TKI treatment. In vitro work on T790M mutant EGFR has shown that the binding 
affinity of ATP to T790M EGFR is increased compared to that measured in active mutant EGFR. TKIs 
no longer have higher binding affinity compared with ATP to bind in the pocket and inhibit the 
tyrosine kinase activity (Yun et al., 2008). 
Understanding how and when this mutation occurs is important for early detection and patient 
selection. Inukai et al reported that the T790M mutation was found in a subpopulation of tumour 
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cells during the development of NSCLC prior to any treatment and that these clones would then be 
selected during gefitinib treatment (Inukai et al., 2006). A study in which resistance to second 
generation TKI drugs was developed in mutant T790M EGFR gefitinib resistant cells showed that this 
double resistance (to gefitinib and 2nd generation TKI) was the result of the amplification of the 
T790M EGFR encoding allele (Ercan et al., 2010). These results are in line with both in vitro and in 
vivo work which has demonstrated that T790M provides cells with a growth advantage (Yoshida et 
al., 2010). This is an important finding and highlights the need of efficient ways of detecting the 
presence of this mutation as early as possible. 
 Other mechanisms of resistance 
Other mechanisms of resistance include less frequent mutations to EGFR including D716Y (Balak et 
al., 2006) and T854A (Bean et al., 2008).  
MET gene amplification is also responsible for resistance to TKI therapy. The role of MET gene in TKI 
resistance first became apparent following in vitro work in which the analysis of resistant cell lines, 
developed following months of exposure to gefitinib, was carried out. The cell lines expressed 5 to 
10 times higher levels of MET oncogene and regained sensitivity to gefitinib after MET inhibition 
(Engelman et al., 2007). This led to the investigation of MET amplification in patient samples where it 
was found to represent an average of 5 to 10 % of cases of TKI resistance (Bean et al., 2008, 
Engelman et al., 2007, Kubo et al., 2009, Sequist et al., 2011). 
Patients who possess activating mutations in their KRAS gene show less response to gefitinib and 
erlotinib treatment compared to patients who express non mutated KRAS (Pao et al., 2005). 15 to 25 
% of adenocarcinoma patients have activating KRAS mutations that lead to TKI resistance (Massarelli 
et al., 2007). 
It has also been suggested that mutations that result in loss of function of phosphatase and tensin 
homolog (PTEN) function could be a cause of resistance to gefitinib. This enzyme dephosphorylates 
Phosphatidylinositol (3,4,5)-triphosphate (PIP3) giving rise to Phosphatidylinositol 4,5-bisphosphate 
(PIP2). If this function is lost the excess of PIP3 will result in activation of AKT/ mammalian target of 
rapamycin (mTOR) pathway and this despite inhibition of the tyrosine kinase activity of EGFR by a 
TKI (Wheeler et al., 2010). 
Owing to the onset of resistance in the majority of patients who undergo treatment with reversible 
TKI agents, a new approach to the inhibition of EGFR is needed. One of the possible ways of 
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overcoming the acquired resistance discussed above is thought to be achieved by treating patients 
with second generation also called irreversible TKIs.  
1.3.4 Overcoming resistance 
1.3.4.1 Second generation of TKI 
This second generation of TKIs are characterised by the irreversible nature of their binding to the 
kinase domain of EGFR. This irreversible binding occurs via a Michael acceptor, an α,β-unsaturated 
carbonyl moiety, that covalently binds to cysteine 773 of EGFR (Figure 4). 
 
Figure 4: Covalent bond formation via Michael acceptor 
Second generation TKI containing a Michael acceptor will form a covalent bond to cysteine 773 in the kinase domain of 
EGFR as described in this schematic. 
The irreversible binding of these compounds leads to a sustained inhibition of EGFR activity in 
comparison to the reversible inhibitors. Many of the second generation drugs being developed 
inhibit other dimerisation partners of EGFR such as HER2 leading to a better blockade of EGFR 
signalling. These molecules have also been reported to overcome the resistance developed following 
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treatment with reversible TKI’s such as erlotinib. Indeed, cell lines expressing resistant mutant EGFR 
show response to irreversible tyrosine kinase inhibitors (Li et al., 2008). Together it is thought that 
these drugs will delay or suppress the resistance seen in the clinic with gefitinib and erlotinib. 
Several of these second generation compounds are currently in clinical trials including EKB-569 and 
afatinib (BIBW-2992), which are reviewed below. 
 EKB-569 
EKB-569, pelitinib (Figure 5), was derived from a 6, 7-disubstituted-4-anilinoquinoline-3-carbonitrile 
core structure by scientists at Wyeth research. It is one of the first irreversible inhibitors of EGFR to 
be developed and demonstrated increased affinity in vitro compared to the 1st generation of TKIs 
(Wissner et al., 2003). Activity of the compound measured by tumour regression was seen in a Phase 
I trial in which EKB-569 was administered to NSCLC patients who had developed resistance to 
gefitinib treatment (Yoshimura et al., 2006). However, no further trials have been planned for EKB-
569 as a single agent. Instead, it has been investigated in combination with several “classical“ 
chemotherapeutic treatments (Folprecht et al., 2008, Laheru et al., 2008), and a Phase I trial 
investigating the combination of m-TOR inhibitor temsirolimus with EKB-569 demonstrated the 
tolerability of this drug combination (Bryce et al., 2012). 
 Afatinib, BIBW2992 
Afatinib (Figure 5) is an irreversible inhibitor with activity against, EGFR, HER2 and HER4. Preclinical 
studies including in vitro kinase activity; cellular receptor phosphorylation and in vivo activity in 
xenograft mouse models, demonstrated the potency of this TKI against both WT and mutant EGFR 
(Li et al., 2008). Furthermore, it was also shown to be active against T790M mutant EGFR harbouring 
cells, and inhibited the growth of mouse xenografts expressing T790M mutant EGFR (Spicer and 
Rudman, 2010). This promising preclinical data led to a series of clinical trials, the LUX-lung 1 to LUX-
lung 8 trials, which investigated afatinib in first, second, third and fourth line therapy for NSCLC. The 
results from these trials, some of which are still ongoing, have recently been summarised by Chen et 
al (Chen et al., 2013b). LUX-Lung 3 in which afatinib was given in first line setting gave PFS of 11.1 
months for patients receiving afatinib compared to 6.9 months for those on the chemotherapy arm. 
Due to the small number of patients in the trial, harbouring T790M mutation, LUX-Lung 3 did not 
allow any conclusions as to the efficacy of afatinib against resistant mutant EGFR to be drawn (C.-H. 
Yang, 2012). LUX-Lung 7 and 8, which are currently in the recruiting phase, will be two arm studies 
comparing afatinib in one arm of the study to gefitinib or erlotinib in the other arm. This will allow 
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direct comparison of this second generation TKI over clinically available gefitinib and erlotinib (Chen 
et al., 2013b). 
Despite the above outcomes, disease progression following afatinib treatment does occur, and thus 
second generation TKIs do not seem to be spared of the development of acquired resistance. 
Resistance to second generation TKI has also been reported in in vitro studies. Others have 
demonstrated that irreversible inhibitors such as CL-387,785 can also cause drug resistance (Yamada 
et al., 2010, Ercan et al., 2010). 
 
Figure 5: Epidermal growth factor receptor tyrosine kinase inhibitor structures. 
The irreversible inhibitors, EKB-569 and afatinib contain the Michael acceptor, described above, which allows covalent 
bonding of these drugs to EGFR. Gefitinib and erlotinib which do not contain a Michael acceptor, bind reversibly to EGFR 
(Fry, 1999, Eskens et al., 2008). 
1.3.4.2 Third generation of TKIs 
Finally, drugs, which specifically target T790M mutant form of EGFR, are currently in development. 
These so called third generation TKIs, are hoped to be a potential therapeutic option for patients 
that acquire the T790M mutation. The first of these is WZ4002. It showed high levels of selectivity 
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bearing mouse xenograft models (Zhou et al., 2009). The second compound is CO-1686 which is 
currently undergoing phase I-II dose escalation trial after showing efficacy at inhibiting the activity of 
T790M mutant EGFR in vitro and causing inhibition in growth of H1975 (L858R/T790M) Xenograft 
(A.O. Walter, 2011). 
1.3.4.3 Multitarget TKI and combination studies 
New approaches to inhibiting the activity of EGFR are needed due to the emergence of resistance 
following treatment with first generation TKI’s such as gefitinib or erlotinib. One approach reviewed 
in section 1.3.4.2 is the use of irreversible inhibitors; another approach involves the development of 
compounds that target more than one type of receptor. 
Several small molecular TKIs, currently in development, target other members of the HER family as 
well as EGFR (e.g. afatinib). EGFR signalling is brought about by receptor homo-or 
heterodimerisation with HER2, HER3 or HER4. Blocking such interactions is thought to lead to an 
improved biological effect of EGFR inhibition (Spicer and Rudman, 2010). Secondly, compounds such 
as ZD6474 (Vandetanib; Astra Zeneca), which target EGFR as well as pro angiogenic receptor VEGFR-
2, increase the efficacy of slowing tumour proliferation (Flanigan et al., 2010). 
Combination therapy is a further approach, which is taken. A number of clinical trials investigating 
the efficacy of combining EGFR targeted therapies with radiotherapy or “classic” cytotoxic 
chemotherapeutics have been and are being carried out (Milano et al., 2008, Nyati et al., 2006). 
It is also thought that changes to the scheduling of cancer therapies will be an effective way to 
overcome the development of resistance and improve treatment outcome. Indeed, rather than 
waiting for a patient to develop resistance, occurring between 9 to 12 months after the start of 
therapy in NSCLC patients treated with gefitinib or erlotinib, to change their course of treatment, 
scheduled breaks in drug administration could prolong the time frame for which the patient 
responds to a particular therapy (Wheeler et al., 2010). Based on the concurrence of mutation to 
other proteins it is thought that combination treatment targeting two or more molecules from the 
same or different pathways could help prevent or overcome resistance. In this regard a study found 
synergistic effect of afatinib and MEK inhibitor SU11274, resulting in reduction of growth and 
increased induction of apoptosis (Chen et al., 2013a). 
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1.4 PET imaging of EGFR 
Before describing the principles of PET in more detail it is important to place PET in the context of 
other available imaging modalities. Table 2 describes several features of the different imaging 
modalities, which are used pre-clinically and clinically. 
Since the major role of EGFR in cancer was identified over 20 years ago several approaches to 
studying this protein and the gene which encodes it have been taken.  
The majority of the techniques approved by the FDA and used in the clinic for diagnosis and 
prognostic studies are histology based and require tumour biopsies to be carried out. The measure 
of EGFR gene amplification can be carried out by fluorescence in situ hybridization using a gene 
specific probe. Measuring the expression level of EGFR at the protein level, which may be a better 
indicator of tumourogenicity, can be assessed by immunohistochemistry using anti EGFR antibodies 
(Petak et al., 2010, Maheswaran et al., 2008). One of the major drawbacks of the majority of 
methods listed above is the dependence on tissue biopsies from patients. This demands invasive 
surgery, which is unpleasant for the patient and depending on the location of the tumour not always 
a possibility. It is estimated that adequate tissue biopsies may not be possible in 1 out of 5 patients 
(Cobo et al., 2007). Recent advances in the detection of low frequency cells from blood samples, 
have allowed the use of circulating cancer cells as a tool to analyse EGFR status without the need to 
carry out tumour biopsies (Maheswaran et al., 2008, Goto et al., 2012, Akca et al., 2013). This 
method is still in the experimental stages and further studies involving larger sample sizes will be 
needed before this method can be validated for routine use. One of the drawbacks of using 
circulating cancer cells from blood samples is that one cannot distinguish between cells originating 
from the primary or metastatic lesions. For these reasons, the use of an imaging modality that can 
probe EGFR in vivo is of great interest. The advantages and disadvantages of these different methods 
have been summarised in Table 3. 
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Table 2: Summary of imaging modalities used pre-clinically and clinically. 
MRI: Magnetic resonance imaging, CT: Computerised tomography, PET: Positron emission tomography, SPECT: Single photon emission computed 
tomography. Adapted from (Weissleder and Pittet, 2008).
Technique Resolution Depth Time Quantitative Imaging agents TarTargets Cost 
Clinical 
use 
MRI 10-100 µm 
No 
limit Minutes to hours YES 




molecular > £200,000 YES 
CT 50 µm 
No 




£200,000  YES 
Ultrasound 50 µm cm 
Seconds to 




£200,000  YES 
PET 1-2 mm 
No 
limit Minutes to hours YES 
18F, 64Cu,  
11C- labelled 
compounds Physiological, molecular > £200,000 YES 
SPECT 1-2 mm 
No 
limit Minutes to hours YES 
99TC, 
 111ln- labelled 
compounds Physiological, molecular 
£60,000 to 




mm cm Minutes NO Luciferins Molecular 
£60,000 to 
£200,000  NO 
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Table 3: Methods for assessing EGFR. 
 Gene sequencing in 
circulating cancer 
cells 
Immunohistochemistry Fluorescence in 
situ 
hybridization  
PET imaging  
Advantages  -low cost 










-Information from the 
whole tumour and 
possible metastasis 
- allows for the 
monitoring at different 
stages of treatment 
Disadvantages  - complex protocol 




-High percentage of 
false negatives 
-experimental 
- requires tissue 
biopsies 
-results are subjective 
and can vary between 
laboratory protocols. 
-EGFR expression 





-Doesn’t look at 







-Access to specialist 
equipment. 
This table indicates both the advantages and disadvantages of the various methods used for the assessment of EGFR (Petak 
et al., 2010) (Maheswaran et al., 2008, Goto et al., 2012). 
 
1.4.1 Principles of Positron emission tomography imaging 
Positron emission tomography (PET) is a highly sensitive, non-invasive, molecular imaging modality 
that can be used to produce images of physiological and pathological functions within the body. 
These features are important in oncology. Unlike some imaging modalities such as X-ray, which 
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measures features at the anatomical level, PET imaging allows the functional assessment of 
biological and biochemical processes in vivo. Functional changes within a tumour can occur rapidly 
after the start of therapy, without being associated with any anatomical changes.  
Currently, clinical response in oncology is assessed using the response evaluation criteria in solid 
tumours (RECIST) (Therasse et al., 2000). These criteria were first described in 2000 and revised in 
2009 (Eisenhauer et al., 2009). These criteria describe the assessment of tumour burden based on 
anatomical measurements, which can be assessed using different techniques including MRI and 
computed tomography (CT). PET can however be used to monitor functional changes that would 
otherwise be unnoticed with anatomical measurements. 
PET imaging relies on the design of a radiotracer or probe. These radiotracers or probes are injected 
into the patient to allow visualisation of the process investigated. PET probes are varied in nature 
and may be analogues of molecules involved in metabolic pathways (e.g. [18F]FDG), analogues of 
nucleotides (e.g. [18F]FLT) or targets of receptors (e.g. [18F]erlotinib) (Phelps, 2000). One common 
feature of all radiotracers is that they contain a radioisotope. Several of the radioisotopes used in 
PET are summarised in Table 4. Carbon, oxygen and nitrogen are found in abundance in organic 
molecules and can therefore be replaced by their radioisotopes for the production of radiolabelled 
probes. Other atoms that are not found in biological compounds are substituted for other atoms 
with the resulting molecules used as analogues of biological molecules.  
Table 4: Radioisotopes used in PET imaging. 
Positron 
isotopes 
11C 13N 15O 18F 64Cu 86Y 86Z 68Ga 
Half-life  20.4min 9.96min 2.07min 109.7min 12.7 h 14.7 h 14.7 h 68 min 
Radioisotopes used in PET imaging with associated half-life (Wong, 2004). 
The radioisotopes are characterised by unstable proton rich nuclei. In order to reach a more stable 
state the nuclei will reduce the number of protons. This is achieved through the decay of a proton 
into a neutron and a positively charged particle, a positron. The Positrons emitted from the 
radionuclide travel a short distance within the body, usually 0.2 to 2 mm, before undergoing an 
annihilation reaction upon interaction with an electron (Baghaei, 2003). This annihilation results in 
the simultaneous release of two γ rays (photons), with an energy of 511 KeV each, in opposite 
directions (approximately 180◦ ). These two γ rays are detected by two scintillation detectors, which 
are positioned opposite each other on a ring within in the scanner. Only γ rays that are detected by 
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opposing detectors within a specific time frame are recorded as coincidence events. These 
coincidence events, are collected and using mathematical algorithms, which correct for scattering 
and attenuation are used to reconstruct images that depict the location of the biochemical or 
metabolic function which was probed by the radiotracer (Basu et al., 2011, Phelps, 2000, Hutchins 
GD, 2008). These different stages of PET imaging are summarised in Figure 6. The advantage of PET 
over other imaging modalities such as MRI is a high sensitivity in the nanomlar range of 
concentrations. Currently scanners that combine both PET and CT allow for both anatomical and 
molecular imaging in the same framework. This helps to overcome the lower resolution of PET 
scanners compared to the high resolution of MRI (Mishani et al., 2008). Furthermore, PET scanners 
that are used specifically for animals, small animal PET, have been developed to help in the discovery 
and assessment of PET radiotracers (Hutchins GD, 2008). More recently, PET/MR systems have also 
been designed for both pre-clinical and clinical imaging. 
 
Figure 6: Principles of PET imaging. 
The annihilation of a positron with an electron leads to the emission of two gamma rays which are detected by the PET 
scanner, coincidence events are registered and the data is then corrected for scatter and random events before an image is 
reconstructed.  
1.4.2 Tracers used in the clinic 
One of the characteristics of cancerous cells is an increased requirement for glucose, to support the 
higher levels of metabolism in these cells. This feature is the basis for the most widely used PET 
tracer in the clinic: [18F]FDG. [18F]FDG is an analogue of glucose in which the hydroxyl group at 
position C2 is replaced by an [18F] fluorine isotope. This glucose analogue is taken up into the 
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commonly overexpressed in tumours. Once [18F]FDG has been taken up into the tumour it will be 
phosphorylated to [18F]FDG-6-phosphate by hexokinase II protein. However, due to its modified 
structure, with a fluorine atom at position 2 in place of a hydroxyl group, [18F]FDG cannot undergo 
further glycolysis and it is trapped in the cell (Wong, 2004, Phelps, 2000). The uptake and trapping of 
[18F]FDG are summarised in Figure 7. In oncology [18F]FDG is used for diagnosis but also for 
monitoring patients throughout their disease, assessing response to treatment and possible 
occurrence of metastasis (Haberkorn et al., 2011). 
Another characteristic of cancerous cells, which has been exploited for imaging, is the high levels of 
proliferation in these cells. Indeed, tumour proliferation is one of the hallmarks of cancer. Increased 
proliferation implies increased DNA replication and therefore increased demand for nucleosides. An 
analogue of the nucleoside thymidine, [18F]FLT has been used for PET imaging of the process of 
tumour proliferation. Like thymidine, [18F]FLT is taken up into cells via equilibrative nucleoside 
transporter 1 (ENT1). Once in the cell it is phosphorylated by thymidine kinase (TK1). The uptake and 
trapping of [18F]FLT are illustrated in Figure 7. This phosphorylated FLT cannot be incorporated into 
the DNA due to the lack of a hydroxyl group on position three of the ribose (Phelps, 2000, Shields et 
al., 1998). The uptake of [18F]FLT within a tumour reflects the activity of TK1 which is increased in 
cells during proliferation (Shields, 2003). To what extent [18F]FLT tumour uptake reflects the 
proliferation index of a tumour is still debated by many in the field and a recent study indicated that 
the proliferation index of a tumour and the levels of tumour uptake of [18F]FLT were not necessarily 
correlated (McKinley et al., 2013). 
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Figure 7: Principles of [18F]FDG and [18F]FLT metabolism. 
GLUT1: Glucose transporter 1, ENT1: equilibrative nucleoside transporter 1, TK1: thymidine kinase 1.[
18
F]FDG is taken into 
cells as glucose by GLUT1 transporters and phosphorylated by hexokinase enzyme. [
18
F]FLT is taken up into the cell as 
thymidine via ENT1 transporters and phosphoryalted by TK1. Adapted from (Rosen et al., 2007) and (McKinley et al., 2013) 
 
1.4.3 PET Imaging and its application in the study of EGFR 
PET imaging in oncology has a broad range of applications ranging from diagnosis to drug efficacy 
monitoring. As mentioned previously in this review changes to levels of EGFR expression occur in 
many cancers. Being able to monitor and measure these levels in vivo, could aid in patient selection 
for EGFR targeted mAb or TKI therapy. Identifying patients with active mutant forms of EGFR is 
important for selection for TKI therapy, and PET imaging of EGFR could also be used in this instance 
(Yeh et al., 2011). 
The majority of tracers, which have been developed for the imaging of EGFR, have been based on 
EGFR targeting therapeutic agents, either antibodies or small molecular TKIs. 
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Several tracers based on cetuximab and panitumumab antibodies have been developed. In mouse 
xenograft models [64Cu]DOTA-cetuximab showed higher levels of accumulation in high vs low EGFR 
expressing tumours (Cai et al., 2007, Ping Li et al., 2008). However, metabolism studies highlighted 
high levels of metabolism of [64Cu]DOTA cetuximab in tumour tissue. Indeed, 4 h post injection only 
15.65 % of authentic intact [64Cu]DOTA cetuximab remained in A431 tumour. There was also high 
retention in the liver rendering this tracer unsuitable for imaging possible metastatic disease in this 
area (Ping Li et al., 2008). 
The humanized mAb panitumumab has also been radiolabelled for use in PET imaging. 
[86Y]Panitumumab showed high accumulation in high EGFR expressing tumour models. Pre-
treatment with non radiolabelled antibody, which resulted in a decrease in tumour uptake of 
[86Y]Panitumumab demonstrated the specificity of [86Y]Panitumumab binding for EGFR (Nayak et al., 
2010, Nayak et al., 2011). A comparative study demonstrated superior characteristics of 
[86Y]Panitumumab over [86Y]Cetuximab. These included lower liver uptake with [86Y]Panitumumab 
than [86Y]Cetuximab, leading to improved tumour to liver ratios for [86Y]-Panitumumab (Nayak et al., 
2011). Panitumumab has also been radiolabelled with other radionuclides such as zirconium, 
[89Zr]DFO-panitumumab (Bhattacharyya et al., 2013). 
Alongside the radiolabelling of antibodies, antibody fragments including Fab’s and affibodies have 
been radiolabelled for the imaging of EGFR. These include, [111ln]DOTA-Z-EGFR:2377 affibody 
(Tolmachev et al., 2010), [64Cu]DOTA-Z-EGFR:1907 (Miao et al., 2010). 
Tracers developed from mAb or affibodies will enable in vivo monitoring of EGFR expression levels 
and the possibility to measure therapeutic mAb/receptor binding throughout the course of 
treatment. However, they will not give any information as to the mutational status of the tyrosine 
kinase domain of EGFR, and the effect of such mutations on response to treatment. This is where 
imaging tracers based on small molecular TKIs could play a key role.  
1.4.3.2 Tracers developed from the first generation TKIs 
Both gefitinib and erlotinib have been radiolabelled for the PET imaging of EGFR. [11C] and 
[18F]gefitinib (Su et al., 2008, Zhang et al., 2010) gave mixed results. There were no differences in the 
uptake of [18F]gefitinib in vitro and in vivo in models that expressed differential levels of EGFR or 
mutant forms of EGFR (Su et al., 2008). On the other hand high levels of [11C]gefitinib uptake 
correlated with high levels of EGFR expression both in vitro and in vivo (Zhang et al., 2010). 
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[11C]erlotinib was initially investigated in vitro and in vivo mouse studies. High levels of [11C]erlotinib 
uptake were measured in HCC827 cells that express high levels of EGFR (del E746-A750) but not in 
A549 or NC1358 cells, both expressing WT EGFR. Furthermore, this tracer showed higher uptake 
levels in HCC827 tumours, 3.7 % of injected dose per gram (% ID/g), compared to only 1.6 % in A549 
tumours. These two findings, correlated with a decrease in HCC827 but not A549 or NCIH358 cell 
proliferation following erlotinib treatment, and made [11C]erlotinib a promising tracer for the 
identification of tumours sensitive to erlotinib treatment (Memon et al., 2009). However, from this 
study one cannot confirm if the higher uptake of [11C]erlotinib in the HCC827 tumours compared to 
the A549 or NCIH358 tumours was a result of the overexpression and or the mutational status of 
EGFR in the HCC827 tumours (Memon et al., 2009). 
Recent results from a clinical trial evaluating the use of [11C]erlotinib for the in vivo assessment of 
EGFR mutational status in NSCLC patients have been published (Bahce et al., 2013). This small trial of 
five patients with exon 19 deletion and five patients with WT EGFR involved two scans (test and 
retest) on the same day, with both [150]H2O, to assess blood perfusion of the tumour, and 
[11C]erlotinib on the same day. Quantification of the uptake of [11C]erlotinib in the tumour by kinetic 
modelling using arterial blood as an input function was carried out. From this, the volume of 
distribution (Vt) was worked out. It was found that Vt was on average two times greater in the exon 
19 deletion EGFR than in the WT EGFR expressing tumours (Bahce et al., 2013). This study only 
looked at one mutant form of EGFR, further investigation of the other prevalent active mutant L858R 
EGFR will be necessary to conclude on the application of [11C]erlotinib for the identification of 
mutant forms of EGFR in vivo. 
1.4.3.3 Tracers developed from second generation of TKI’s 
Radiotracers are injected in picomolar concentrations and it is thought that at such doses, 
radiolabelled reversible binding TKIs such as erlotinib and gefitinib would be out competed for the 
kinase binding site of EGFR by high in vivo levels of ATP. For this reason inhibitors which bind 
irreversible to EGFR are thought to be better suited for PET imaging of EGFR and this is the direction 
which was taken for the majority of TKI based tracers (Gelovani, 2008). 
Several groups have investigated radiolabelled irreversible binding TKI for the imaging of EGFR. 
Many of the tracers developed showed disappointing results in vivo. One compound, ML04, showed 
strong but not exclusive selectivity for EGFR in vitro. Mishani et al were able to use ML04 to quantify 
the number of EGFR molecules in vitro in A431 cells. (Abourbeh et al., 2007). Furthermore, the 
stability of ML04 in vivo was significantly greater than that of ML03, a tracer that showed high levels 
   
 44 
of metabolism, and was a previously developed tracer in the group. In fact, at 3 h post injection the 
tumour activity uptake was 18 times greater with [18F]ML04 compared to [11C]ML03. However, the 
EGFR specific uptake of ML04 was poor. Firstly, the levels of uptake measured in EGFR negative 
U138MG human glioma tumours were elevated. Secondly, a blocking experiment in which non-
radiolabelled ML04 was administered in the mouse 1 h before injection of the tracer showed no 
decrease in the uptake of the radiotracer in the tumour. Both these results led to the conclusion that 
the activity measured was not EGFR-specific and the use of this compound as a PET tracer was 
deemed unfavourable (Abourbeh et al., 2007). 
An Iodine radiolabelled compound, [131I ]IPQA, showed selective binding to active (phosphorylated) 
EGFR rather than inactive EGFR. In vivo PET imaging, demonstrated that the tracer showed higher 
levels of uptake in A431 (EGFR overexpressing) vs K562 tumour bearing mouse xenografts and also 
higher levels of uptake in U87 ΔWT (expressing EGFRIII mutant) vs U87WT mouse xenografts. This 
backs up the in vitro radiotracer accumulation finding in which [131I ]IPQA bound to active but not 
inactive EGFR (Pal et al., 2006). Although this tracer demonstrated good tumour uptake and good 
specificity, there were high levels of liver and intestinal uptake, which would render imaging in these 
regions impossible. Furthermore, the tracer was highly metabolised. 
In order to overcome the high levels of liver metabolism seen with previously mentioned 
anilinoquinazoline tracers such as ML03, ML04 and IPQA, compounds with a reduced log P and an 
increased solubility needed to be developed (Gelovani, 2008). One approach consisted of the 
addition of a polyethylene glycol (PEG) group at position 7of the quinazoline moiety. Three such 
PEG-anilinoquinazoline-based radiotracers were developed. They were labelled with [124I], [18F] or 
[11C] and investigated for the imaging of EGFR by small animal PET, using mouse xenografts 
(Pantaleo et al., 2010). Two human glioblastoma cell lines were used including U138MG (which lacks 
EGFR expression) and U87MG WT EGFR (which overexpresses EGFR). The tumour uptake of these 
radiotracers was poor over time and no significant difference in uptake was seen between U138MG 
and U87MG masses. Enzyme linked immunosorbent assay was carried out to evaluate the levels of 
total and phosphor-EGFR in the two tumour types. The total levels of EGFR measured were 
significantly higher in the U87MG tissue (just under 0.25 ng/mg of protein) compared to that 
measured in U138MG (under 0.05 ng/mg of protein). However, there was no significant difference in 
the levels of phospho/total EGFR ratios between the two tumours and this was hypothesized as the 
reason for the similar levels of uptake in the two tumour models (Pantaleo et al., 2010). 
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To date, the most promising radiotracer for the imaging of mutant EGFR is a derivative from the PEG 
series of compounds discussed above. [18F]F-PEG6-IPQA, was shown to bind with higher selectivity 
and specificity both in vitro and in vivo to the L858R activating mutant EGFR expressing cell line and 
tumour xenografts. Indeed, this tracer showed a 7.6 fold higher uptake in H3225 (L858R EGFR) 
xenograft compared to H1975 (L858R/T790M EGFR) xenograft (Figure 8). The fold changes in uptake 
of [18F]F-PEG6-IPQA were however not as significant when comparing to wild type EGFR. There was 
only 1.4 fold increase in the uptake of the tracer in the H3255 compared to H441 (WT EGFR) 
xenografts. Furthermore, expression levels of EGFR were higher in H3255 compared to H1975, and 
this could be responsible, at least in part, for the increased uptake of [18F]F-PEG6-IPQA in H3255 
compared to H1975 xenografts (Yeh et al., 2011). One characteristic of this radiotracer was a rapid 
plasma clearance, by 30 min only 16.2 % (± 8.6 %) of the radiotracer present in the blood was [18F]F-
PEG6-IPQA, whilst the remaining radioactivity corresponded to [18F]F-PEG6. As [18F]F-PEG6 does not 
cross the cell membrane and is rapidly cleared by the kidneys it does not confound the imaging of 
[18F]F-PEG6-IPQA (Yeh et al., 2011). 
 
Figure 8: PET image of [18F]-PEG6-IPQA in mouse xenografts 
Representative coronal and axial PET/CT images obtained 120 min post radiotracer injection of mice bearing H1975 
(resistant mutant EGFR), PC14 (WT EGFR xenografts) or H441 (WT EGFR),H3255 (L858R EGFR)tumours (Yeh et al., 2011). 
Biodistribution, metabolism and pharmacokinetics of [18F]F-PEG6-IPQA have been carried out in non 
human primates. This study demonstrated acceptable radiation absorbed doses to vital organs 
including, heart, liver, kidney and gall bladder. They showed that the radiotracer was cleared from 
the body via both hepatobiliary and renal clearance. They concluded that this radiotracer would be 
safe for PET in human patients (Tian et al., 2011). 
1.4.3.4 FED Compounds 
A series of fluorine containing 3-cyanoquinoline derivatives based on the core structure of the 
irreversible TKI, EKB-569, were synthesized by a radiochemist within our centre. As with other 
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tracers based on irreversible compounds, the first aim for this series of molecules was to increase 
the binding of the compound to EGFR and reduce the washout by ATP, seen with reversible 
compounds. The second goal was to increase the metabolic stability compared to other probes 
previously designed for the imaging of EGFR (Pisaneschi et al., 2010). 
Three key features characterized the cyanoquinoline compounds. First, an aniline moiety at C-4, 
which is thought to increase the occupancy of the hydrophobic pocket of the receptors active site. 
Second, a Michael acceptor at C-6, which leads to the covalent binding of the compound with 
cysteine residue 773 of EGFR. Third, a secondary amine as opposed to a tertiary amine as the 
Michael acceptor to increase metabolic stability. The Quinoline compound, FED6 (Figure 9) showed 
high in vitro affinity against isolated WT EGFR protein (IC50 1.8 nM) and ease of radiolabeling via 
“click” chemistry (Kolb et al., 2001), a method that is characterised by simple reaction conditions. 
This chemistry method is especially important for radiochemistry where synthesis needs to be 
carried out in the shortest possible time and with the smallest number of reaction steps, so as to 
reduce the radiation exposure to the radiochemist and to maximise the radiochemistry yield.  FED6 
was selected as the lead compound to use for PET imaging. The metabolic stability of [18F]FED6 was 
assessed by analysing plasma and liver extracts taken after 2, 30 and 60 min post radiotracer 
injection. At 60 min, the parent radiotracer was present at 50 % in the plasma and 75 % in the liver, 
which was indicative of relatively good stability. [18F]FED6 showed high levels of uptake in A431, 
EGFR overexpressing tumours, compared to HCT116, low EGFR expressing tumours (Pisaneschi et al., 
2010). 
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Figure 9: Radiolabelled irreversible inhibitors of EGFR. 







I]. Radiolabelling on the quinazoline core or on the side chain (Pal et al., 2006, Pantaleo et al., 2010, Abourbeh 
et al., 2007, Pisaneschi et al., 2010, Ortu et al., 2002). 
 
1.4.4 Summary of EGFR PET imaging agents and future application in the clinic 
As reviewed above research over the last decade has led to the development of a number of PET 
probes that target EGFR. These have included both mAb and TKI derived radiotracers. Radiolabelled 
Mab showed good specificity and sensitivity for EGFR. However, their long half life and large size 
result in slow excretion, which are a disadvantage for sequential scanning in a clinical setting. 
Smaller antibody fragments such as, the affibodies introduced above, could help to overcome this 
timing drawback.  
In terms of TKI derived radiotracers, despite strong in vitro data, the first developed radiotracers 







   
 48 
this reason the trend was to move toward irreversible TKI based radiotracers (e.g. ML04, FED6) 
(Pisaneschi et al., 2010, Abourbeh et al., 2007). These showed higher affinity for EGFR but often had 
high levels of non specific binding especially in liver and gastrointestinal tract. The next step in the 
field of EGFR radiotracer probes then involved lowering the lipophilicity of radiotracers by adding a 
PEG moiety to the structure. This led to improvement in stability and reduced non specific binding. 
The most recent radiotracer in this class being the [18F]F-PEG6-IPQA. Despite this progress, there are 
still no EGFR targeting PET probes available for clinical use. The transition of radiotracers from the 
pre-clinical to the clinical setting will come with a new set of challenges. These may include higher 
levels of tumour heterogeneity in terms of EGFR expression and activity in humans compared to 
mouse models, difficulties in understanding the significance of a “negative” PET scan for treatment 
selection, and overcoming high levels of uptake in organs involved in the clearance and metabolism 
of the radiotracers (Pantaleo et al., 2009). 
 
1.5 Biomarkers of response, failure of response to TKI treatment in NSCLC 
A biomarker can be defined as: “a characteristic that is objectively measured and evaluated as an 
indicator of normal biological processes, pathogenic processes or pharmacological responses to a 
therapeutic intervention” (Downing, 2001). This definition highlights the broad range of areas and 
applications in which biomarkers can be used. In the context of this thesis, the focus will be in 
predictive biomarkers of therapeutic response. These biomarkers are especially important for the 
selection of patients who will respond to treatment and more importantly identify those that will 
not. 
In NSCLC many studies have investigated potential biomarkers of response to TKI, gefitinib and 
erlotinib. The majority of these biomarkers have been evaluated pre-treatment and correlated with 
response or failure of response to TKI treatment. 
 
1.5.1 Biomarkers obtained from tissue samples. 
EGFR copy numbers, mutational status and protein expression have been evaluated as potential 
biomarkers or therapeutic response. 
A high EGFR gene copy number was shown to correspond to an increased response to EGFR TKI 
(Hirsch et al., 2005). A recent meta-analysis reviewing over 50 clinical trials in NSCLC patients looked 
into the correlation between somatic mutations and response to gefitinib or erlotinib. EGFR 
mutations were found to show both strong sensitivity and specificity as a predictive biomarker of 
response to TKI inhibitor treatment (Dahabreh et al., 2010). It has also been shown that EGFR 
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mutations are a better predictor of TKI response compared to EGFR expression levels as assessed by 
methods including immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) (Sholl et 
al., 2010). Other molecules have also been studied as biomarkers of response to TKI. It has been 
shown that patients whose tumours were positive for p-AKT showed increased response rate and 
progression free survival than those whose tumours were p-AKT negative. Thus, P-AKT assessment 
prior to TKI treatment could be used as a biomarker of response to therapy (Cappuzzo et al., 2004). 
KRAS has also been investigated as a negative biomarker of response to gefitinib treatment. Two 
meta-analysis studies showed that patients who had KRAS mutations showed an absence of 
response or decrease in overall response rates to TKI treatment (Linardou et al., 2008, Mao et al., 
2010). Murray et al carried out a study looking at several of the above mentioned biomarkers in 59 
NSCLC patients that underwent TKI treatment. They assessed several biomarkers including MET 
amplification, KRAS mutational status and EGFR expression and mutational analysis. They found 
EGFR mutations to predict response to TKI treatment. However, the small sample size made it 
impossible to draw any conclusions on the other tested biomarkers (Murray et al., 2012). The 
disadvantage with the above biomarkers is that they all require tumour biopsies. Furthermore, they 
are evaluated before the start of treatment and are not useful for detecting patients who may 
initially respond and then fail to respond to treatment.  
Early prediction of response to treatment and particularly TKI treatment such as gefitinib and 
erlotinib is important for several reasons. First, If patients are not responding to treatment, rapid 
initiation of alternative approaches need to be taken so that patients do not continue a course of 
treatment, often associated with side effects, which is not benefitting them. 
Biomarkers that can be assessed during the course of therapy would instead allow resistance to 
therapy to be detected. Increased serum levels of α1 antitrypsin were shown in a small study to be 
predictive of disease progression following gefitinib treatment (Zhao et al., 2013). 
 
In this regard PET imaging which allows non invasive detection and can be performed both before 
and during treatment can overcome the disadvantages of biopsy collections. The use of an in vivo 
PET imaging probe soon after the start of therapy could allow assessment of response to therapy. 
1.5.2 Predicting response to TKI treatment: PET Imaging with [18F]FDG and [18F]FLT 
[18F]FDG is commonly used for staging and detection of NSCLC (Weber et al., 2003), but has also 
been used to predict response in patients receiving chemotherapy or TKIs (see review by Hicks et al 
,2009) (Hicks, 2009). [18F]FLT, which was developed as a marker to measure cellular proliferation in 
vivo, can also be used to determine drug-induced cell cycle inhibition in vivo (Shields et al., 1998). 
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Several preclinical and many clinical studies have been published in recent years investigating the 
use of both [18F]FDG and [18F]FLT as tools for the early detection of response or failure of response to 
TKI gefitinib and erlotinib in NSCLC. 
1.5.2.1 Pre-clinical findings 
The pre-clinical studies which investigated the use of early [18F]FDG and [18F]FLT PET imaging, to 
predict treatment outcome, have shown contradicting results. Ullrich et al showed a significant 
decrease in [18F]FLT uptake in sensitive but not T790M EGFR mutant resistant NSCLC tumour 
xenograft models, following 48 h erlotinib treatment. They found that the decrease in [18F]FLT 
uptake correlated with a decrease in proliferation marker Ki67 and G1 arrest of the tumour cells. 
They found no significant decrease in the uptake of [18F]FDG following gefitinib treatment in neither 
the sensitive nor the resistant NSCLC xenografts (Ullrich et al., 2008). Zannetti et al also found a 
significant decrease in [18F]FLT uptake (-45 %) following 3 days erlotinib treatment in a sensitive 
NSCLC xenograft model. They further showed an increase in uptake of [18F]FLT in the T790M 
resistant mutant EGFR xenografts following gefitinib treatment, and this as a result of tumour 
proliferation (Zannetti et al., 2012). 
On the other hand Su et al demonstrated a decrease in [18F]FDG uptake after two days of gefitinib 
treatment in sensitive NSCLC xenografts (Su et al., 2006). 
 
1.5.2.2 Clinical findings 
As with the preclinical studies both early PET imaging with [18F]FDG and [18F]FLT PET have been 
investigated for the prediction of long term response to TKI treatment in NSCLC. 
Several studies involving NSCLC patients showed that changes to [18F]FDG uptake correlated with 
response to TKI treatment.  
Sunaga et al showed that a decrease in standard uptake values (SUV) of [18F]FDG, after two days of 
gefitinib treatment compared to baseline, correlated with patients with partial response or stable 
disease (Sunaga et al., 2008). Others correlated the decrease in SUV of [18F]FDG at two days post 
treatment with morphological changes, measured by decrease in tumour size by CT at 1 month after 
start of treatment (Takahashi et al., 2012). Zander et al investigated early response to erlotinib 
treatment independent of mutational status in NSCLC. Decreases in [18F]FDG uptake after 1 week 
treatment correlated with an increase in both PFS and OS as well as non progression after 6 weeks. 
Whereas, decreases in [18F]FLT uptake did not correlate with changes to OS and were not predictive 
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of non progression after 6 weeks (Zander et al., 2011). These findings did not correlate to the 
preclinical studies, which were carried out by the same group, where they found a decrease in 
[18F]FLT but not [18F]FDG following erlotinib treatment (Ullrich et al., 2008). In another study, low 
residual uptake of both [18F]FDG and [18F]FLT uptake at 1 week post treatment was associated with 
an increase in PFS (Kobe et al., 2012). Sohn et al also confirmed that [18F]FLT predicted response to 
gefitinib (Sohn et al., 2008). A recent study looking at use of FDG and FLT to predict therapeutic 
outcome before the start of therapy showed that a low SUV max at baseline with [18F]FDG and 
[18F]FLT was associated with an increased response to erlotinib treatment but not with a PFS 
(Scheffler et al., 2013). The different findings as to the predictability of either radiotracer for 
measuring response to TKI treatment in NSCLC, emphasise the need for further clinical trials in this 
field before early routine scanning with [18F]FLT or [18F]FDG could be implemented. 
The above section reviewed the potential biomarkers for the assessment of response to therapy in 
NSCLC. One metabolic pathway which has been extensively linked to an oncogenic phenotype is 
choline metabolism. The metabolism of choline in cancer is discussed in the following section. 
1.6 Choline metabolism in Cancer 
Choline is an essential nutrient and is a key precursor in several biochemical pathways within the 
cell. Choline metabolism involves several pathways including choline phosphorylation, oxidation and 
acetylation. The positively charged choline molecule relies on active transport into the cells via 
transporters, including organic cation transporters and choline transporter-like proteins. Once 
internalized choline will either be oxidized forming betaine or phosphorylated into phosphocholine 
(Glunde et al., 2011). 
Changes to choline metabolism in malignant transformation, were first identified in the 1980’s 
following the detection of increased levels of choline metabolites, including phosphocholine, from 
31P and 1H magnetic resonance spectroscopy (MRS) studies in tumours (Griffiths et al., 1983, Leach 
et al., 1998). It was first hypothesized that the increase in choline metabolism was in line with a need 
for increased cell proliferation of the malignant cells. However, it was later shown that the changes 
in choline metabolism did not correlate with proliferation rates in malignant and non malignant cells 
but instead changes to choline metabolites were linked to malignant transformation. In breast 
cancer it was found that there was a gradual increase in levels of choline phospholipid metabolites 
as cells become more malignant (Aboagye and Bhujwalla, 1999).  
Choline metabolism is an important mechanism for the production and maintenance of the cell 
membrane. Indeed, phosphatidylcholine, the most abundant phospholipid in the cell membrane is a 
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product of choline metabolism. The pathway that results in the de novo synthesis of 
phosphatidylcholine is the Kennedy pathway (Aboagye and Bhujwalla, 1999, Gibellini and Smith, 
2010).This pathway is summarised in Figure 10. 
 
Figure 10: Kennedy pathway. 
The phosphoryltaion of choline by ChK to form phosphocholine forms the initial step of the kennedy pathway. 
Phosphocholine is then converted into phosphatidylcholine following two separate reactions. Adapted from (Aboagye and 
Bhujwalla, 1999) and (Gibellini and Smith, 2010). 
 
The involvement of choline metabolites, including in a number of signalling pathways is illustrated in 
Figure 11. Phosphatidylcholine is a precursor of diacylglycerol (DAG), arachidionic acid and 
phosphatidic acid. These molecules have been shown to act as second messengers, activating 
mitogenic pathways such as the MAPK pathway, thus promoting cell proliferation in cancer. 
Furthermore, downstream metabolites of phosphatidylcholine, eicosnaoids, play an important role 
in cell motility and metastatic dissemination of cancer cells (Ackerstaff et al., 2003). 
1.6.1 Choline kinase  
Choline kinase, which is the first enzyme in this pathway, consists of a dimer of the three isoforms of 
ChK. These are ChKα1 and ChKα2, and ChKβ. Chkα1 and Chkα2 are a result of alternate splicing of 
the same ChKα1 gene. The three isoforms combine as hetero or homodimers leading to functional 
ChK enzyme (Aoyama et al., 2004). ChKα but not ChKβ has been associated with malignancy and has 
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Overexpression and increased activity of ChKα have been shown in many cancers including, lung, 
breast, prostate, ovarian and colorectal cancer (Lenkinski et al., 2008, Iorio et al., 2010, Ramirez de 
Molina et al., 2002a). The overexpression of ChKα has been linked to increased tumour 
aggressiveness (Hernando et al., 2009) as well as increased invasiveness and drug resistance (Shah et 
al., 2010). In lung cancer, ChKα was found to be a valuable prognostic marker. A study, which looked 
at 167 NSCLC patients, showed a correlation between increased levels of ChKα and poor clinical 
outcome (Ramirez de Molina et al., 2007). 
Regulation of choline metabolism and ChKα in cancer 
The regulation of choline metabolism has been shown to involve several oncogenic pathways 
including MAPK and PI3K-AKT. It has been shown that the increases in phosphocholine that are 
measured in tumours result in part from the activation of ChKα by Rho GTPases as well as PI3K 
signalling (Ramirez de Molina et al., 2002b, Ramirez de Molina et al., 2005). Inhibition of ChKα 
results in a decrease in the MAPK and PI3K signalling pathways(Glunde et al., 2011). 
A study in which microarrays were established following ChKα over expression showed an up 
regulation of over 280 genes (Ramirez de Molina et al., 2008). These were involved in mechanisms of 
metabolism, cell proliferation, cell cycle and apoptosis. ChKα led to increases in the expression of 
cyclin D1 and D3 as well as a decrease in expression of P21 and P27, defining ChKα as a key molecule 
in the regulation of the transition from G1 to S phase of the cell cycle (Ramirez de Molina et al., 
2008). 
ChKα has also been shown to form a complex with EGFR in the presence of c-SRC. In breast cancer 
models, Miyake et al showed that EGFR and ChKα immunoprecipitated together in the presence of 
kinase active but not kinase inactive c-SRC. EGFR kinase activity was however not necessary for the 
EGFR-ChKα interaction to occur. They further showed that this complex of EGFR-c-SRC and ChKα led 
to an increase in the activity of ChKα (Miyake and Parsons, 2012). 
The oncogenic regulation of choline kinase and choline kinase metabolism are summarised in Figure 
11. 
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Figure 11: Schematic of ChKα and metabolic control. 
Summary figure of the different oncogenic regulations of ChKα and choline metabolism pathway. ChK: choline kinase; DAG: 
Diacylglycerol; JNK: JUN N-terminal kinase; RALGDS: RAL GTPase guianine nucleotide dissociation stimulator; PLA2: 
phosphatidylcholine-specific phospholipase A2; PLC phosphatidylcholine-specific phospholipase C. PLD 
phosphatidylcholine-specific phospholipase D. Red arrows indicate interaction between ChKα and signalling pathways, 
these include the MAPK and PI3K pathways. 
 
Since it was first discovered that choline metabolism played a crucial role in malignant 
transformation, assessing this in patients for detection, staging and measuring therapy response was 
pursued. 
1.6.2 In vivo imaging of choline metabolism  
In vivo imaging of choline metabolism allows for the non invasive assessment of changes to choline 
metabolism. Two main imaging modalities are used for the assessment of choline metabolism. These 
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1.6.2.1 MRS imaging   
MRS imaging exploits the differential resonance frequencies of atoms when placed in differential 
electric fields. The resonance frequencies reflect the chemical groups present in that particular 
tissue section. Therefore, measuring these different frequencies allows the collection of information 
on the specific metabolites present (Kauppinen and Peet, 2011). MRS can be used for the in situ 
measuring of total choline containing molecules, by detecting alteration to 31P and 1H MRS spectral 
profiles. MRS quantification of total choline metabolites has been used as part of the diagnostic and 
staging of cancers including brain (McKnight et al., 2007), breast (Katz-Brull et al., 2002) and prostate 
(Squillaci et al., 2005). Furthermore MRS has also been selected to monitor therapeutic response 
(Kurhanewicz et al., 2000, Leach et al., 1998). One disadvantage of this imaging modality is that In 
vivo MRS only provides information on total choline metabolites, as a result of reduced spectral and 
spatial resolution. This is in contrast to in vitro MRS, which is a high resolution NMR technique and 
provides spectral resolution of different choline components. With advances in clinical MR scanners 
this draw back could be improved (Glunde et al., 2011). 
1.6.2.2 PET imaging of choline metabolism 
To date several PET radiotracers have been developed for the imaging of choline metabolism. The 
first of these was [11C]choline which has been used for the study of several cancers including breast 
cancer (Hara et al., 1998, Kitajima et al., 2013, Contractor et al., 2011a, Contractor et al., 2011b). 
Other tracers including [18F]fluoromethylcholine (Kwee et al., 2004, DeGrado et al., 2001a), were 
designed to overcome the short half-life of [11C]choline. [18F]fluoromethylcholine has been used to 
detect tumours in brain, breast and prostate (DeGrado et al., 2001a, DeGrado et al., 2001b). 
[18F]fluoromethylcholine shows high levels of systemic metabolism and this is especially problematic 
when longer scanning times are required as both parent and catabolites are detected. 
To overcome this instability, Leyton et al developed a derivative of [18F]fluoromethylcholine, 
[18F]D4Choline. This radiotracer contains a deuterium moiety that had been shown to render the 
molecule more stable to oxidation. The authors showed an increase in tumour radiotracer levels and 
a reduction in oxidation with [18F]D4Choline compared to [18F]fluoromethylcholine (Leyton et al., 
2009). A comparative study of [18F]D4Choline, [11C]choline and [11C]D4choline showed that both 
fluorination and deuteration rendered the choline radiotracer more stable to oxidation (Witney et 
al., 2012). 
As in MRS, PET imaging can also be used to monitor therapeutic response. Leyton et al showed a 
decrease in uptake of [18F]D4Choline in mouse xenograft following MAPK inhibitor treatment (Leyton 
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et al., 2009). A clinical study investigated [11C]Choline imaging in the context of measuring response 
to antibody therapy in breast cancer patients. Kenny et al showed a decrease in tumour uptake of 
[11C]Choline following trastuzumab treatment (Kenny et al., 2010). 
As discussed in section 1.3.3, the development of resistance to therapy is a common feature of 
cancer. One such mechanism of resistance, involves the overexpression of a member of a family of 
transporters called the ATP binding cassette (ABC) transporters. These transporter proteins and their 
interaction with TKI will be discussed in the following section. 
1.7 ATP binding cassette (ABC) transporters and TKI interaction 
1.7.1 ABC Transporters 
ABC transporters form a large family of over 48 proteins, divided into seven subfamilies (Dean et al., 
2001). These transporters are highly conserved from prokaryotes to humans, and are localised on 
both intra and extracellular membranes. They are expressed physiologically in a wide range of 
organs including, blood-brain barrier, lungs, liver and intestines. Their main function is one of 
protection, by actively excluding endogenous metabolites and xenobiotics from the different organs 
where they are expressed in conjunction with the hydrolysis of ATP (Figure 12) (Szakacs et al., 2008, 
Litman et al., 2001). 
 
 
Figure 12: Topological and hypothetical schematic of typical ABC transporter in cellular 
membrane.  
Representation of membrane spanning ABC transporter molecule indicating role of ATP in the efflux activity of these 
transporters, reproduced from (Szakacs et al., 2008). 
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The overexpression of ABC transporters has been shown to be a major cause of multidrug resistant 
phenotype, named MDR. MDR has been extensively studied in the context of cancer where 
prolonged exposure to a given chemotherapeutic agent often leads to the development of drug 
resistance. Indeed, upregulation of ABC transporters at the cell surface of a tumour result in lower 
accumulation of a given drug in the tumour, due to the active efflux of the drug via the transporters, 
this lower drug exposure, can lead to patients developing resistance to therapy. 
Three members of the ABC transporter family which have been linked to MDR are ABCB1 also called 
permeability glycoprotein (Pgp), ABCG2 also called breast cancer resistance protein (BCRP) and 
ABCC1 also referred to as multidrug resistant protein 1 (MRP1) (Litman et al., 2001, Shi et al., 2007, 
Munoz et al., 2007). 
ABCB1 is encoded by the MDR1 gene and is formed of two homologous subunits which are joined 
together by a linker (Ambudkar et al., 1999). A number of molecules have been shown to interact 
with the ABCB1 pump, from several therapeutic classes. These include anticancer drugs (e.g. 
paclitaxel), vinca alkaloids (e.g. vinblastine), Hiv–therapies (e.g. ritonavir), and fluorescent dyes (e.g. 
calcein AM) (Didziapetris et al., 2003). Several studies have investigated the potential characteristics 
of drugs that increase their substrate specificity for ABCB1. These parameters include (MW) > 400, 
hydrophobicity determined by 1 < log P > 5, sum of oxygen and nitrogen atoms > 8, polar surface 
area (PSA), defined as the sum of surfaces of polar atoms (usually oxygen, nitrogen, and attached 
hydrogen) > 85Å2 (Varma et al., 2005, Dellinger et al., 1992, Gottesman and Pastan, 1993, Kaliszczak 
et al., 2010, Didziapetris et al., 2003). Knowing what characteristics lead to recognition and efflux of 
a drug by ABCB1 is important for designing out any substrate specificity during the drug 
development process. 
The second transporter linked with MDR is ABCG2. This half transporter was first discovered in 
breast cancer (Doyle et al., 1998), and has since been found to be overexpressed in a wide range of 
both hematopoietic and solid tumours (Mo and Zhang, 2012). As for ABCB1 the substrate specificity 
of drugs for ABCG2 encompass a wide variety of chemical structures. Substrates of ABCG2 include, 
anticancer drugs of the topoisomerase inhibitor class (e.g. mitoxantrone), anthracyclines (e.g. 
doxorubicin), tyrosine kinase inhibitors (e.g. gefitinib, erlotinib) (Doyle and Ross, 2003, Hegedus et 
al., 2012, Ozvegy-Laczka et al., 2004, Ozvegy et al., 2001). A planar structure has been shown to be 
an important feature for determining the substrate specificity of a drug for ABCG2 (Saito et al., 
2006). The number of aromatic rings in a compound have also been shown to influence ABCG2 
substrate specificity, with compounds containing greater than two aromatic rings showing increased 
substrate specificity for ABCG2 (Nakagawa et al., 2006). 
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Finally, ABCC1 also referred to as MRP1, is involved in MDR. This transporter was first identified in 
lung cancer and is overexpressed in a wide range of cancers (Cole et al., 1992, Deeley and Cole, 
2006).Substrates of ABCC1 include anionic molecules as well as molecules that have been 
conjugated to either glutathione, sulphate or glucuronide (Munoz et al., 2007, Ozvegy-Laczka et al., 
2004). As for the two previously mentioned transporters ABCC1 recognises a wide range of drugs 
including, antivirals (e.g. ritonavir), anthracycline (e.g. doxorubicin), fluorescent molecules (e.g. 
calcein AM) (Munoz et al., 2007, Hollo et al., 1994). 
Some drugs are substrates for just one of the transporters whilst others may be substrate for two or 
all three. The overlapping substrate specificity of various drugs for these three ABC transporters 
have been summarised in Figure 13. 
 
Figure 13: Diagram illustrating the overlapping substrate specificity for ABCB1, ABCG2 and ABCC1 
transporters of a variety of drugs. 
Molecules including anthracyclines, tryrosine kinase inhibitors, antivirals are listed. This figure highlights a few examples 
but is not exhaustive. 
 
1.7.2 TKI and ABC transporter protein interaction. 
Several groups have investigated the interactions between EGFR TKIs and ABC transporters involved 
in MDR. The nature of the interaction between EGFR TKIs and MDR transporters is at two levels. TKIs 
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 TKIs as substrates for ABC transporters 
Both first and second generation TKIs have been shown to have substrate specificity for ABCG2 and 
ABCB1 including dasatinib, nilotinib, pelitinib, gefitinib and erlotinib (Hegedus et al., 2009, Shi et al., 
2007, Hegedus et al., 2012). An in vitro study investigating the interaction of ABCG2 and gefitinib 
demonstrated an overexpression of ABCG2 following chronic exposure to gefitinib treatment which 
accounted for the subsequent acquired resistance to gefitinib (Chen et al., 2011). This finding is 
important as patients receiving TKIs as 2nd or third line treatments following pre-exposure to 
chemotherapeutic drugs that lead to MDR could explain the reduced action of TKI in these patients 
(Hegedus et al., 2012). 
 TKIs as inhibitors of ABC transporters 
 In addition to being a substrate for ABCB1 and ABCG2, both gefitinib and erlotinib have been shown 
to inhibit ABCG2 and ABCB1 activity (Kitazaki et al., 2005, Ozvegy-Laczka et al., 2004, Nakamura et 
al., 2005, Shi et al., 2007). In these studies gefitinib reversed resistance to chemotherapeutic drugs 
by acting as an inhibitor of ABCG2 and ABCB1. In these studies when gefitinib was given in 
combination with mitoxantrone, a known substrate for both ABCB1 and ABCG2, an increase in cell 
cytotoxicity in cell lines which overexpressed the MDR proteins was found. A recent study 
demonstrated the involvement of the PI3K/AKT pathway in the modulation of expression levels of 
ABCG2. It was found that combination treatment of gefitinib with LY294002 (AKT inhibitor) led to a 
decrease in expression of ABCG2. This combination treatment could be promising for the potential 
reversal of MDR caused by overexpresssion of ABCG2 (Pick and Wiese, 2012, Huang et al., 2011). 
Second generation TKI have also been shown to exhibit inhibitory activity against ABCG2, these 
include EKB-569 (pelitinib), neratinib and vandetanib (Hegedus et al., 2012).  
A recent review summarised the various tyrosine kinase inhibitors which have been shown to 
reverse MDR (He and Wei, 2012). 
 
1.7.3 Tracers and ABC transporter interaction 
As the majority of radiotracers for the imaging of EGFR have been designed on core structures of 
TKIs used in therapy, it is fair to assume that interactions that have been reported for TKI with the 
ABC transporters also exist between TKI based EGFR radiotracers and the ABC transporters. 
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The interaction of the radiolabelled tracer with ABC transporters can have a significant impact on the 
biodistribution of the tracer in vivo especially if the tumour to be imaged expresses high levels of 
these transporters. As radiotracers are injected in pM to nM concentrations, the lack of 
accumulation due to efflux via the ABC transporters will render the tracer unsuitable in the clinic. 
Mishani et al carried out two experiments to investigate the possible interaction between ML04 
radiotracer they developed and the ABCB1 efflux pump (Abourbeh et al., 2007). To find out if ML04 
was a substrate of ABCB1 they investigated the uptake of [11C] radiolabelled ML04 in two cell lines, 
the CEM wild type cell line and its isogenic CEM col1000 cell line which expressed multi drug 
resistant phenotype following sustained colchicine treatment. They found that the uptake of 
radiolabelled ML04 in CEM col1000 cells increased with increasing concentrations of ABCB1 
inhibitor, verapamil. Furthermore, following ABCB1 inhibition, the uptake of ML04 in the 
CEMcol1000 cell line approached that of the wild type CEM cells (Abourbeh et al., 2007). 
These findings are important as they can help in the design of new tracers that have reduced ABCB1 
substrate properties. This would limit the confounding effect of ABC transporters on the in vivo 
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Aims 
Since the cyanoquinoline series of compounds, which were designed for the PET imaging of EGFR, 
were developed, the importance of mutant forms of EGFR and the role these mutations play in 
therapeutic response in NSCLC have emerged. 
1- The first aim of this project was to investigate the previously characterised cyanoquinoline 
compound, FED6, for the imaging of mutant EGFR. Could [18F]FED6 be used to discriminate between 
mutant and WT EGFR ? The ability to image mutant vs WT EGFR could be used alongside histological 
tests to select patients suitable for TKI therapy. 
The cyanoquinoline compounds shared structural similarities with drugs, which have been shown to 
interact with MDR ABC transporters.  
2- The Second aim of this project was to investigate, the substrate specificity of FED6, and other 
members of the cyanoquinoline series (Pisaneschi et al., 2010), for ABC transporters. Is FED6 a 
substrate for the ABC transporters? If so how will this affect PET imaging with [18F]FED6 and can this 
be modulated by inhibiting these transporters? 
One of the most important decisions in oncology therapy is choosing when to change the course of 
treatment of a patient, in order for them to be given the most suitable drugs to which they will 
respond. To help with these decisions, being able to predict the response to therapy at an early 
stage can be crucial.  
3- The third aim of this project was to investigate ChKα as a potential biomarker of response, failure 
of response to gefitinib treatment in NSCLC. Can PET imaging of choline kinase metabolism be used 
to predict early response to TKI treatment in NSCLC? How does [18F]D4Choline compare to other 
radiotracers, [18F]FDG and [18F]FLT for this purpose? 
 
  





Chapter 2: Methods 
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2.1 Chemical structure analysis 
The chemical structures of compounds investigated in this work were drawn using the Chemdraw 
pro 11.0 software (PerkinElmer informatics, Waltham, USA). The hydrophobicity (Log P) and Polar 
surface area (PSA) and pKa: logarythmic value of acid dissociation constants were calculated by 
importing Chemdraw structures into MarvinSketch/Chemaxon online software. 
2.2 Cell culture 
Cell lines used to investigate the ABC transporter substrate specificity included: the breast cancer 
cell line MCF7 and a mitoxantrone drug resistant subclone MCF7MX, which were donated by Dr E. 
Schneider, University of Maryland, USA. Murine fibroblast cell line 3T3, transfected with non 
targeting scramble cDNA and the 3T3 cell line stably transfected with human MDR1 gene (referred 
to as 3T3-MDR1 hereafter) were donated by Dr E. Schietz, St Jude’s Children Research Hospital 
Memphis, TN USA. Caco2 cells used in the transwell assay were purchased from ATCC (Rockville 
USA). Cell lines utilised to investigate the mutational status of EGFR included, NSCLC A549, H1650, 
H358, H1975 and H3255 from ATCC. Dr O. Pardo, Imperial College London, donated PC9 cells, and 
erlotinib resistant derivative PC9ER cells. Cell lines: A549, A431, MCF7, MCF7MX, 3T3 and 3T3-MDR1 
cells, were grown in DMEM growth media (Invitrogen, Carlsbad, USA), supplemented with 1 % 
penicillin/streptomycin and 10 % foetal bovine serum (FBS) (all purchased from Invitrogen ). High 
glucose DMEM supplemented with 20 % FBS 1 % penicillin streptomycin was used for the Caco2 cell 
line. Lung cancer cell lines H358, H1650, H1975, H3255, PC9 and PC9ER were grown in RPMI1640 
(Invitrogen), supplemented with 1 % L-glutamine 1 % penicillin streptomycin and 10 % foetal bovine 
serum (FBS). All cells were grown in a humidified atmosphere, at 37 ◦C and 5 % CO2. When 
confluency of 80 to 90 % was reached, cells were passaged upon addition of trypsin EDTA 
(Invitrogen). The cell lines utilised, along with their EGFR mutation status are summarised in Table 5. 
Table 5: Summary of cell lines used. 
Cell line Source EGFR mutation status Other genes Growth media
H1650 ATCC Del 746-750 PTEN null RPMI
H358 ATCC WT RPMI
A549 ATCC WT k-RAS mutant RPMI
H3255 ATCC L858R RPMI
H1975 ATCC L858R/T790M RPMI
PC9 Dr Olivier Pardo Del 746-750 RPMI
PC9ER Dr Olivier Pardo Del 746-750/T790M RPMI
A431 ATCC WT DMEM
MCF-7 Dr E. Schneider, University of Maryland, USA WT DMEM
MCF-7 MX Dr E. Schneider, University of Maryland, USA WT ABCG2 DMEM
3T3 Dr E. Schietz, TN USA WT DMEM
3T3- MDR1 Dr E. Schietz, TN USA WT MDR1 DMEM  
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2.3 siRNA transfection 
SiRNA transfections were carried out using ON TARGET plus-SMARTpool siRNA or non targeting 
siRNA (Dharmacon, Lafayette, USA). Lipofectamine RNAiMAX (Invitrogen) was the transfection 
reagent used and was prepared as indicated on product protocol. A list of siRNAs used are 
summarised in Table 6. 
Table 6: List of Dharmacon ON TARGET plus- SMARTpool siRNA used 
 
2.3.1.siRNA transfection in 6-well plates 
siRNA transfections were carried out using the reverse transfection method. siRNA was diluted first 
in 1 x siRNA buffer (Invitrogen) then in FCS and antibiotic free opti-MEM media. Lipofectamine 
RNAiMAX (Invitrogen) was separately diluted in FCS and antibiotic free opti-MEM media. The siRNA 
and Lipofectamine were then mixed in a one to one ratio and incubated at room temperature for 20 
min. 
Cells prepared in antibiotic free, L-glutamine and 10 %FCS supplemented DMEM or RPMI were then 
added to the siRNA and Lipofectamine complexes and seeded into 6 well plates. A final 
concentration of siRNA of 25 nM was used for all siRNA’s unless otherwise stated. 
After 24 h media were removed and replaced with DMEM or RPMI containing L-glutamine, 10 % FCS 
and 1 % penicillin streptomycin. Cells were lysed for RNA extraction or protein lysis after 72 h unless 
otherwise stated. 
2.3.2. siRNA in 96-well plates 
Cells were seeded in antibiotic free media in black 96 well plates. On the day of transfection siRNA 
and Lipofectamine were separately diluted in opti-MEM media and then mixed in a 1 to 1 ratio and 
incubated at room temperature for 20 min. The siRNA-Lipofectamine complexes were then added to 
the cells in the 96-well plate. After 24 h, fresh media containing 1 % penicillin streptomycin were 
added to the cells. After 72 h transfection, Hoechst 33324 fluorescent assays were carried out on 
cells as described below (section 2.10). 
siRNA product code
ABCG2 L-009924-00-0005 
SRC L-003175-00-0005   
EGFR L-003114-00-0005 
Scramble (Non-targeting) D-001810-10-05
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2.4 RNA quantification  
2.4.1 RNA extraction  
Cells were seeded in 6 well plates to a confluency of 60 to 80 %. Cells were washed twice, with room 
temperature phosphate buffered saline (PBS). Cells were then lysed, by addition of RLT cell lysis 
reagent, from the RNeasy mini kit (Qiagen,Hilden, Germany).Cells were then scraped and transferred 
into RNase and DNase free tubes. RNA extraction was then performed using the RNeasy mini kit 
(Qiagen), following the product protocol. The concentration of the eluted RNA was assessed by 
measuring the absorbance at 260 nm on the nanodrop ND1000 spectrophotometer (Labtech 
International, UK). Extracted RNA was stored at – 80 ◦C. 
2.4.2 cDNA synthesis 
Five hundred nanograms of RNA were retrotranscribed into cDNA using the QuantiTech reverse 
transcription kit (Qiagen) following the product protocol. cDNA was diluted 1 in 5 with RNase and 
DNase free water and was stored at -20 ◦C. 
2.4.3 RT-PCR 
Real time PCR was carried out using SYBR green rox reagent (Invitrogen). A master mix was prepared 
for each set of primers used as follows:  
10 µL SYBR green buffer 
0.8 µL ROX reagent  
1 µL forward + reverse Primer (10 µM) 
3.2 µL RNase and DNase free H2O 
5 µL of cDNA sample was pipetted into 96 well Microamp, fast optical plate (Applied Biosystems, 
Foster City, USA), to which 15 µL of the master mix was added. Plates were sealed using Optical 
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The thermal cycle profile was: 
 
Steps Temperature Time 
 
Carry over prevention 50◦ C 2 min 
 
PCR activation step  95◦ C 2 min 
40 x( 
Denaturation step 95◦ C 3 sec 
Combined annealing and extension step 60◦ C 30 sec 
 
Samples were run in duplicate. mRNA of interest was normalised to GAPDH mRNA levels and was 
expressed relative to a control sample using the ddCT value (Schmittgen and Livak, 2008). The 
primers used for Q-PCR are summarised in Table 7. 
Table 7: Primers used for Q-PCR 
Gene Compagny Product code
ABCB1 Qiagen(Quantitect primer assay) QT00081928
ABCG2 Qiagen(Quantitect primer assay) QT00073206
ABCC1 Qiagen(Quantitect primer assay) QT00061159
SRC Qiagen(Quantitect primer assay) QT00039326
for 5’CGGAAGTATCCCACCAAGAA 3’
rev 5’ TCCCCAGAGGAAATGAGATG 3’
for 5’ ATCACCATCTTCCAGGAGCG 3’




2.5 Inhibition of EGFR activation  
Inhibition of EGFR activation via FED6 (Dr Pisaneschi, CCIC Imperial college), FED20 (Dr Pisaneschi, 
CCIC Imperial college), and gefitinib (selleck chemicals, Houston, USA) were assessed by measuring 
changes to p-EGFR Y1068 via western blot. 
On day one, cells were seeded in 6 well plates. Cells were serum starved overnight on day two. On 
day three, cells were treated with increasing concentrations of either FED6, FED20 or gefitinib 
prepared in serum-free growth media from a DMSO stock, for 3 h at 37 ◦C. Cells were stimulated by 
addition of 100 ng/mL of EGF for the last 15 minutes of drug incubation. After 3 h, cells were placed 
on ice. Media were removed and cells were washed twice with ice cold PBS. Cell lysates were 
prepared and analysed as described in 2.6.  
2.6 Western blotting 
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2.6.1 Cell lysate preparation  
Cells were grown to 70-80% confluence. Cells were then washed twice in ice cold PBS. Cells were 
lysed by addition of radioimmunoprecipitation assay (RIPA) (Thermo Fisher scientific, Waltham, USA) 
buffer (50 mM Tris-HCl pH 7.2, 150 mM NaCl, 1 % NP40, 1 % sodium deoxycholate, 0.1 % sodium 
dodecyl sulphate). In order to preserve protein phosphorylation and to protect the cell lysates from 
protein degradation, the RIPA buffer was supplemented with 1 X protease and phosphatase inhibitor 
cocktail (1 mm 4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride, 800 nM aprotinin, 50 µM 
bestatin, 15 µM E-64, 5µM EDTA, 20 µM leupeptin, 10 µM pepstatin A; Thermo scientific). Cells were 
detached using a cell scraper, collected into an eppendorf and placed on ice. Samples were then 
sonicated for 30 seconds on ice. Levels of protein were assessed by carrying out a bicinchonidic acid 
(BCA) protein assay as indicated in user’s manual(Thermo Fisher scientific).  
2.6.2 Sample processing 
 
Protein lysates were prepared by addition of 10 x reducing agent (Invitrogen) and 4x NuPAGE® LDS 
Sample Buffer (4X) (lithium dodecyl sulphate) (Invitrogen) to give a final volume of 200 µL. The 
protein lysates were then denatured by heating for 10 minutes at 70 ◦C. Unless otherwise stated 
15 µg of the protein samples were separated using SDS-polyacrylamide gel electrophoresis (SDS-
PAGE). For this 4/15 % polyacrylamid Mini-PROTEAN TGX precast gels (Bio-Rad, Hercules, USA) were 
used. Samples were transferred to polyvinylidene difluoride (PVDF) membrane using Trans-Blot 
Turbo system from BIO-RAD. Membranes were blocked with 5 % milk or 5 % bovine serum albumin 
(BSA) (Sigma-Aldrich, St Louis, USA) in tris-buffered saline tween 20 (TBST, 50 mM Tris, 150 nM NaCl, 
0.05 % tween 20) according to manufacturers guidance for each antibody utilised, for 1 h at room 
temperature. The membranes were then incubated overnight with primary antibody prepared in 1 % 
milk or 1 % BSA in TBST. Table 8 summarises the antibodies used. After overnight incubation, 
membranes were washed three times for 10 minutes with TBST before incubating with secondary 
goat anti-rabbit or goat anti-mouse antibody at 1/2000 dilution for 1 h at room temperature. 
Membranes were washed a further three times for 10 minutes with TBST. Blots were visualized 
using chemoluminescence ECL (GE Healthcare, Little Chalfont, UK) and exposed on Amersham 
Hyperfilm ECL (GE healthcare). Unless otherwise specified, β-Actin was used as a loading control. 
 
Densitometry  
Intensity of the protein bands were obtained using GS-800 calibrated densitometer (BioRad). 
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To evaluate EGFR inhibition via FED6, FED20 or gefitinib densitometry values of p-EGFR (Y1068) were 
obtained, normalised for levels of EGFR then plotted against the concentration of compound using 
the sigmoid curve fit with variable slope in GraphPad prism (version 5.01, La Jolla, USA). 
The concentration of compound causing 50 % inhibition of p-EGFR (Y1068) (IC50) were obtained for 
each experiment. 
 
Table 8: Source and working dilutions of antibodies used. 
Antibody Source Blocking agent Dilution 
EGFR Cell signalling 5 % milk TBST 1 in 2000 
p-EGFR Y1068 Cell signalling 5 % BSA TBST 1 in 1000 
SRC Cell signalling 5 % milk TBST 1 in 5000 
p-SRC Y416 Cell signalling 5 % BSA TBST 1 in 3000 
Chkα Sigma 5 % milk TBST 1 in 1000 
p-AKT Cell signalling 5 % BSA TBST 1 in 2000 
AKT Cell signalling 5 % milk TBST 1 in 2000 
p-ERK Cell signalling 5 % BSA TBST 1 in 2000 
ERK Cell signalling 5 % milk TBST 1 in 2000 
GLUT1 Cell signalling 5 % milk TBST 1 in 1000 
TK1 Abcam 5 % milk TBST 1 in 1000 
Na+/k+ ATPase Abcam 5 % milk TBST 1 in 5000 
ABCG2 Abcam 5 % milk TBST 1 in1000 
ABCB1 Abcam 5 % milk TBST 1 in 1000 
β-Actin  Sigma 5 % milk TBST 1 in 5000 
Cell-signalling, Ipswich, USA; Abcam,Cambridge,UK 
2.7 Cell viability assay 
2.7.1 General protocol 
A sulforhodamine B (SRB) assay was carried out to assess cell growth and cytotoxicity of tested 
compounds on cells (Skehan et al., 1990). This assay was carried out in 96 well plates. Cells were 
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seeded at densities of 3500 to 5000 cells per well for 24 h. Cells were then treated with drugs for 72 
h, at 37 °C unless otherwise specified. After drug treatment, cells were fixed by addition of 50 % 
trichloroacetic acid (TCA) for 1 h at 4 ◦C. Plates were washed ten times with tap water and left to dry 
on the bench. Cells were then stained with a 0.4 % solution of sulforhodamine B (Sigma) in 1 % 
acetic acid for 30 minutes. Excess dye was removed upon washing with 1 % acetic acid (Sigma) 
solution four times. Plates were dried and bound protein was solubilised upon addition of 150 µL of 
10 mM Tris base buffer. Absorbance was measured at 540 nm using Thermo Multiskan-Ex plate 
reader. 
2.7.2 Cell viability assay with drug pre-treatment 
Cells were seeded on 96 well plates. 1 h prior to drug treatment, MCF7MX and MCF7 cells were pre-
treated or not with 10 µM fumitremorgin C (FTC) (Sigma), 3T3 and 3T3-MDR1 with or without 
0.3 µM of zosuquidar (Selleck Chemicals) and A549 with or without 50 µM of MK-571 (Enzo life 
science). Cells were then treated with drug for 72 h. After 72 h, the SRB assay protocol was carried 
out as described above. 
2.7.3 Data analysis 
Cell viability vs compound concentration curves were plotted as a percentage of control cells. The 
concentration of drug that gave 50 % inhibition in cell growth (GI50) was extrapolated from these 
curves using the sigmoid curve fit with variable slope in GraphPad prism (version 5.01, La Jolla 
California, USA). Three to six replicate wells were used for each drug concentration and experiments 
were carried out on three separate occasions for each compound. 
For the SRB assays carried out to investigate the ABC transporter substrate specificity, ratios of GI50 
of the paired cell lines were carried out. A ratio of the GI50’s was carried out for each experiment and 
used to compute the mean ratio. 
2.8 EGFR tyrosine kinase enzyme inhibition assay 
The inhibitory activity of FED20 against EGFR kinase activity was measured using a fluorescence 
assay (DELFIA, Perkin–Elmer Life Sciences, Boston, MA, USA). FED20 was serially diluted in DMSO. 
FED20 was incubated with EGFR protein (E-3641, Sigma) and a kinase buffer for 15 min at room 
temperature in accordance with manufacturer’s instructions (DELFIA Tyrosine kinase kit; Perkin–
Elmer). The kinase reaction was started by addition of 25 µM ATP, 25 mM MgCl2, and 0.25 µM/L of 
biotinylated poly (Glu, Ala, Tyr) in 10 mM HEPES buffer, pH 7.4. The samples were kept at room 
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temperature for 1 h. The reaction was stopped by addition of 100 mM EDTA. The enzyme reaction 
solution was diluted 1 in 20 in assay buffer (provided in the kit) and 200 µL were added to 96-well 
ELISA streptavidin coated plates. The plates were washed three times with washing buffer. Europium 
labelled antiphosphotyrosine antibody (PT66; Perkin–Elmer) was added at a concentration of 50 ng 
per well. Plates were washed six times with washing buffer. 200 µL of enhancement solution was 
added per well and fluorescence measured on Victor3 multi-label counter (Perkin–Elmer) using the 
Europium protocol. Percentage inhibition of receptor phosphorylation activity over concentration of 
FED20 curve was plotted. The concentration of compound that inhibited 50 % of receptor 
phosphorylation activity (IC50) was estimated by non-linear regression analysis using GraphPad 
Prism. IC50 of other cyanoquinoline compounds have previously been determined (Pisaneschi et al., 
2010). 
2.9 Calcein-AM assay  
Cells were seeded in black 96 well plates. On day two cells were treated with an increasing 
concentration range of zosuquidar (Selleckchem) (up to 3 µM) or MK-571 (Enzo life science) (up to 
100 µM) in 3T3-MDR1 or A549 cells, respectively. DMSO was used as a control. After 1 h incubation 
at 37 ◦C cells were treated by addition of Calcein-AM (Sigma) at a final concentration of 250 nM per 
well and incubated for 30 minutes at 37 ◦C. Calcein-AM is taken up by the cells and hydrolyzed by 
esterases into a green-fluorescent molecule: Calcein. Calcein is cell membrane impermeable and 
therefore trapped in the cell. One of the properties of Calcein AM is its substrate specificity to ABCB1 
and ABCC1 (Hollo et al., 1994, Limtrakul et al., 2007). Reaction was stopped by placing cells on ice. 
Cells were washed twice by addition of 100 µL per well of cold PBS. Finally, 150 µL PBS was added 
per well and fluorescence measured at an excitation wavelength of 485 nm and an emission of 535 
nm using the Victor3 multi-label counter plate reader. 
2.10 Hoechst 33324 uptake assay. 
Cells were seeded in black 96 well plates. On day two cells were pre-treated with either gefitinib, 
FTC or FED6 and DMSO as control for 1 h or at 37 ◦C. Cells were then treated by addition of Hoechst 
33324 (Sigma, UK) at a final concentration of 3 µM per well and incubated for 30 minutes at 37 ◦C. 
One of the properties of Hoechst 33324 is its substrate specificity for ABCG2. Hoechst 33324 dye will 
therefore be effluxed out of cells that overexpress ABCG2 (Scharenberg et al., 2002). 
The reaction was stopped by placing cells on ice. Cells were washed twice by addition of 100 µL per 
well of cold PBS. Finally, 150 µL PBS was added per well and fluorescence measured at an excitation 
wavelength of 355 nm and an emission of 460 nm using the Victor plate reader. Cells were then 
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fixed by addition of 50 % TCA (Sigma). An SRB assay was then carried out. Fluorescent values were 
normalised to protein levels using the absorbance values from the SRB assay. 
2.11 Caco2 transwell assay. 
 
Figure 14: Schematic of transwell and transporter localisation on a Caco2 cell. 
Following differentiation Caoc2 cells will express ABCB1 and ABCG2 transporters on the apical side and ABCC1 on the basal 
side of the cell. 
 
2.11.1 Transwell preparation. 
Caco2 cells were seeded at a density of 60,000 cells per well in a 24 well transwell plate (Millipore, 
Billerica, USA), and maintained in DMEM supplemented with 4.5 g/mL glucose (20 % FBS, 1 % 
Penicillin streptomycin, 1 % glutamine) for 21 days at 37 ◦C in 5 % CO2. After 21 days the cells 
differentiate into enterocytes and express all three MDR proteins, ABCB1 and ABCG2 at the apical 
side and ABCC1 on the basal side (Figure 14). The caco-2 monolayer and the orientation of the 
transporters resemble that of the intestinal epithelial layer where the transporters have a protective 
role, effluxing xenobiotics into the gut lumen for excretion (Sarkadi et al., 2006). 
On day 21, cells were washed three times with Hank's Balanced Salt Solution (HBSS) (Thermo-Fisher 
scientific) and the trans-epithelial electric resistance (TERR) was measured using an Epithelial 
Voltohmmeter (EVOM) (World Precision Instruments, Sarasota, USA); only transwells with TERR of 
400 Ω/cm2 or above were used for the experiment. 
Cells were treated either at the apical (n = 3) or basal (n = 3) side of the transwell by addition of 
10 µM of cyanoquinoline compound or 50 µM vinblastine prepared in a volume of 400 µL HBSS 
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When transport inhibitors FTC (10 µM) and zosuquidar (0.3 µM) were utilised they were added to 
both the apical and basal wells 1 h prior to drug treatment. After 1 h pre-treatment media was 
removed from the wells and cells were treated with the compounds prepared in HBSS containing 
FTC or Zosuquidar. 
Plates were then incubated in a shaker incubator at 37 ◦C and 60 rpm for 120 minutes. After 
incubation, 400 µL samples from the apical and the basal wells were collected and analysed using 
high protein liquid chromatography (HPLC). 
 
2.11.2 HPLC analysis 
In order to determine the amount of compound in the apical and the basal side of the transwell 
plates, high protein liquid chromatography (HPLC) was used. Samples were run on a Millipore 
Waters HPLC system which included a 717 plus autosampler and 2487 dual wavelength absorbance 
detector system. The stationary phase comprised a Phenomenex Luna C18 (2) reverse phase column 
(150 X 4.6 mm; 5 µm particle size.) The mobile phase comprised 0.1 % trifluoroacetic acid (TFA) and 
acetonitrile 0.1 % TFA (80:20 v/v) at a flow rate of 1 mL/min for all compounds except vinblastine. 
For vinblastine, the stationary phase comprised a Supelcosil LC-ABZ reverse phase column (5 X 4.6 
mm; 5 µm particle size). The mobile phase comprised 0.1 % formic acid and methanol. (90:10 to 
10:90 v/v gradient). 
2.11.3 Data analysis 
Peak areas corresponding to the compounds of interest were recorded. Using a standard curve, peak 
areas under the curve were converted into concentrations of compound. The permeability 
coefficient (Paap) was calculated using the following equation (Artursson and Karlsson, 1991): 
Papp = (dQ/dt)/A C0 
Where A is the surface area of the transwell membrane in cm2 (= 0.33 cm2), C0 is the drug 
concentration in the donor chamber at time t = 0 and dQ/dt is the rate of transfer of the compound 
to the receiver chamber, determined from the slope of the graph of concentration (dQ) versus time 
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Where B is the concentration of compound in the receiver chamber at time t = 7200 sec (120 
minutes) and C is the concentration of compound in the receiver chamber at time t = 0. T is the time 
of transfer T = 7200 sec. As no compound is added to the receiver chamber at t = 0 C = 0. The 







Papp values corresponding to absorption and secretion were calculated and used to calculate efflux 
ratios.  
              
          
          
 
Where Papp B-A = Papp secretion and Papp A-B = Papp absorption. 
2.11.4 Membrane integrity 
The integrity of the Caco2 cell membrane was accessed for each well following the experiment by 
addition of a 100 µM solution of luciferase yellow (sigma) in HBSS to the apical side of the plate. The 
plates were placed in a shaker incubator for 1 h at 37 ◦C and 60 rpm. Samples from the basal wells 
were transferred into a 96 well plate and the levels of luciferase yellow were assessed by measuring 
with an excitation of 450 nm and an absorbance of 540 nm using the PerkinElmer Wallac 1420 
multilabel counter. The membrane was considered intact if levels of fluorescence in the basal side 
were inferior to 2 % of levels measured in the apical side. 
2.12 Caspase glow assay 
Levels of apoptosis, following drug treatment were established by carrying out a Caspase 3/7-Glo 
assay (Promega, Fitchburg, USA). This luminescence assay kit, measures levels of activity of caspase 
3 and 7, both of which play a key role in apoptosis (Taylor et al., 2008). 
The kit includes a proluminescent substrate, which contains a DEVD peptide and an ultraGlow 
luciferase enzyme. Upon cleavage of the substrate via cellular caspases amnioluciferin is released 
and reacts with luciferase to emit light. The light emitted is proportional to the activity of caspase 3 
and 7. Cells were seeded in white 96-well plates. Following drug treatment, levels of apoptosis were 
measured by carrying out a caspase 3/7glow assay. Caspase Glow reagent (Promega) was added to 
cells in a 1:3 (v/v) ratio, and incubated at room temperature for 1 h. The luminescence was then 
measured using a luminometer (TopCount NXT, Packard Instruments, Meriden, USA). Media alone 
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plus caspase reagent was used to correct for background luminescence. Luminescence values were 
normalised to protein levels by undertaking an SRB cell viability assay, in parallel to the caspase glow 
assay. Four to six replicates were carried out for each condition and experiments were repeated 
twice. 
2.13 Cell cycle analysis via flow cytometry using propidium iodide 
The distribution of cells within the different phases of the cell cycle, were assessed by performing 
DNA staining with propidium iodide (PI). Stained cells were then analysed via Flow cytometry. 
Cells were seeded in 6 well plates. On day two, cells were treated with gefitinib or DMSO as control. 
After 6, 24 or 48 h treatment the supernatant was collected. Adherent cells were trypsinised and 
combined to the supernatant before centrifugation to obtain a cell pellet. Cells were resuspended in 
1 mL of ice cold PBS, which was then added drop by drop to 9 mL of 70 % ethanol, in order to fix the 
cells. Samples were then incubated at -20 ◦C overnight. Cells were centrifuged at 600 g and the 
supernatant was discarded. The cell pellet was rehydrated in PBS for 15 minutes before being 
stained with PI staining buffer containing: 100 mM Tris (pH 7.4), 150 mM NaCl, 1 mM CaCl2, 0.5 mM 
Mg Cl2, 0.1 % Triton-X, 0.1 mg/mL RNase A and 25 µg/mL PI. Cells were incubated in staining buffer 
for 3 h at 37 ◦C. Cells were then analysed using a BD FACS Canto cytometer (BD, Oxford, UK). Cell 
debris and doublets were excluded by performing gating of the samples. For each condition 10,000 
cells were counted.  
Data analysis was performed using FlowJo software version 7.6.5 (Treestar, Ashland,.USA) 
2.14 Radiopharmaceuticals 
[18F]FDG and [18F]FLT were both purchased from PETNET solutions (Nottingham, UK).[3H]Choline was 
purchased from PerkinElmer (Waltham, USA). 
[18F]FED6 was produced by Dr. Pisaneschi from the Comprehensive Cancer Imaging Centre, Imperial 
College London, as described in (Pisaneschi et al., 2010). [18F]FED20 was synthesised by Dr.Pisaneschi 
using “Click” radiochemistry using a method adapted from Maschauer et al (Maschauer and Prante, 
2009).  
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2.15 Cell uptake assay 
2.15.1 [3H]choline  
 
In order to assess the activity of ChK, [3H]choline uptake experiments were carried out in PC9 and 
PC9ER cells. These assays measure the transport and phosphorylation of choline in whole cells. 
 Whole cell [3H] choline uptake 
Cells were seeded in 6 well plates. Following drug or siRNA treatment the [3H]choline uptake 
experiment was carried out. A volume of 100 μL of media, containing 3.7 KBq of [3H]choline (Perkin-
Elmer), was added per well and cells were incubated at 37 ◦C for 1 h. Supernatant containing floating 
cells was collected and a cell pellet was obtained via centrifugation. Cells in plates were washed 
twice with room temperature PBS. Cells were then trypsinised and collected. Cells were centrifuged 
for 3 minutes at 2000 RPM to obtain a cell pellet. The cell pellet was washed once with PBS and then 
resuspended in 200 µL of RIPA buffer. One hundred and fifty microliters of cell lysate was then 
transferred to a scintillation tube to which 4 mL of Ultima Gold™ XR scintillation cocktail (Perkin 
Elmer) was added. Scintillation counts were acquired on a LS6500 multipurpose scintillation counter 
(Beckman Coulter, Pasadena, USA) using a 5 minute accession. Scintillation values in counts per 
minute (CPM) were then normalized to total protein using Pierce® BCA Protein Assay Kit (Thermo 
Scientific) which was carried out on the remaining 50 µL of cell lysate. 
Experiments were carried out at least three times using triplicates of samples for each experiment.  
 
 [3H]Phosphocholine extraction 
Phosphocholine formation was assessed using a modified Bligh and Dyer extraction as described in 
(Sebastian Trousil, 2013). Cells were seeded in 6 well plates. Following drug treatment [3H]choline 
uptake experiment was carried out. A volume of 100 μL of media, containing 37 KBq of [3H]choline, 
was added per well and cells were incubated at 37 ◦C for 1 h. Supernatant and any floating cells were 
collected and cell pellet obtained via centrifugation. Cells were washed twice with room 
temperature PBS. Cells were then trypsinised and collected. Any further reaction was stopped by 
addition of 750 µL of a 2:1 ratio of methanol/chloroform. After 10 minutes, incubation at room 
temperature cells were transferred to a microcentrifuge tube and 200 µL of H20 was added. Cells 
were centrifuged at 200 g for 10 minutes. The aqueous upper phase, 750 μL, was transferred to a 
new tube to which 250 μL of chloroform and 250 μL of H2O were added and samples vortexed and 
centrifuged. 650 μL of the upper aqueous phase was transferred to a fresh microcentrifuge tube to 
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which 500 μL of 12 mM sodium phosphate (pH 7.0) and 750 μL 5 mg/mL tetraphenylborate (TPB) 
(Sigma) in heptan-4-one (Sigma) was added. Samples were vortexed and centrifuged. The upper 
phase, containing the choline was discarded. Residual choline was re-extracted from the lower 
phosphocholine phase with 500 μL TPB. After vortexing and centrifugation, 200 μL of the lower 
aqueous phase was added to 4 mL of Ultima Gold™ XR scintillation cocktail and scintillation 
measured on scintillation counter. Scintillation values were then normalised to total protein using 
Pierce® BCA Protein Assay Kit (Thermo Scientific) which was carried out on parallel processed 
samples. Experiments were carried out a minimum of three times using triplicates of samples for 
each experiment. Method summarised in Figure 15. 
 
Figure 15: Schematic of phosphocholine extraction. 
Following 1 h incubation with [
3
H]Choline the phosphocholine component was extracted as described in this diagram.TPB: 
Tetraphenylborate;Pcho: phosphocholine;Cho: Choline Aqu: Aqueous 
 
2.15.2 [18F] uptake experiments  
 
Cells were seeded in 6 well plates. Cells were seeded in complete medium with the exception of the 
FED20 blocking experiment and the uptake assays in the NSCLC using [18F]FED6 and [18F]FED20, for 
which cells were serum starved overnight and stimulated upon addition of 100 ng/mL of EGF 15 
minutes before incubation with radiotracer. On the day of the cell uptake, cells which had been pre-
treated or not, were incubated for 1 h at 37 °C upon addition of [18F]FED6 (Imanova, London, UK), 
[18F]FDG (PETNET, Nottingham, UK) or [18F]FLT (PETNET, Nottingham, UK) or [18F]FED20 (Imanova, 
London, UK), at 0.37 MBq well (unless otherwise stated). Following incubation, the medium was 
removed and cells were washed twice by addition of 500 µL of room temperature PBS. Cells were 
then trypsinised and collected. Cells were centrifuged for 3 minutes at 2000 RPM to obtain a cell 
pellet. The cell pellet was washed once with PBS. The cell pellet was then resuspended in 200 µL of 
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RIPA buffer. Cell lysates were transferred to gamma counting tubes. The radioactivity in the pellet 
was measured on a (Packard 109 cobra II gamma counter, Perkin-Elmer). 
Following radioactive decay, protein concentrations of the samples were evaluated using Pierce® 
BCA Protein Assay Kit (Thermo Fisher Scientific). Data were decay corrected and expressed in 
corrected counts per minute acquired (CCPMA) per µg of protein.  
2.16 In vivo 
2.16.1 Tumour inoculation  
Cells were grown as described in 3.1. Fresh media were added to the cells the night before tumour 
inoculation. Cells were trypsinised, then centrifuged and resuspended in PBS. 6 to 8 week old BALB/c 
nu/nu female mice from (Harlan UK Ltd, Bicester, United Kingdom) were injected with 5 x 106 A431, 
H1650 or A549 Cells, 2 x 106 PC9 cells or 3.5x106 PC9ER cells. Cells were injected as a suspension in 
100 µl of PBS subcutaneously on the back of the neck. Tumour volumes were assessed by caliper 
measurement every other day. Volume was calculated using the following equation  




Where w is the width, l the length, and h the height of the tumour. 
2.16.2 Positron emission tomography imaging 
The different schematics of drug treatment for the different PET studies which were carried out are 
shown in Figure 16. Vehicle was 0.4 % tween 20 PBS. Gefitinib was prepared by diluting powdered 
gefitinib (selleck Chemicals) in 0.4 % tween 20 PBS and homogenised by vortexing and sonicating 
briefly. 
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Figure 16: Schematic of drug treatments before PET scan 
A- Scheme used for A431 xenografts which were pre-treated with gefitinib 1 h prior to performing [
18
F]FED6 PET scan. B-
Scheme used for PC9 and PC9ER xenografts scanned before treatment or after 48 h of vehicle or 50 mg/kg of gefitinib with 
[
18
F]FLT or after 48 h of vehicle or 50 mg/kg of gefitinib with [
18
F]D4choline. C-Scheme used for PC9 and PC9ER xenografts 
scanned with [
18
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Female BALB/c nu/nu mice bearing xenografts with tumours of an average size of 100 mm3 were 
imaged by positron emission tomography. All animals were scanned on a small animal CT/PET 
scanner (Siemens Multimodality Inveon, Siemens Molecular Imaging Inc., Knoxville, USA). During this 
procedure, mice were anesthetized using 2.5 % isoflurane. A CT scan was first carried out and these 
data were later used to correct for attenuation of the PET data; 3.7 MBq of [18F]FED6, [18F]FDG, 
[18F]FLT or [18F]D4choline was injected as a bolus solution in PBS via a cannular to the tail vein. 
Dynamic emission scans were acquired in list-mode format over 60 minutes. 
Cumulative images of the dynamic data were reconstructed by an iterative (OSEMD3D) method and 
used for visualization of radiotracer uptake to define the regions of interest (ROIs) with the Siemens 
Inveon Research Workplace software (IRW; Siemens, Frimley, UK). Three-dimensional ROIs were 
defined for each tumour. Time-activity curves (TACs) were obtained from these ROI. Tumour TACs 
were then normalized to the total injected dose (ID) to obtain the normalized uptake value 
expressed as % ID/mL. Area under the curve (AUC) measurements were calculated. These 
corresponded to the area under the curve of the TAC of the tumour. Normalised uptake values at 60 
min (NUV60) were also determined and corresponded to the uptake of radiotracer in the tumour at 
time t = 60 min after the start of the PET acquisition. Two other parameters were determined. These 
were, the highest mean quartile of tracer uptake in the tumour and the fractional retention of the 
tracer (FRT). The highest quartile of tracer uptake was determined by selecting values corresponding 
to the tumour voxels, from the 30 to 60 min time frames, then ordering them and calculating the 
average of the highest quartile for each tumour. The FRT was calculated as the uptake of the tracer 
in the tumour at 60 min over the uptake of the tracer at 3.5 min. A minimum of n = 3 mice per 
cohort for [18F]FED6 studies and n = 4 mice per cohort for [18F]FDG, [18F]FLT or [18F]D4choline studies 
were imaged. These numbers of animals were used to obtain initial estimates of drug effect on 
radiotracer tumour location. 
All animal work was performed according to the United Kingdom’s “Animals (scientific Procedures) 
Act 1986“(Workman et al., 2010). 
 
2.16.3 Biodistribution 
A biodistribution was carried out for the A431 xenograft study. At the end of the PET scan, animals 
were sacrificed; blood was obtained via cardiac puncture. Tissues (21 in total), were collected from 
the animal and the radioactivity of each tissue was measured in a gamma counter. Tissues were 
weighed and radioactivity in each tissue was expressed as CCPMA/µg tissue. 
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2.16.4 Tumour lysate preparation 
Following PET imaging tumours were collected and divided in two sections. One section was 
preserved in 10 % formalin for immunohistochemistry processing, while the other was snap frozen in 
liquid nitrogen and stored at - 80◦  C.  
The snap frozen tumour sections were used to prepare protein lysates for western blot analysis. 
Briefly, tumour sections were transferred to Precellys® CK14 ceramic bead containing tubes (Bertin 
Technology,Toulouse, France) along with RIPA buffer supplemented with 1 X protease and 
phosphatase inhibitor (Thermo scientific). Tumour samples were homogenised using the Precellys® 
24 tissue homogeniser (Bertin Technology) at 5000 RPM for 2 x 30 sec. Samples were then 
centrifuged for 5 min at 4 ◦C to obtain a supernatant. The supernatant was then sonicated for 2 x 30 
sec and protein concentration was assessed by carrying out a BCA assay. Samples were then 
processed for western blot analysis as described in section 2.6.2 and 2.6.3. 
2.17 Statistics 
Unless otherwise specified data were expressed as mean ± standard error. After testing that the 
data were normally distributed, data were compared using an unpaired, two tail Student’s t-test 
(Prism 3.03 software, GraphPad). Data that showed statistical significant differences, were indicated 
with one (p value ≤ 0.05) or two (p value ≤ 0.01) stars. The in vivo work consisted of pilot studies, 
power tests estimating the number of animals to be used in the PET studies would be carried out for 
complete studies. 
  





Chapter 3: Imaging mutant EGFR with [18F]FED6 
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As described in chapter 1, a series of cyanoquinoline compounds have previously been developed in 
the group for the imaging of EGFR. One member of this family of compounds, FED6, has been 
radiolabelled and was shown to give rise to higher levels of uptake in A431 (EGFR overexpressing) 
xenografts compared to HCT116 (low EGFR) xenografts (Pisaneschi et al., 2010). Before examining 
the potential of labelled FED6 to discriminate mutant forms of EGFR the interaction of FED6 for WT 
EGFR was further confirmed. 
3.1 Binding of [18F]FED6 to EGFR overexpressing cells 
To verify the results of the initial FED6 study indicated above, we first asked the question, can FED6 
discriminate cells with differing levels of EGFR. To address this, the uptake of [18F]FED6 was 
measured in EGFR overexpressing A431, and low EGFR expressing MCF7 cells (Figure 17A). The 
uptake of [18F]FED6 was 3.5 fold higher in A431 cells than in MCF7 cells (Figure 17 A). Higher 
expression of both p-EGFR (Y1068), which corresponds to active EGFR and EGFR in A431 compared 
to MCF7 cells was confirmed by western blot (Figure 17B). To verify if the difference in [18F]FED6 
uptake between A431 and MCF7 cells was EGFR related, the protein was silenced by siRNA. There 
was a 50 % decrease in the uptake of [18F]FED6 at 72 h after treatment with EGFR siRNA compared 
to scramble treated A431 cells (Figure 17C). Finally, specificity of the radiotracer was further 
assessed with a blocking study, which involved pre-treatment of A431 cells with 10 µM of non-
radiolabelled FED6. Rather than an expected decrease, a 4.5 fold increase in uptake of [18F]FED6 was 
measured (Figure 17C). Western blot analysis confirmed a decrease in p-EGFR (Y1068) expression 
following both FED6 and EGFR siRNA pre-treatment, and a knock down of EGFR following siRNA 
treatment (Figure 17D). 
These uptake experiments suggested that [18F]FED6 was sensitive for EGFR expression, binding with 
higher affinity to EGFR overexpressing cells than to low EGFR expressing cells. Transfection with 
EGFR siRNA also confirmed the sensitivity of FED6 for EGFR. There appeared to be a component of 
non specific binding, as indicated by relatively high residual uptake of [18F]FED6 in the A431 cells 
after EGFR siRNA transfection, although the outcome could be explained in part by the incomplete 
knockdown of EGFR in this cell line. However, the increase in tracer uptake following pre-treatment 
with non radiolabelled FED6 goes against the other findings and warrants further investigation. 
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Figure 17: In vitro uptake of [18F]FED6 following EGFR siRNA treatment. 
A- Protein normalised uptake of [
18
F]FED6 in MCF7 and A431 cells following 1 h incubation with 0.37 MBq [
18
F]FED6. 
B- Protein expression of p-EGFR (Y1068) and EGFR in MCF7 and A431 cells. C- Protein normalised uptake of [
18
F]FED6 in 
A431 cells following 1 h incubation with 0.37 MBq [
18
F]FED6 after 72 h transfection with 25 nM EGFR or scramble siRNA or 
1 h pre-treatment with 10 μM FED6. D- p-EGFR (Y1068) and EGFR protein expression in A431 cells following EGFR or 
scramble siRNA treatment. Data show mean ± SE of triplicate from one representative experiment carried out twice. Stars 
indicate statistical difference between values of two-tailed unpaired t-test (* p ≤ 0.05 **p ≤ 0.01). 
 
Since the cyanoquinoline compounds were designed, the significance of the mutational status of 
EGFR, particularly in NSCLC, has emerged. In fact, mutational status has been shown to play an 
important role in the therapeutic response of NSCLC patient (Mok et al., 2009). Patients expressing 
active mutant forms of EGFR show greater response to TKI treatment compared to patients 
expressing wild type EGFR. With this in mind, having confirmed the sensitivity of FED6 for EGFR, 
FED6 was investigated in the context of binding to mutant EGFR. 
3.2 Sensitivity of wild type and active mutant EGFR expressing NSCLC to FED6 
In order to assess the cyanoquinoline molecule, FED6, as a probe for the imaging of mutant vs WT 
EGFR, the affinity of FED6 for WT and del 746-750 active mutant EGFR, was measured and compared 
with the affinity of gefitinib in a cell based setting. As a proxy for receptor affinity, the inhibitory 
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which both expressed WT EGFR and H1650 that expressed del 746-750 EGFR. The inhibition of EGFR 
activation was measured following 3 h of gefitinib or FED6 treatment by measuring the 
phosphorylation of tyrosine 1068 which is involved in the autophosphorylation and activation of 
EGFR (Downward et al., 1984a). 
The active mutant EGFR, H1650 cell line, constitutively expressed activated EGFR, as indicated by the 
presence of p-EGFR (Y1068) in unstimulated conditions (Figure 18A). This was in opposition to wild 
type expressing EGFR cell lines, A549 and H358, which only expressed p-EGFR (Y1068) upon EGF 
stimulation. The densitometry measurements from the blots were used to determine the 
percentage inhibition of p-EGFR (Y1068) (Figure 18B). The IC50 values obtained from these plots were 
tabulated in Figure 18C. The IC50 value of gefitinib was highest in the A549 cells at 0.4 μM compared 
to 0.08 and 0.1 in H358 and H1650 cells, respectively (Figure 18C1). The IC50 value of gefitinib in the 
H1650 cells expressing del 746-750 mutant EGFR, was not significantly different to the IC50 values 
measured in WT EGFR cells lines. As previously reported in the literature despite expressing del 746-
750 mutant EGFR, H1650 cells were resistant to gefitinib (Sos et al., 2009). In contrast, the IC50 of 
FED6 was over 10 fold lower in the del746-750 mutant EGFR expressing H1650 cell line with a value 
of 0.04 μM compared to 0.72 μM and 0.65 μM in WT EGFR expressing A549 and H358 cell lines, 
respectively (Figure 18C2). 
In summary, gefitinib appeared more active at inhibiting EGFR compared to FED6 in WT EGFR 
expressing cells lines, and this was illustrated with lower IC50 values. However, FED6 appeared more 
selective for mutant EGFR. 
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Figure 18: Inhibition of EGFR activation in WT and del 746-750 mutant EGFR expressing cells 
following gefitinib and FED6 treatment. 
A- Western blots showing the changes in phosphorylation of EGFR at tyrosine 1068 following gefitinib (A1) or FED6 (A2) 
treatment. B- Percentage inhibition of p-EGFR (Y1068) normalised to EGFR levels following gefitinib (B1) or FED6 (B2) 
treatment determined from densitometry of western blots. C- Table summarising the average IC50 values ± SE, obtained 
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To investigate whether the increased affinity of FED6, for del 746-750 EGFR, compared to WT EGFR, 
would translate into preferential binding of [18F] radiolabelled FED6 in active mutant EGFR 
expressing cells, the uptake of [18F]FED6 was measured in these cells. 
3.3 [18F]FED6 in vitro and in vivo uptake in A549 vs H1650 
In order to assess the binding of [18F]FED6 to mutant and WT EGFR, a cell uptake assay in A549, H358 
and H1650 cells was carried out. After 1 h incubation with [18F]FED6, H358 cells showed the highest 
levels of uptake of [18F]FED6, over 80 CCPMA/μg of protein. The uptake in the A549 cells was 25 
CCPMA/μg of protein, 2.5 times higher than the uptake in the H1650 cells which was 10 CCPMA/μg 
of protein (Figure 19A). The expression of both p-EGFR (Y1068) and EGFR were highest in the A549 
cells compared to H1650 and H358 cells, as indicated by the western blot and corresponding 
densitometry in Figure 19BC. Therefore, the higher uptake of [18F]FED6 in the H358 cells was not 
related the level of expression of EGFR.  
 
Figure 19: In vitro uptake of [18F]FED6 in H1650, H358 and A549 cells. 
A- [
18
F]FED6 uptake in H358, A549 and H1650 cells following 1 h incubation with 0.37 MBq of [
18
F]FED6. Data show mean 
values of corrected counts per minute acquired per µg of protein ± SE of triplicate samples from one representative 
experiment carried out three times. Stars indicate statistical difference between values of two-tailed unpaired t-test 
(**p≤ 0.01).B- Differential protein expression of p-EGFR (Y1068) and EGFR in H358, A549 and H1560 cells. C- Densitometry 
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Furthermore, higher affinity of FED6 for del 746-750 EGFR (Figure 18C2) did not correspond to 
higher uptake of [18F]FED6 in del 746-750 EGFR expressing H1650 cells (Figure 19A). 
 
Following the in vitro uptake of [18F]FED6 and to establish that the effects seen were not simply due 
to an in vitro artefact, the uptake of [18F]FED6 in xenograft models of the cell lines studied was 
undertaken via PET imaging. Imaging studies of the H358 xenografts could not be completed, as 
these tumours became extensively angiogenic, and formed pockets of blood, as soon as the tumour 
volumes reached 30 to 40 mm3. PET imaging of A549 and H1650 xenografts was therefore carried 
out. Both H1650 and A549 mouse xenograft were injected intravenously via the tail vein with 3.7 
MBq of [18F]FED6 and underwent a 60 min dynamic PET scan. The result of the PET scan are 
summarised in Figure 20. The sagittal images indicated that the uptake of [18F]FED6 in the tumours, 
marked by white arrows, was relatively low compared with a high uptake in the gastrointestinal tract 
(Figure 20A). The time activity curves of [18F]FED6 in the tumours, which were plotted in Figure 20B, 
showed an initial uptake of the radiotracer in the tumour followed by washout and decrease in 
[18F]FED6 with time. There was no statistical significant difference between the normalised uptake 
value at 60 min (NUV60) post [
18F]FED6 injection in the A549 and the H1650 xenografts (Figure 20C). 
The NUV60 values were 0.32 and 0.39 % ID/mL in A549 and H1650 tumours, respectively. The area 
under the time activity curves (AUC), were the same in both models with an average value of 25 
%ID/mL*min. 
The protein expression analysis of the tumour lysates showed that p-EGFR (Y1068) and total EGFR 
were slightly higher in the A549 tumours than in the H1650 tumours (Figure 21). 
  




Figure 20: In vivo PET imaging of A549 and H1650 xenografts with [18F]FED6. 
A- Sagittal merged CT/PET image of a BALB/c nu/nu mouse obtained at 60 min following an i.v. injection of 3.7 MBq of 
[
18
F]FED6 with the scanning of. A1- H1650 xenograft. A2- A549 xenograft. Tumour position indicated by white arrow. Data 
show images collected from one representative mouse from each group B- Time activity curves, corresponding to the 
uptake of [
18
F]FED6 in the tumour against time. C- Uptake of [
18
F]FED6 at 60 min post tracer injection normalised to 
injected dose. D- Area under the tumour time activity curve values. For B-D- Data represent mean ± SE of n=3 per group. 
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Figure 21: p-EGFR and EGFR levels of A549 and H1650 tumours. 
Expression of p-EGFR (Y1068) and EGFR in tumour lysates of A549 and H1650 xenografts previously imaged via PET. Each 
column represents one lysed tumour sample.  
 In summary, the in vivo PET imaging data did not correlate with the in vitro cell uptake experiment 
that showed a 2.5 fold higher uptake of [18F]FED6 in A549 cells compared to H1650 cells. 
3.4 Testing FED6 in active and resistant mutant NSCLC cell lines 
3.4.1 Western blot analysis of gefitinib and FED6 Inhibition of p-EGFR. 
To further investigate FED6 in the context of imaging mutant EGFR, cell lines expressing mutant 
forms of EGFR, including L858R active mutant and T790M resistant mutant EGFR were used. First, 
the inhibition of EGFR activation following 3 h treatment with gefitinib or FED6 was determined. PC9 
(del 746-750), PC9ER (del 746-750/T790M), H3255 (L858R) and H1975 (L858R/T790M) all showed 
constitutive activation of EGFR as indicated by the presence of the p-EGFR (Y1068) band in 
unstimulated conditions (Figure 22A). Both gefitinib and FED6 treatment led to higher levels of p-
EGFR Y1068 inhibition in active mutant EGFR expressing cells, H3255 and PC9 compared to resistant 
mutant expressing H1975 and PC9ER, as depicted in Figure 22.  
The densitometry measurements from the blots were used to determine the percentage inhibition 
of p-EGFR (Y1068) (Figure 22B). The IC50 values obtained from these plots were tabulated in Figure 
22C. The IC50 values for gefitinib were lowest in PC9 and H3255 cells at 0.014 and 0.15 µM, 
respectively compared to 1.1 and > 10 µM in PC9ER and H1975 cells, respectively. 
The IC50 of FED6 was lowest in the H3255 cells, at 0.008 µM, compared with 0.02 µM in PC9 and 
0.045 µM in PC9ER cells. At the concentrations selected, the IC50 of FED6 was not reached in the 
resistant mutant EGFR expressing H1975 cells. In addition, FED6 showed a stronger affinity for EGFR 
in H3255 and PC9ER cells compared to gefitinib. The IC50 of FED6 was 24 fold lower than the IC50 of 
gefitinib in PC9ER cells. The irreversible nature of FED6 binding could explain the increased affinity of 
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Figure 22: Inhibition of EGFR activation in NSCLC following gefitinib and FED6 treatment. 
A- Western blots showing changes in phosphorylation of EGFR at tyrosine 1068 following gefitinib (A1) or FED6 (A2) 
treatment of PC9, PC9ER, H3255 and H1975 cells. B- Percentage inhibition of p-EGFR (Y1068) normalised to EGFR levels 
following gefitinib (B1) or FED6 (B2) treatment determined from densitometry of western blots. C- Table summarising the 
average IC50 values ± SE, obtained from the percentage inhibition of p-EGFR plots, of gefitinib (C1) or FED6 (C2). Data show 
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3.4.2 [18F]FED6 in vitro uptake in active and resistant mutant NSCLC cells. 
 
A cell uptake assay was performed in the different NSCLC cells, to investigate whether the higher 
affinity of FED6 for active mutant EGFR and lower affinity of FED6 for resistant mutant EGFR, was 
translated into differential binding of [18F]FED6 (Figure 23A). H3255 cells showed the highest uptake 
of [18F]FED6 with a value of 130 CCPMA/µg of protein and the lowest level of tracer uptake was 
measured in H1975 cells with a value of 12 CCPMA/µg of protein. Finally, the uptake of [18F]FED6 
was higher in the active mutant PC9 compared to resistant mutant PC9ER cells, with values of 88, 
and 72 CCPMA/µg of protein, respectively. This difference was however not statistically significant. 
H3255 cells which had the highest uptake of [18F]FED6 also expressed the highest levels of p-EGFR 
(Y1068) and total EGFR (Figure 23BC). Furthermore, H1975 cells which had the lowest uptake of 
[18F]FED6 also expressed the lowest levels of both p-EGFR (Y1068) and total EGFR (Figure 23BC). 
Thus, the difference in uptake could also be a result of the levels of expression of EGFR rather than 
differential binding to active and resistant mutant EGFR. The levels of expression of p-EGFR (Y1068) 
and EGFR were similar in PC9 and PC9ER cells. 
 
Figure 23: In vitro uptake of [18F]FED6 in NSCLC. 
A- Protein normalised uptake of [
18
F]FED6 in NSCLC cells following 1 h incubation with 0.22 MBq [
18
F]FED6. Data show 
mean ± SE of triplicates from one representative experiment performed two times. Stars indicate statistical difference 
between values of two-tailed unpaired t-test (**p≤ 0.01) B- Differential protein expression of p-EGFR (Y1068) and EGFR in 
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In order to better understand whether the differential uptake of [18F]FED6 in the NSCLC studied was 
linked to p-EGFR (Y1068) protein expression, EGFR protein expression and or FED6 affinity in these 
different cell lines, correlation graphs were plotted (Figure 24). With the exception of the H358 cells 
there was a strong correlation between levels of p-EGFR (Y1068) and EGFR protein expression and 
[18F]FED6 uptake. With the highest levels of [18F]FED6 uptake corresponding to the highest 
expression of p-EGFR (Y1068) or EGFR (Figure 24AB). There didn’t seem to be a direct correlation 
between the uptake of [18F]FED6 and the IC50 of FED6 which were obtained from the western blots 
and plotted in Figure 18 and Figure 22. The higher affinity of FED6 in active mutant EGFR expressing 
cell lines did not always correlate with a higher uptake of [18F]FED6 as is illustrated with the H1650 
cell line (Figure 24C). 
 
 
Figure 24: Correlation between [18F]FED6 uptake, EGFR protein expression andFED6 IC50. 
A- [
18
F]FED6 uptake over protein expression of p-EGFR (Y1068) normalised to β-Actin. B- [
18
F]FED6 uptake over protein 
expression of EGFR normalised to β-Actin. Protein expression values obtained from densitometry reading of western blots. 
Data show values from one representative experiment carried out in triplicate. C- [
18
F]FED6 uptake over IC50 of FED6. IC50 
values expressed as mean of IC50 values obtained from p-EGFR (Y1068) inhibition plots following FED6 treatment from 
three separate experiments. r
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In conclusion, higher levels of binding of [18F]FED6 in EGFR overexpressing vs low EGFR expressing 
cells were confirmed. Then, FED6 showed higher affinity for inhibiting EGFR activity in active mutant 
EGFR vs WT or resistant mutant expressing NSCLC cells. The in vitro uptake of [18F]FED6 in the 
different mutant expressing cell lines gave mixed results, with the uptake of the radiotracer not 
consistently correlating with the previously measured affinity of FED6 in these different cells. 
Furthermore, the in vivo PET imaging of A549 and H1650 xenografts showed no differential tumour 
uptake of [18F]FED6 in these two models. The tumour uptake was low and the TAC indicated a 
gradual washout of the tracer over time. 
The inconclusive results of the in vitro uptake experiments and the low tumour uptake in vivo led us 
to further investigate the properties of FED6. This suggests that other factors could affect the 
relationship between affinity of FED6 to active mutant or resistant mutant EGFR and the cell uptake 
of [18F]FED6. Indeed, other quinoline based molecules have been demonstrated to be substrates of 
the ABC transporters. Abourbeh et al showed that the EGFR tracer they had developed, ML04, was a 
substrate for ABCB1 and that low tumour uptake of this tracer was a result of efflux via ABCB1 
transporter (Abourbeh et al., 2007). 
The possible substrate specificity of FED6 for the ABC transporters was investigated, to establish 
whether this could explain some of the results discussed above. 
  





Chapter 4: Interaction of FED6 with ABC transporters 
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MDR, which can result in the overexpression of members of the ABC transporters has been reported 
in several cancers (Litman et al., 2001). The expression of these transporters in tumours is an 
important factor to take into account when designing a radiotracer. Indeed, if a radiotracer is a 
substrate of the ABC transporter, it will be actively extruded from the tumour, especially if the 
tumour expresses high levels of transporters. This will result in poor accumulation of the radiotracer 
in the tumour. Several EGFR targeting TKIs have been shown to interact with the ABC transporters, 
this includes EKB-569 from which the cyanoquinoline series of compounds were designed (Kitazaki 
et al., 2005, Ozvegy-Laczka et al., 2004, Nakamura et al., 2005, Hegedus et al., 2012). It was 
therefore important to investigate the possible substrate specificity of FED6 and other members of 
the cyanoquinoline family for ABC transporters, and determine how this may impact the PET imaging 
of EGFR with [18F]FED6. 
4.1 Physico-chemical properties of compounds can help predict ABC transporter substrate 
specificity. 
It has been reported in the literature that substrates of the ABC transporters share common physico-
chemical properties. For instance substrates for ABCB1 are characterised by one or more of the 
following: a molecular weight (MW) > 400, hydrophobicity determined by 1 < log P > 5, sum of 
oxygen and nitrogen atoms > 8, polar surface area (PSA), defined as the sum of surfaces of polar 
atoms (usually oxygen, nitrogen, and attached hydrogen) > 85Å2 (Varma et al., 2005, Dellinger et al., 
1992, Gottesman and Pastan, 1993, Kaliszczak et al., 2010). The number of aromatic rings in a 
compound have been reported to influence ABCG2 substrate specificity with compounds containing 
greater than two aromatic rings showing increased substrate specificity for ABCG2 (Nakagawa et al., 
2006). Finally the pKa of a molecule has also been reported to play a role in ABC transporter 
substrate specificity, and this by modifying the thresholds listed above (Didziapetris et al., 2003, 
Varma et al., 2005). 
In order to predict the substrate specificity of FED6 and other closely related members of the 
cyanoquinoline family of molecules for the different transporters and to use this information to 
design future compounds, the relevant physico-chemical properties of the series of compounds 
were tabulated (Table 9). 
The cyanoquinoline series of compounds possess several of the physico-chemical properties, which 
are associated with ABCB1 substrate specificity. With the exception of FED14 (precursor molecule in 
the series), all the compounds in the series had MW > 400, PSA > 85 Å2, and 1 < log P > 5.   
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Table 9: Physico-chemical properties of the FED series in relation to prediction of ABC transporter 
substrate specificity 
 
MW: Molecular weight and the sum of oxygen and nitrogen atoms (N+O) calculated Log P and polar surface area (PSA) 
were determined as described in materials and methods. pKa : logarithmic value of acid dissociation constant. Values in 
red indicate properties characteristic of substrate specificity to ABC transporters. 
 
4.2 Testing for ABCB1, ABCG2, ABCC1 substrate specificity. 
ABC transporters form a large family of over 48 proteins, divided into seven subfamilies (Dean et al., 
2001). Three members of this large family which have been most commonly involved in MDR; 
ABCB1, ABCG2 and ABCC1 will be investigated in this report (Fletcher et al., 2010). 
4.2.1 Substrate specificity for ABCB1  
 
With a MW > 400, log P > 3 and a PSA > 85 Å2, the physicochemical determinants of FED6 would 
predict its interaction with ABCB1. To verify its interaction with the transporter, an isogenic model 
was used: 3T3 cells (transfected with an empty vector) and 3T3-MDR1 cells (transfected with the 
Compounds Structures MW Log P* PSA (N+O) Aromatic rings pKa
EKB-569   
468 4.18 90 7 3 8.8
FED2
454 3.8 100 7 3 9.6
FED3
500 4.38 90 7 3 7.2
FED6
567 3.85 130 10 3 7.4
FED9
500 3.73 100 7 3 8.4
FED14
357 3.54 84 5 3 4.6
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human MDR1 gene which encodes for ABCB1), with a differential expression of the transporter 
(Figure 25), and investigated the impact of FED6 treatment on cell viability. If a drug is a substrate for 
ABCB1, it will be actively transported out of the cell. Thus, higher concentrations of the drug will be 
required to cause cytotoxicity in the cell line that overexpresses ABCB1 compared to the cell line 
expressing no transporter.  
 
 
Figure 25: ABCB1 protein expression in 3T3 and 3T3-MDR1. 
Levels of ABCB1 (MDR1) protein expression as determined by western blotting.  
 
The cyanoquinoline series have been designed based on the structure of TKI, EKB-569 that is 
associated with anti-proliferative activity. FED6 and other derivatives could also induce cytotoxicity 
and this characteristic could be exploited to assess ABCB1 substrate specificity.  
As well as comparing the levels of cytotoxicity in 3T3 and 3T3-MDR1 cells the impact of a specific 
inhibitor of ABCB1, zosuquidar (Shepard et al., 2003) on the cytotoxicity of FED6 in 3T3 and 3T3-
MDR1 cells was assessed. 
The optimal concentration of zosuquidar required to inhibit ABCB1 was assessed by measuring the 
change in fluorescence levels of calcein by performing a calcein acetomethoxy (calcein AM) assay. 
Traditionally used to monitor cell viability, calcein AM, a known substrate of ABCB1 (Varma et al., 
2005), has also been used to monitor active efflux. In live cells, the non-fluorescent calcein AM is 
converted to a green-fluorescent calcein after acetoxymethyl ester hydrolysis by intracellular 
esterases. In cells expressing ABCB1, calcein AM will be extruded out the cells, leading to low levels 
of fluorescent calcein. At baseline, the levels of fluorescence in untreated control 3T3-MDR1 cells 
were equal to background levels due to high levels of efflux of calcein AM. This was in opposition to 
the high fluorescence measured in the 3T3 cells (Figure 26). Levels of fluorescence increased dose 
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concentrations of zosuquidar did not lead to increased fluorescence. At 0.3 µM of zosuquidar, the 
activity of ABCB1 was completely inhibited and it no longer extruded calcein AM. This resulted in 
levels of fluorescence in the 3T3-MDR1 reaching those measured in the 3T3 cells. The optimal 







Figure 26: Calcein fluorescence in 3T3 and 3T3-MDR1 cells following zosuquidar treatment. 
Levels of calcein, in 3T3 or 3T3-MDR1 cells following 1 h pre-treatment with increasing concentrations of zosuquidar. Data 
show means ± SE of quadruplet from one representative experiment. A.U.: Arbitrary unit of fluorescence. 
 
Vinblastine is a known substrate of ABCB1 and was used as a positive control (Ambudkar et al., 
1999). Growth inhibitory effect of vinblastine was tested in 3T3 and 3T3-MDR1 cells with or without 
pre-treatment with zosuquidar at 0.3 μM. 3T3-MDR1 cells were more resistant to vinblastine than 
3T3 cells (Figure 27A). Following zosuquidar pre-treatment the sensitivity of 3T3-MDR1 cells was the 
same as that of 3T3 cells (Figure 27B). The GI50 (i.e: 50 % reduction in cell growth) of vinblastine 
decreased from 220 nM, without pre-treatment, to 1.1 nM, with zosuquidar pre-treatment, in the 
3T3-MDR1 cells. This represented a 200 fold increase in the cytotoxicity of vinblastine following 
zosuquidar pre-treatment. In the 3T3 cells, the GI50 was 1.8 nM without pre-treatment and 1.5 nM 
with pre-treatment. 
Inhibition of ABCB1 efflux of vinblastine via zosuquidar, led to an increase in the cytotoxicity of 
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Figure 27: Cell viability curves showing reversal of resistance to vinblastine in 3T3-MDR1 following 
zosuquidar treatment. 
A-B- Cell viability plots of 3T3 and 3T3-MDR1 cells following vinblastine treatment with (B) or without (A) pre-treatment 
with 0.3 µM of zosuquidar. Data show mean ± SE of n = 3 replicates from one experiment carried out three times. 
 
Having characterised the cells with known inhibitors, further testing of the growth inhibitory effect 
of the cyanoquinoline series was performed. FED6 and FED2 were associated with a GI50 of > 100 
and 37 μM in the 3T3-MDR1 cells, respectively, and with a GI50 of 10 and 7 µM in the 3T3 cells. This 
represents a 10- and 5-fold increase in GI50 values, for FED6 and FED2, respectively, in the ABCB1 
overexpressing cell line (Table 9). This suggested that both compounds were being effluxed via 
ABCB1. The GI50 values of FED14, the core cyanoquinoline moiety, from which other cyanoquinoline 
molecules were synthesised, were similar in both cell lines. Following zosuquidar pre-treatment of 
the 3T3-MDR1 cells, the GI50 value decreased over 7-fold for FED6, 6.1-fold for FED2, and 2.1-fold for 
EKB-569 (Table 10).This confirmed that the lower cytotoxicity of EKB-569, FED2 and FED6 in the 3T3-
MDR1 cells was a result of efflux via ABCB1. 
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Table 10: Growth inhibitory effect associated with the series of cyanoquinoline molecules in 3T3 
and 3T3-MDR1 cells. 
 
GI50 values were obtained for each experiment. Data represents mean GI50 and SE obtained from three separate 
experiments. 
 
Ratios of the GI50 in 3T3-MDR1 to GI50 in 3T3, in the presence and absence of zosuquidar, were 
plotted in Figure 28. Compounds associated with a ratio > 2 were considered to be actively effluxed 
by the ABC transporters. This in turn limited their growth inhibitory effect. In the absence of ABCB1 
inhibitor, zosuquidar, EKB-569, FED2 and FED6 had ratios of GI50 of 4.4, 5.4 and > 20, respectively. In 
the presence of zosuquidar all ratios were below the threshold of 2, further indicating substrate 










Figure 28: Impact of zosuquidar on the cytotoxicity of cyanoquinoline derivatives. 
Ratios of GI50 in 3T3-MDR1 and GI50 in 3T3 were determined for each experiment. Data show mean ± SE of ratios from 
three experiments. Vinblastine was used as a positive control. Red dashed line indicates threshold for ABCB1 substrate 
specificity. FED6 indicated in red. Zos: zosuquidar. Stars indicate statistical difference between values of two-tailed 
unpaired t-test (**p≤ 0.01). 
3T3 3T3-MDR1
control + zosuquidar control + zosuquidar
EKB-569
GI50 (µM) 1.1 1.2 5.8 2.7
SE 0.6 0.6 0.7 0.8
FED2
GI50 (µM) 7 4.5 36 5.9
SE 1.2 0.8 1.1 0.6
FED6 
GI50 (µM) 11 7.8 >100 14
SE 1 0.7 0.6
FED14
GI50 (µM) 15 15 8.7 12
SE 0.7 0.7 0.7 0.6
Vinblastine
GI50 (nM) 1.8 1.5 220 1.1






















































































   
 101 
4.2.2 Substrate specificity for ABCG2 
FED6 is associated with physicochemical features that would predict its interaction with ABCG2: It 
contains three aromatic rings and has a sum of nitrogen and oxygen atoms above ten. To verify its 
interaction with the transporter, MCF7 and a mitoxantrone resistant, MCF7MX cell line, which 
overexpresses ABCG2 were used to investigate the impact of FED6 treatment on cell viability (Figure 
29). 
 
Figure 29: Protein expression of ABCG2 in MCF7 and MCF7MX. 
Levels of ABCG2 protein expression as determined by western blot. 
To investigate the ABCG2 substrate specificity of the cyanoquinoline derivatives, cells were pre-
treated with or without the ABCG2 specific inhibitor fumitremorgin C (FTC) (Rabindran et al., 2000). 
A concentration of 10 µM was previously shown to inhibit ABCG2 without causing toxicity (Robey et 
al., 2001) and was used in subsequent studies. 
The growth inhibitory effect of mitoxantrone, a known substrate of ABCG2 was evaluated in MCF7 
and MCF7-MX cells (Doyle and Ross, 2003). The GI50 was 11 μM in MCF7 cells and 2500 μM in 
MCF7MX cells without pre-treatment, representing a 234 fold decrease in cytotoxicity in the ABCG2 
expressing cells. Following FTC pre-treatment the sensitivity of MCF7MX cells was increased and was 
similar to that of MCF7 cells (Figure 30). The GI50 was 23 μM in MCF7MXcells after pre-treatment 
with FTC, representing a 110 fold increase in cytotoxicity of mitoxantrone. This was indicative of an 
efflux of mitoxantrone via ABCG2 in the MCF7MX cells resulting in reduced toxicity. 
The impact of ABCG2 on the growth inhibitory effect of the cyanoquinoline derivatives was 
evaluated in MCF7 and MCF7MX. Vinblastine is not a substrate of ABCG2 and was chosen as a 
negative control. The GI50 values are summarised in  
Table 11. EKB-569, FED2 and FED6 were associated with GI50 values of 4.3, 28 and 76 μM in MCF7MX 
without pre-treatment, compared to 2.6, 8.6 and 12 μM in MCF7 without pre-treatment. Following 
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the MCF7MX whereas the GI50 values were unchanged in the MCF7 cells. The GI50 value of FED14 
was higher in the MCF7 (12 μM) than in the MCF7MX (6.5 μM) (Table 11). 
 
Figure 30: Cell viability assays showing reversal of resistance to mitoxantrone in MCF7MX 
following FTC treatment. 
A- Cell viability plots of MCF7 and MCF7MX cells following mitoxantrone treatment with (B) or without (A) pre-treatment 
with 10 μM FTC. Data show mean ± SE of n = 3 replicates from one experiment carried out three times. 
 
Table 11: Growth inhibitory effect associated with the series of cyanoquinoline molecules in MCF7 
and MCF7MX cells. 
 











































-ftc +ftc -ftc +ftc
EKB-569
GI50 (µM) 2.61 2.55 4.28 1.54
SE 0.07 0.04 0.23 0.06
FED2
GI50 (µM) 14.93 14.77 27.55 10.29
SE 1.8 1.78 1.11 1.47
FED6
GI50 (µM) 11.98 12.29 75.92 37.85
SE 0.03 0.83 4.92 17.18
FED14
GI50 (µM) 11.41 11.18 6.53 10.09
SE 1.36 1.11 0.34 0.73
vinblastine
GI50 (nM) 5.12 5.36 2.08 2.66
SE 0.74 0.63 0.41 0.66
Mitoxantrone
GI50 (nM) 10.73 6.62 2503.50 22.75
SE 0.50 0.74 316.50 2.35
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The impact of ABCG2 was plotted as a ratio between the GI50 of the compound in MCF7MX over the 
GI50 of the compound in MCF7 cells (Figure 31). Compounds associated with a ratio >2 were 
considered to be actively effluxed by the ABC transporters (Szakacs et al., 2006). In the absence of 
ABCG2 inhibitor, FTC, EKB-569, FED2, FED6 and FED14 have GI50 ratios of 1.6, 1.9, 6.3 and 0.6, 
respectively. In the presence of FTC these ratios decreased to 0.6, 0.7, 3.1 and 0.9 for EKB-569, FED2, 
FED6 and FED14, respectively. FED6 was associated with a ratio > 2 suggesting its substrate 
specificity towards ABCG2. Following FTC pre-treatment the ratio of GI50’s for FED6 remained >2, 
which could be due to an inability of FTC to completely block the efflux of FED6 via ABCG2 or other 
non-related factors that led to lower cytotoxicity of FED6 in the MCF7MX cells. 











Figure 31. Impact of FTC on the cytotoxicity of cyanoquinoline derivatives. 
Data show ratio between GI50 in MCF7MX and GI50 in MCF7 cells expressed as mean ± SE of ratios from three experiments. 
Mitoxantrone was used as a positive control. Red dashed line indicates threshold for ABCB1 substrate specificity. FED6 
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4.2.3 Substrate specificity for ABCC1 
 
Substrate specificity of the cyanoquinoline derivatives for ABCC1 was investigated in A549 cells, 
which overexpress ABCC1; the impact of MK-571, a specific inhibitor of ABCC1 was also evaluated 
(Regina et al., 1998, Pham et al., 2009). 
Calcein-AM is a substrate of ABCC1 and could be used to monitor the active efflux mediated by the 
transporter. To determine the optimal concentration of MK-571 to inhibit ABCC1 cells, the impact of 
increasing concentration of the inhibitor on intracellular levels of calcein in A549 cells was 
evaluated. Fifty micro molar of MK-571 led to a 1.5 fold increase in fluorescence compared to 
baseline (Figure 32). An optimal concentration of the inhibitor (100 µM) led to a higher level of 
fluorescence. However, this concentration also led to a decrease in cell viability when A549 cells 
were incubated with MK-571 for more than 24 h. The lower concentration of 50 μM of MK-571 was 









Figure 32: Calcein fluorescence in A549 cells following MK-571 treatment. 
Fluorescence of calcein in A549 cells following a calcein AM assay performed after pre-treatment with or without 
increasing concentrations of ABCC1 inhibitor MK-571 for 1 h. Data show means ± SE of quadruplet of calcein fluorescence. 
A.U.: Arbitrary unit  
 
The impact of MK-571 on the growth inhibitory effect of the cyanoquinoline derivatives was further 
evaluated in Figure 33 The GI50 values are summarised in Table 12. EKB-569, FED2, FED6 and FED14 
were associated with GI50 values of 1.6, 28, 35 and 6.5 μM, respectively in A549, compared to 1.4, 
25, 21, and 6.9 μM in A549 when the cells were pre-treated with MK-571 (Table 12). 
0 1
2.




































Figure 33: Cell viability assays in A549 cells with and without pre-treatment with ABCC1 inhibitor 
MK-571. 
Cell viability plots of A549 cells following FED6  treatment with (B) or without (A) pre-treatment with 50 μM MK-571. Data 
show mean ± SE of n = 3 replicates from one experiment carried out three times. 
 
Table 12: Growth inhibitory effect associated with the series of cyanoquinoline molecules in A549 
and A549 cells treated with MK-571 
  
GI50 values were obtained for each experiment. Data represent mean GI50 and SE obtained from three separate 
experiments. 
GI50 ratio in A549 to A549 + MK-571 were plotted in Figure 34. Compounds associated with a ratio > 
2 were considered to be actively effluxed by ABCC1. EKB-569, FED2, FED6 and FED14 have GI50 ratios 
of 1.1, 1.2, 1.8, 1.1 μM, respectively (Figure 34). 




A549 A549 + MK-571
EKB-569
GI50 (µM) 1.6 1.4
SE 0.3 0.1
FED2
GI50 (µM) 28 25
SE 5.7 5.6
FED6 
GI50 (µM) 35 21
SE 2.5 1.7
FED14
GI50 (µM) 6.5 6.9
SE 1.2 1.7




























Figure 34: Impact of MK-571 on the cytotoxicity of cynanoquinolines derivatives in A549 cells. 
Data show ratio between GI50 in A549 cells and GI50 in A549 pre-treated with MK-571 expressed as mean ± SE of ratios 
from three experiments. 
 
4.2.4 ABC transporters and uptake of [18F]FED6 in vitro.  
 
The preceding section highlighted FED6 as a potential substrate of ABCB1 and ABCG2. To verify that 
radiolabelled FED6 (used in tracer amount) could also be substrate of ABCB1 and ABCG2, the 
differential uptake of [18F] radiolabelled FED6 was investigated in ABCB1 and ABCG2 overexpressing 
cell lines, and by using specific inhibitors.  
The uptake of [18F]FED6 was more than 20 times greater in 3T3 cells (22 CCPMA/µg of protein) than 
in 3T3-MDR1 cells (0.74 CCPMA/µg) (Figure 35A). The uptake of [18F]FED6 increased to over 12 
CCPMA/µg of protein in the 3T3-MDR1 cells, following pre-treatment with zosuquidar. The latter did 
not have any effect in 3T3 cells (Figure 35A). These results indicate that [18F]FED6 is a substrate for 
ABCB1. 
MCF7MX cells also showed low levels of uptake of [18F]FED6; 7 CCPMA/µg of protein compared to 80 
CCPMA/µg of protein in MCF7 cells (Figure 35B). When cells were pre-treated with 10 µM of FTC, 1 h 
prior to incubation with the radiotracer, the uptake of [18F]FED6 increased to 31 CCPMA/µg of 
protein in MCF7MX cells. There was a small increase in the uptake in the MCF7 cells following pre-
treatment with FTC, but this was not statistically significant. These results indicate that [18F]FED6 is a 
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Figure 35: [18F]FED6 uptake in ABC transporter expressing cells. 
Protein normalised uptake of [
18
F]FED6 in 3T3, 3T3-MDR1 cells, following 1 h incubation with 0.22 MBq of [
18
F]FED6, with 
or without pre-treatment with zosuquidar at 0.3 µM for 1 h. B- Protein normalised uptake of [
18
F]FED6 in MCF7 and 
MCF7MX cells, following 1 h incubation with 0.22 MBq of [
18
F]FED6, with or without pre-treatment with 10 μM FTC for 1 h. 
All data show mean ± SE of triplicates of one representative experiment carried out in duplicate. Statistical difference 
between data indicated on graph. Stars indicate statistical difference between values of two-tailed unpaired t-test 
(**p ≤ 0.01). 
 
4.2.5 Caco2 cell permeability assay. 
The Caco2 model of permeability has been widely used to investigate the absorption properties and 
the active transport of drugs (Szakacs et al., 2006). Here, the transporter expression profile of these 
cells was used, as an alternative model to further investigate the active efflux of the cyanoquinoline 
compounds by ABCB1 and ABCG2.  
It has been reported that a ratio between the secretion (Papp B-A) and absorption (Papp A-B), referred 
to as the efflux ratio, with values greater than 2 corresponds to molecules which are actively 
extruded by the cell via the ABC transporters (ABCB1 and/or ABCG2) (Szakacs et al., 2006).  
The efflux ratios of EKB-569, FED2, FED6, and FED14 are summarised in Figure 36. EKB-569, FED2 
and FED6 were actively effluxed as indicated by efflux ratios (Papp B-A /Papp A-B) of 3.4, 6.6 and 6.9, 
respectively (Figure 36). The efflux ratio for FED14 was below 1 indicating a lack of active Transport. 
Vinblastine was chosen as a control compound and has an efflux ratio above 2 due to the substrate 









































































































Figure 36: Active efflux of cyanonquinoline derivatives across Caco2 cells. 
Data are expressed as ratios between permeability of secretion and permeability of absorption. Positive control 
vinblastine, is shown for comparison. Data show mean ± SE of efflux ratios obtained from triplicates of one representative 
experiment 
 
We further evaluated the impact of inhibitors of the ABC transporters on the permeability of FED6 
(Figure 37). Following FTC pre-treatment, the active efflux of FED6 was partially inhibited. This was 
indicated by a decrease in the efflux ratio of FED6 from 6.9 without pre-treatment to 5 with FTC 
(Figure 37A). Pre-treatment with FTC did not completely reverse the efflux ratio suggesting that 
FED6 may also be extruded via ABCB1. Zosuquidar pre-treatment did not inhibit the active efflux of 
FED6, suggesting that ABCG2 participated in the active efflux of FED6 (Figure 37B). The efflux ratio 
for FED6 decreased significantly following pre-treatment with verapamil, a non-specific inhibitor of 
ABCB1 which also shows inhibitory potential against ABCG2 (Rogan et al., 1984), from 6.9 without 
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Figure 37: Efflux ratio of cyanoquinoline compounds in the presence of ABC transporter inhibitors. 
Efflux ratios of FED6 and vinblastine with or without 1 h pre-treatment with 10 mg/ml of verapamil or FTC (A) or 0.3 μM 
zosuquidar (B) obtained from a Caco2 transwell assay. Data show mean efflux ratios ±SE of n = 3 of one representative 
experiment. Stars indicate statistical difference between values of two-tailed unpaired t-test (**p ≤ 0.01). 
 
These results show that FED6, FED2 and EKB-569 were actively effluxed out of the cell via the ABC 
transporters, and that pre-treatment with verapamil led to a significant decrease in the efflux ratio 
of FED6. These experiments further confirmed the substrate specificity of FED6 for the ABC 
transporters. 
4.3 Impact of ABC transporter substrate specificity of FED6 for imaging EGFR. 
4.3.1 Levels of ABC transporters across a panel of cell lines  
A panel of cell lines was previously used to study the affinity of FED6 for EGFR (Cf chapter 3). To 
further investigate the impact of ABC transporters, on the uptake of [18F]FED6, across the different 
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Figure 38: mRNA and protein expression of ABCB1 and ABCG2 in cell lines studied. 
A-B- mRNA levels of ABCB1 (A) and ABCG2 (B) in different cell lines studied, assessed by RT-PCR. Data show mean ± SE 
values of relative levels of ABCB1 and ABCG2 normalised for GAPDH from three experiments. C-D- Protein expression of 
ABCB1 (C) and ABCG2 (D) in different cell lines studied.  
 
ABCB1 expression was below the levels of detection in all cell lines. ABCG2 was expressed to a 
variable but appreciable extent in all cell lines assessed. The MCF7MX cells expressed levels of 
ABCG2 mRNA 130 fold higher than the other cell lines tested. A431 and A549 cells showed more 
physiological levels of mRNA and protein expression of ABCG2. H3255 and H358 were the only cell 
lines that expressed ABCG2 below the limit of detection by western blot. As ABCB1 was not detected 
in the cell lines studied, the interaction between FED6 and ABCG2 was the focus for the rest of this 
work. 
4.3.2 Overcoming ABCG2 efflux.  
4.3.2.1 Inhibition of ABCG2 in MCF7MX cells. 
 
FED6 was previously shown to be a substrate for ABCG2. Furthermore, low to moderate levels of this 
transporter were expressed in the cell lines which were chosen to study the imaging characteristics 
of EGFR with [18F]FED6. The aim was to investigate whether or not the efflux via ABCG2 could be 
inhibited by pharmacological means and whether the blocking of ABCG2 efflux would lead to an 
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Hoechst 33324 dye, is a known substrate for ABCG2 and its accumulation in cells overexpressing the 
transporter is significantly reduced (Kim et al., 2002). Using the fluorescence properties of Hoechst 
33324, the accumulation of this dye in MCF7 and in MCF7MX cells following pre-treatment with 
ABCG2 specific inhibitor FTC and gefitinib was determined. Gefitinib has been reported by several 
groups to act as an inhibitor of ABCG2 (Nakamura et al., 2005, Hegedus et al., 2012). Following drug 
inhibition, the ABCG2 transporter will no longer be expected to efflux the Hoechst dye. This dye will 
accumulate in the cells giving a rise in fluorescence. 
At baseline the fluorescence values recorded in MCF7MX (350 A.U.) were 16 fold lower than the 
fluorescence recorded in MCF7 cells (5500 A.U.) (Figure 39). This reflected the efflux of Hoechst 
33324 dye via the ABCG2 transporter in the MCF7MX cells. FTC pre-treatment lead to a dose 
dependent increase in fluorescence in the MCF7MX cells, reaching 2700 A.U. at 10 µM FTC (8-fold 
increase in fluorescence from baseline), whilst no change was measured in MCF7 cells (Figure 39A, 
B). Gefitinib pre-treatment led to a concentration dependent increase in fluorescence with 
concentrations above 6 µM gefitinib in MCF7MX, reaching 4800 A.U. at 100 µM gefitinib (Figure 
39C), whilst no changes in fluorescence were measured in the MCF7 cells (Figure 39D). Pre-
treatment of MCF7MX cells with concentrations of FED6 as high as 100 μM, did not lead to a 
significant increase in the fluorescence of Hoechst 33324 (Figure 39E). 
In conclusion, FTC and gefitinib but not FED6 inhibited ABCG2, causing a decrease in efflux of 
Hoechst 3334 from the cells and a subsequential increase in measured fluorescence. For further 
experiments, concentrations of 100 μM gefitinib and 10 μM FTC were selected. 
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Figure 39: Hoechst 33324 uptake in MCF7 and MCF7MX cells following FTC or gefitinib pre-
treatment 
A-B- Hoechst 33324 fluorescence in MCF7MX (A) and MCF7 (B) cells following 1h pre-treatment with FTC. C-D- Hoechst 
33324 fluorescence in MCF7MX (C) and MCF7 (D) cells following 1 h pre-treatment with gefitinib. E.-F- Hoechst 33324 
fluorescence in MCF7MX (E) and MCF7 (F) cells following 1 h pre-treatment with FED6. Fluorescence values were 
normalised for protein levels by carrying out an SRB assay. Data show mean ± SE of minimum of n = 4 replicates from one 
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To demonstrate the specific role of ABCG2 in relation to the changes to Hoechst 33324 uptake, 
ABCG2 protein expression was knocked down via ABCG2 siRNA transfection in MCF7MX cells. 
Fluorescence levels increased 4.2-fold to 562 A.U., following treatment of MCF7MX cells, with 
ABCG2 siRNA compared to 135 A.U. in scramble siRNA treated cells. The increase in Hoechst 33324 
fluorescence was the greatest following 1 h pre-treatment with either 10 µM FTC or 100 µM 
gefitinib, where the fluorescence increased fourfold (Figure 40A). Hoechst 33324 fluorescence 
values did not reach the levels measured in MCF7 cells. There was no change in the fluorescence of 
Hoechst in MCF7 cells following drug treatment (Figure 40B).  
 
Figure 40: Hoechst 33324 uptake in MCF7MX and MCF7 following siRNA and drug inhibition of 
ABCG2. 
A- Normalised fluorescence values in MCF7MX cells after ABCG2 siRNA transfection or drug pre-treatment. B- Normalised 
fluorescence values in MCF7 cells after drug pre-treatment. Data show means ± SE of minimum of n = 4 replicates from one 
experiment carried out 3 times. A.U.: Arbitrary Unit. Statistical differences from two-tailed unpaired t-test performed 
between treatments and control (untreated cells) indicated on graph by stars.(**= P ≤ 0.01). C-D- ABCG2, p-EGFR (Y1068) 
and EGFR protein expression in MCF7MX (C) and MCF7 (D) cells following siRNA or drug treatment. 
 
Knock down of ABCG2 in the MCF7MX cells was confirmed by western blot. Levels of ABCG2 were 
significantly decreased in the ABCG2 siRNA treated MCF7MX cells. However, knock down of ABCG2 
was incomplete (Figure 41A). Levels of p-EGFR (Y1068) were completely knocked down following 
gefitinib treatment, levels of EGFR were unchanged following both FTC and gefitinib treatment in 
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Figure 41: ABCG2 knock down in MCF7MX cells. 
Protein expression of ABCG2, p-EGFR (Y1068) and EGFR in MCF7MX (A) and MCF7 (B) cells following pre-treatment with 
ABCG2 or scramble siRNA for 72h and FTC or gefitinib for 1 h. 
 
After showing that both gefitinib and FTC led to an increase in fluorescence, as a result of a 
reduction of the efflux of the Hoechst dye, a substrate of ABCG2, the role of these two drugs at 
inhibiting the efflux of [18F]FED6 by ABCG2 was assessed. To investigate whether ABCG2 mediated 
efflux of [18F]FED6 could be overcome the impact of ABCG2 was evaluated by genetic means and 
using ABCG2 inhibitors. [18F]FED6 uptake was 10 fold higher in ABCG2 siRNA transfected MCF7MX 
cells (3.5 CCPMA/µg of protein) compared to scramble siRNA transfected cells (0.6 CCPMA/µg of 
protein), but did not reach the values of uptake measured in the MCF7 cells (17 CCPMA/µg of 
protein) (Figure 42AB). Pre-treatment with either gefitinib or FTC led to uptake values of [18F]FED6 of 
6.3 and 6 CCPMA/µg of protein compared to 0.4 CCPMA/µg of protein in the control sample in 



























































































Figure 42: [18F] FED6 uptake in MCF7MX cells following ABCG2 knock down or drug inhibition.  
A- Uptake of [
18
F] FED6 in MCF7MX cells after 1 h incubation with 0.22MBq of [
18
F]FED6 following ABCG2 siRNA 
transfection or drug pre-treatment. B- Uptake of [
18
F] FED6 in MCF7 cells with or without drug pre-treatment. Data show 
means ± SE of triplicate of one representative experiment carried out three times. Statistical differences from two-tailed 
unpaired t-test performed between treatments and control (untreated cells) indicated on graph by stars (**= P ≤ 0.01). 
 
4.3.2.2 Inhibition of ABCG2 in A431 cells in vitro and in vivo  
We have previously investigated the impact of ABCG2 inhibition using a cell line that overexpressed 
the transporter (i.e. MCF7MX). To translate these findings into more physiological conditions, A431 
that expressed intermediate levels of ABCG2 and were previously chosen to assess the specificity of 
[18F]FED6 for EGFR were investigated (Figure 38). 
4.3.2.2.1 Inhibition of ABCG2 in A431 cells. 
The modulation of the uptake of, Hoechst 33324, in A431 cells following ABCG2 siRNA transfection 
or drug pre-treatment was first measured. There were no differences between the fluorescence of 
scramble and ABCG2 siRNA treated A431 cells, using conditions optimised for in the MCF7MX cells. 
Fluorescence values increased from 3900 A.U. in untreated control cells to 5600 and 5100 A.U. 
following FTC and gefitinib pre-treatment. This corresponded to a 1.5 and 1.3-fold increase in 
fluorescence after FTC and gefitinib treatment, respectively (Figure 43). These results suggested that 
the increase in fluorescence following FTC or gefitinib pre-treatment involved other factors than 
ABCG2. In addition, the baseline levels of fluorescence measured in the A431 cells were similar to 
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ABCG2 siRNA treatment in A431 cells could be due to an already near maximal uptake of Hoechst 
33324 in these cells.  
ABCG2 siRNA knock down was confirmed by western blot (Figure 44). Levels of ABCG2 were 
unchanged following both gefitinib and FTC treatment. Expression of p-EGFR (Y1068) was unchanged 
following pre-treatment with siRNA or FTC, whereas gefitinib treatment led to a complete knock 










Figure 43: Hoechst 33324 uptake in A431 cells following ABCG2 siRNA transfection and drug 
treatment. 
A- Hoechst fluorescence in A431 cells following ABCG2 siRNA or drug pre-treatment. Data shows mean fluorescence values 
normalised for protein ± SE of minimum of n = 6 replicates from one experiment carried out 3 times. A.U.: arbitrary unit. 
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Figure 44: ABCG2 knock down in A431 cells. 
Protein expression of ABCG2, p-EGFR (Y1068) and EGFR in A431 cells following pre-treatment with ABCG2 or scramble 
siRNA for 72h and FTC or gefitinib for 1 h. 
 
The effect of blocking ABCG2 on the uptake of [18F]FED6 in A431 cells was then assessed. The uptake 
of [18F]FED6 increased 1.5-fold from 34 CCPMA/µg of protein in scramble treated cells to 49 
CCPMA/μg of protein in ABCG2 siRNA treated cells. There was a 1.8 and 2.3 fold increase in 
radiotracer uptake following FTC and gefitinib treatment, respectively ( 
Figure 45). The higher levels of uptake of [18F]FED6 following gefitinib pre-treatment compared to 
ABCG2 siRNA or FTC pre-treatment would indicate that the effect of gefitinib is not solely related to 































































Figure 45: [18F]FED6 uptake in A431 cells following inhibition of ABCG2. 
Uptake of [
18
F] FED6 in A431 cells after 1 h incubation with 0.22 MBq of [
18
F]FED6, following ABCG2 siRNA transfection or 
drug pre-treatment. Data show means ± SE of triplicate of one representative experiment carried out three times. 
Statistical differences from two-tailed unpaired t-test performed between treatments and control (untreated or scramble 
treated cells) indicated on graph by stars (**= P ≤ 0.01). 
 
In conclusion, the in vitro data from the Hoechst 33324 fluorescence assay and the [18F]FED6 uptake 
experiments indicated that efflux via ABCG2 could be reduced following pre-treatment with FTC or 
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4.3.2.3 In vivo modulation of ABCG2 efflux of [18F]FED6. 
FTC could not be used in vivo due to high levels of neurotoxicity (Rabindran et al., 2000). Therefore, 
in order to translate the impact of ABCG2 inhibition on [18F]FED6 uptake measured in vitro to an in 
vivo setting, the effects of gefitinib at inhibiting the efflux of [18F]FED6 via ABCG2 was assessed. A 
CT/PET scan was performed in female BALB/c nu/nu A431 xenograft bearing mice to assess the 
uptake of [18F]FED6 following pre-treatment with gefitinib. There was a 2-fold increase in [18F]FED6 
uptake in the A431 tumours, which were pre-treated with gefitinib: From 3.5 % I.D / mL of tissue in 
the untreated control group to 0.7 % I.D / mL of tissue in gefitinib treated mice (Figure 46). 
We hypothesized that pre-treatment with gefitinib would not lead to significant changes in the 
uptake of [18F]FED6 in tissues other than the tumour. The biodistribution of the tracer has previously 
been reported (Pisaneschi et al., 2010). Similar to the previous findings, there was a high level of 
uptake in the gastrointestinal system. The uptake of [18F]FED6 was unchanged in the majority of 
tissues following pre-treatment with gefitinib with the exception of tumour and muscle tissues. In 
muscle, gefitinib pre-treatment led to a decrease in [18F]FED6 uptake. The uptake in the tumour 
increased in the gefitinib pre-treated group.  
  




Figure 46: In vivo uptake of [18F]FED6 in A431 xenograft after gefitinib pre-treatment. 
A- Merged PET/CT image of representative sagittal cross section of a female nude mouse expressing A431 xenograft 
following 1 h dynamic scan post i.v. injection of 3.7 MBq of [
18
F]FED6, with (right) or without (left) 1 h pre-treatment of 100 
mg/Kg of gefitinib via i.p. injection. Tumour delignated by white dotted line. B- Tumour time activity curves of A431 
xenografts with or without pre-treatment. C- Normalised uptake value (NUV60) in the tumour and area under the curve 
(AUC) values. D- Biodistribution data showing the uptake of [
18
F]FED6 in different organs of A431 mouse xenograft with or 
without pre-treatment with gefitinib. Data represent average of n = 3 mice per group ± SE. Stars indicate statistical 
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As well as inhibiting ABCG2 gefitinib will be binding to an inhibiting EGFR. To measure the inhibition 
of EGFR autophosphorylation by gefitinib levels of p-EGFR (Y1068) and EGFR were determined in 
A431 tumour lysates. A decrease in levels of p-EGFR in tumours acquired from mice pre-treated with 
100 mg/Kg of gefitinib was measured (Figure 47). 
 
 
Figure 47: p-EGFR and EGFR protein expression of A431 tumours following gefitinib treatment. 
Protein expression in A431 xenograft tumour lysates. Each column represents one lysed tumour sample.  
 
In summary, the in vivo data correlated with the in vitro findings showing an increase [18F]FED6 
uptake of in the A431 xenografts following gefitinib pre-treatment. FED6 was shown to be a 
substrate for both ABCB1 and ABCG2, with a preferential binding affinity for the latter. Although a 
relative increase in [18F]FED6 uptake was demonstrated both in vitro and in vivo, following inhibition 
of ABCG2, the overall levels of uptake in the tumour were below 2 % of ID/mL of tissue. 
Furthermore, there were high levels of non-specific binding or elimination in other organs. 
Rather than employing pharmacological inhibition of ABC transporter activity to overcome ABC 
transporter efflux, which can be associated with toxcicity, the optimal radiotracer should lack 
substrate specificity to ABC transporters. 
Therefore, it is crucial to design derivatives that are non-substrates of the ABC transporters. 
4.4 Investigation of an alternative cyanoquinoline molecule 
4.4.1 Affinity of FED20 for EGFR 
The main aim in the design of FED20, was to have a compound that maintained specificity and 
strong affinity for EGFR but lacked substrate specificity for the ABC transporters. As lowering the 
lipophilicity of other compounds of the aniloquinolines family had been reported to improve the 
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specificity of the radiotracer, this aspect was the focus in the design of FED20. The physico-chemical 
properties of FED20 are summarised in Table 13. 
Table 13: Physico-chemical properties of FED20. 
 
Measures of hydrophobicity,LogP and polar surface area (PSA) Mw:Molecular weight and the sum of oxygen and nitrogen 
atoms (N+O).were determined as described in methods. pKa : logarythmic value of acid dissociation constant. Values in red 
indicate characteristics favourable for substrate specificity to ABC transporters. 
 
In comparison to FED6 which has a log p of 3.85 (Table 9), the log P of FED20 is significantly lower at 
2.13; this is below the log P threshold of 3 which is associated with substrate specificity for ABC 
transporters. The MW of FED20 is relatively high at 685.08 g/mol. This property may play a role in 
the substrate specificity of this molecule for the ABC transporters, in particular ABCB1 as it is > 400 
which has been shown to be a defining characteristic of substrates (Varma et al., 2005, Dellinger et 
al., 1992, Gottesman and Pastan, 1993, Kaliszczak et al., 2010). 
In order to investigate the affinity of FED20 for EGFR, the sensitivity of FED20 for the EGFR enzyme 
was investigated, both in a cell free, and then in a cell based setting. First, the IC50 of FED20 against 
purified EGFR enzyme was evaluated using a DELFIA tyrosine kinase assay. The IC50 of FED20 against 
EGFR was determined at 4.46 (±0.7) nM, which was over 2 fold higher than the IC50 for FED6 
(1.81 nM) (Pisaneschi et al., 2010). 
The activity of FED20 against EGFR was assessed in vitro. In EGFR overexpressing A431 cells, FED20 
treatment led to a dose dependent decrease in the autophosphorylation of EGFR as measured by a 
decrease in p-EGFR at tyrosine 1068 (Figure 48). 
 
Figure 48: Inhibition of p-EGFR via FED20. 
Expression of p-EGFR (Y1068) and EGFR in A431 cells following FED20 treatment. 
Compound Structures MW Log P* PSA (N+O) Aromatic rings pKa
FED20 685.08 2.13 199.7 14 3 7.2
EGFR
β-actin
0     0 0.05        0.2      0.5    1        2      10       
EGF (100ng/ml) - +        +       +    +      +       +       +
p-EGFR (Y1068)
FED20 (µM)
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4.4.2 Specificity of FED20 for EGFR 
To further evaluate the specificity of FED20 for EGFR, an uptake assay measuring levels of [18F]FED20 
uptake in high (A431) versus low (MCF7) EGFR expressing cells was carried out. Furthermore, a 
blocking study in which A431 and MCF7 cells were pre-treated with 10 μM of none-radiolabelled 
FED20 for 1 h before adding the radiotracer to the cells were assessed (Figure 49). The uptake of 
[18F]FED20 was 2.8 fold higher in the A431 cells compared to the MCF7 cells. Pre-treatment with 
FED20 led to a decrease in [18F]FED20 uptake in the A431 cells compared to untreated cells. 
However, this decrease was not statistically significant. There was no change in the tracer uptake 
following pre-treatment in the MCF7 cells. Overall, the uptake values of [18F]FED20 were significantly 
lower than those of [18F]FED6 with values under 2 CCPMA/μg of protein. Western blot analysis 
confirmed the high expression of EGFR in the A431 compared to low EGFR in the MCF7 cells. P-EGFR 
(Y1068) was lower in both cell lines following pre-treatment with FED20 (Figure 49B) suggesting that 
despite the inhibition of EGFR activity the uptake of [18F]FED20 did not decrease significantly. 
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Figure 49: [18F]FED20 uptake in high vs low EGFR expressing cells. 
A- [
18
F]FED20 uptake values in A431 and MCF7 cells treated with 0.55 MBq of [
18
F]FED20 for 1 h following pre-treatment 
with or without 10 µM of FED20 for 1 h. Data show mean ± SE of triplicates from one representative experiment carried 
out twice. B- Protein expression of p-EGFR (Y1068) and EGFR in A431 and MCF7 cells after pre-treatment with or without 
10 μM of FED20. Short and long exposures of the blot are shown. 
 
4.4.3 Substrate specificity of FED20 for the ABC transporters. 
The cytotoxic assays, which were carried out in the paired cell lines in order to indirectly assess the 
substrate specificity of the cyanoquinoline compounds for the ABC transporters (see section 4.2.) 
were also performed with FED20. However, under the conditions used FED20 did not lead to high 
levels of cytotoxicity and assays based on cellular toxicity of FED20 could therefore not be utilised to 
assess the substrate specificity of FED20 for the ABC transporters. 
To test the ABCG2 substrate specificity of FED20, the efflux ratios of FED20 were measured using the 
Caco2 transwell model. FED20 was associated with an efflux ratio < 2, indicating that it was not 
actively effluxed by the ABC transporters. Furthermore, pre-treatment with verapamil had no effect 
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Figure 50: Efflux ratio of FED20 in Caco2 cells with and without pre-treatment with verapamil. 
Efflux ratios of FED20 and vinblastine with or without 1 h pre-treatment with 10 mg/ml of verapamil obtained from a 
Caco2 transwell assay. Data show mean efflux ratios ± SE of n = 3 of one representative experiment. Stars indicate 
statistical difference between values of two-tailed unpaired t-test (**p ≤ 0.01). 
 
The substrate specificity of FED20 for the ABC transporter was assessed by determining the uptake 
of [18F]FED20 in cell lines with differential expression of the transporters: ABCG2 overexpressing cell 
lines MCF7MX and MCF7 and ABCB1 overexpressing cell lines 3T3-MDR1 and 3T3 using 
concentrations of pharmacological modulators optimised for FED6 (Figure 51). 
 
Figure 51: [18F]FED20 uptake in ABC transporter expressing cells. 
A- Protein normalised uptake of [
18
F]FED20 in MCF7 and MCF7MX cells after 1 h incubation with 0.55 MBq [
18
F]FED20 with 
or without pre-treatment with FTC. B- Protein normalised uptake of [
18
F]FED20 in 3T3, 3T3-MDR1 cells after 1 h incubation 
with 0.55MBq [
18
F]FED20 with or without pre-treatment with zosuquidar. Zos.: zosuquidar All data show mean ± SE of 
triplicates of one representative experiment carried out in duplicate. Stars indicate statistical difference between values of 
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The uptake of [18F]FED20 was higher in MCF7 (0.4 CCPM/μg of protein) compared to MCF7MX cells 
(0.2 CCPM/μg of protein). However, there was no increase in the uptake of [18F]FED20 following 
inhibition of ABCG2 by FTC (Figure 51A). These results suggest that the difference in uptake of 
[18F]FED20 between MCF7 and MCF7MX cells was not related to ABCG2 efflux of the radiotracer. 
Similarly, the uptake of [18F]FED20 was higher in 3T3 (0.3 CCPMA/µg protein) compared to 3T3-
MDR1 cells (0.2 CCPMA/µg of protein). There was no statistically significant difference in the uptake 
values of [18F]FED20 following zosuquidar pre-treatment (Figure 51B) suggesting that the difference 
in uptake of [18F]FED20 between 3T3 and 3T3-MDR1 cells was not related to ABCB1 efflux of the 
radiotracer. 
The lack of increase in uptake of [18F]FED20 following FTC treatment in MCF7MX and zosuquidar 
treatment in 3T3-MDR1 indicate that FED20 is not a substrate for ABCB1 nor ABCG2. 
4.4.4 FED20 in the context of mutant EGFR in NSCLC  
The affinity of FED20 for EGFR was in the nanomolar range and caused inhibition of p-EGFR (Y1068) 
as did FED6. Furthermore, FED20 was not found to be a substrate for either ABCB1 or ABCG2. Then, 
the affinity of FED20 to different mutant forms of EGFR was investigated. The inhibition of EGFR 
autophosphorylation following FED20 treatment in a series of NSCLC expressing either wild type, 
active or resistant mutant forms of EGFR (Figure 52) was determined. FED20 showed the strongest 
levels of inhibition of p-EGFR in the cells lines that express active mutant forms of EGFR, PC9, H3255 
and H1650. Only the highest concentration of 10 μM of FED20 led to changes in p-EGFR in wild type 
EGFR expressing A549 and H358 cells and resistant mutant expressing H1975 cells. The IC50 values of 
FED20 were 0.3 µM in the PC9 and H3255 compared to 7.1 µM in the H1975 cells (Figure 52 B2). 
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Figure 52: Differential FED20 inhibition of p-EGFR in NSCLC cell lines expressing mutant or wild 
type EGFR. 
A- Protein expression of p-EGFR (Y1068) and EGFR in NSCLC cells, treated with increasing concentrations of FED20. B1- 
Percentage inhibition of p-EGFR (Y1068) normalised to EGFR levels following FED20 treatment determined from the 
densitometry of the western blots. B2- Table summarising the average IC50 values ± SE, obtained from the percentage 
inhibition of p-EGFR plots. Data show mean ± SE from three separate experiments. 
 
0     0 0.05        0.2       0.5      1     2     10       
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Cell line IC50 (μM)
PC9 0.3 (± 0.08)
PC9ER 0.7 (± 0.3)
H3255 0.3 (± 0.02)
H1975 7.1 (± 0.8)
H358 3.3 (± 0.6)
A549 1.8 (± 0.3)
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To investigate a potential relationship between the differential inhibition of EGFR 
autophosphorylation in mutant EGFR by FED20, and the binding of radiolabeled [18F]FED20 to the 
different mutant forms of EGFR, the uptake of [18F]FED20 in wild type and mutant EGFR expressing 
NSCLC cell lines was carried out (Figure 53). 
 
Figure 53: Differential uptake of [18F]FED20 in active and resistant mutant EGFR. 
A- Protein normalised uptake of [
18
F]FED20 in NSCLC cells expressing mutant or WT EGFR following 1 h incubation with 
0.55 MBq of [
18
F]FED20. Data show mean of triplicate ± SE from one representative experiment performed twice. Stars 
indicate statistical difference between values of two-tailed unpaired t-test (**p ≤ 0.01). B- Differential protein expression 
of p-EGFR (Y1068) and EGFR in NSCLC cell lines. C- Densitometry values of p-EGFR (Y1068) and EGFR protein expression 
normalised for β-actin protein expression. 
 
Cell lines expressing active mutant forms of EGFR, showed the highest levels of uptake of the tracer, 
with values of 1.2 and 1.3 CCPMA/µg of protein in PC9 and H3255 cells, respectively (Figure 53A). 
However, the uptake of [18F]FED20 in H1650 cells, which also express active mutant EGFR, was low 
at 0.41 CCPMA/µg of protein. Wild type EGFR expressing A549 and resistant mutant expressing 
H1975 and PC9ER showed the lowest levels of uptake, with values of 0.4, 0.5 and 0.5 CCPMA/µg of 
protein, respectively (Figure 53A). H358 cells which also expressed wild type EGFR showed slightly 
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different mutant forms of EGFR the different NSCLC studied also expressed differential levels of both 
p-EGFR (Y1068) and EGFR (Figure 53B). The densitometry measures obtained from the western blots 
indicated that H3255 cells expressed the highest levels of p-EGFR (Y1068) and EGFR whilst H1650, 
H1975 and H358 expressed the lowest levels of p-EGFR (Y1068) and EGFR (Figure 53C). 
 
Figure 54: Correlation between [18F]FED20 uptake, EGFR protein expression and FED20 IC50 status. 
A- [
18
F]FED20 uptake over protein expression of p-EGFR (Y1068) normalised to β-Actin. B- [
18
F]FED20 uptake over protein 
expression of EGFR normalised to β-Actin. Protein expression values obtained from densitometry reading of western blots. 
Data show values from one representative carried out in triplicate. C- [
18
F]FED20 uptake over IC50 of FED20. IC50 values 
expressed as mean of IC50 values obtained from p-EGFR (Y1068) inhibition plots following FED20 treatment from three 
separate experiments. r2 correlation values indicated on the plots, statistically significant correlation indicated by p≤0.05. 
 
 
In order to better understand whether the differential uptake of [18F]FED20 in the NSCLC studied 
was linked to p-EGFR (Y1068) protein expression, EGFR protein expression and or FED20 affinity in 
these different cell lines, correlation graphs were plotted (Figure 54). The higher expression of p-
EGFR (Y1068) and EGFR in H3255 correlated to a high uptake of [18F]FED20, whilst the low 
expression of p-EGFR (Y1068) and EGFR in H1975, H1650 and A549 correlated with low cell uptake of 
[18F]FED20 (Figure 54A,B). The levels of uptake of [18F]FED20 did not seem to correlate to p-EGFR 
(Y1068) or EGFR levels in the H358, PC9 or PC9ER cells (Figure 54A,B). The low IC50 of FED20 in H3255 
and PC9 corresponded to higher uptake of [18F]FED20 whilst the high IC50 of FED20 in H1975 
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correlated with a low tracer uptake in these cells. However, there wasn’t a clear correlation between 
the affinity of FED20 in the other NSCLC studied and the uptake of [18F]FED20 as indicated by a lack 
of statistical correlation and r2 correlation values of 0.672 and 0.660 (Figure 54). The direct 
correlation of the affinity of FED20 in these different cells lines, which reflected the mutational 
status of EGFR, with the uptake of [18F]FED20 is confounded by differential levels of expression of 
both p-EGFR (Y1068) and EGFR in the majority of the cell line investigated. In this regard, the 
differential uptake of [18F]FED20 in PC9 and PC9ER cells, which express identical levels of EGFR, could 
be attributed to the differential affinity of FED20 in these two cell lines.  
 
In conclusion, FED20 was sensitive to EGFR expression and as for FED6, FED20 also showed higher 
affinity against active mutant EGFR compared to WT or resistant mutant EGFR. There was also a 
better correlation between the uptake of [18F]FED20 in the NSCLC and the affinity of FED20 for the 
different mutant forms of EGFR than was the case for [18F]FED6, despite a lack of correlation in 
several of the NSCLC cell lines tested. We hypothesize that this is a consequence of the lack of 
substrate specificity of FED20 for ABCG2 or ABCB1. Indeed, the substrate specificity of FED6 for 
ABCG2 confounded the results of the uptake of [18F]FED6 in the NSCLC that were shown to express 
ABCG2. 
  





Chapter 5: Monitoring response to gefitinib treatment 
in NSCLC  
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As well as investigating EGFR directly by PET imaging for potential therapy evaluation, another 
approach is to measure changes in other molecules, known to interact with EGFR as a surrogate of 
response to treatment. One such molecule, which will be investigated hereafter, is ChKα. 
5.1 Choline kinase alpha as a biomarker of response to gefitinib 
5.1.1 In vitro assessment of choline kinase alpha as a biomarker of response to gefitinib treatment in 
PC9 and PC9ER cells 
Choline kinase plays a key role in the metabolism of choline (see Figure 11), it is the first enzyme in 
the kennedy pathway and leads to the conversion of choline to phosphocholine (Gibellini and Smith, 
2010). The role of Chkα as a component in the regulation of the activity of EGFR has been elucidated 
in breast cancer and was shown to involve the interaction of ChKα with EGFR and SRC. The 
mechanistic involvement of ChKα as part of this complex makes it an important molecule to 
investigate for the assessment of response to therapies directed against EGFR. As well as the 
mechanistic link between ChKα and EGFR, the biological relevance of studying ChKα in the context of 
lung cancer is also significant. Overexpression and or increased activity of ChKα have been reported 
in many cancers including, brain, breast, lung and colorectal (Glunde et al., 2011). It has also been 
shown to act as a prognostic biomarker of survival in lung cancer. (Ramirez de Molina et al., 2007). 
Based on these findings, the aim was to investigate whether choline kinase could be used as a 
biomarker of response/resistance to gefitinib treatment in lung cancer. 
The effect of gefitinib treatment was measured in vitro in the sensitive PC9 and resistant PC9ER cells. 
The differential sensitivity of these two cell lines to gefitinib was confirmed by performing cell 
viability assays after 6, 24, 48 and 72 h treatment. The GI50 values determined are plotted in Table 
14. 
For the rest of the experiments, three time points were assessed, 6, 24 and 48 h treatment. The 6 
and 24 h time points would be predictors of pharmacodynamic interactions whereas the 48 h time 
point focused on response to treatment. The same concentrations of gefitinib were chosen for the 6 
and 24 h time points. However, these concentrations were too toxic to the gefitinib sensitive PC9 
cells when treating for 48 h. Therefore, lower concentrations of gefitinib were selected for the 48 h 
time point. As a prelude to measurement of ChKα function (expression and activity, linked to 
upstream and downstream signalling), changes in the cell cycle and apoptosis were determined. 
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Table 14: GI50 of gefitinib in PC9 and PC9ER cells. 
 
GI50 values were determined by performing a cell viability SRB assay following, 6, 24, 48, and 72 h gefitinib treatment of 
PC9 and PC9ER cells. Data represent means ± SE of GI50 values obtained from three separate experiments. GI50 Values 
expressed in μM. 
 
5.1.1.1 Cell cycle profile following 6, 24 and 48 h gefitinib treatment. 
 
Choline kinase has been shown to play an important role in the regulation of cell proliferation and 
appears to be involved in the regulating the G1 to S phase transition (Ramirez de Molina et al., 
2008). Therefore, as well as investigating the changes to choline kinase activity and expression the 
effect of gefitinib treatment on the cell cycle profile was assessed in order to correlate any changes 
with changes to ChKα. For this, PI staining of the DNA obtained from gefitinib treated cells was 
performed, and the stained samples were analysed by FACS flow cytometry. 
The cell cycle profile of the PC9 cells after 6, 24 and 48 h gefitinib treatment are illustrated in Figure 
55A. The peak at 50K was characteristic of cells in G1 phase of the cycle and the peak at 100K was 
characteristic of cells in G2/M phase. There were no changes in the cell cycle profile after 6 h 
gefitinib treatment. Over 40 % of the PC9 cells were in G1 phase. After both 24 and 48 h treatment 
there was a significant increase in the number of cells in sub-G1 phase illustrated by appearance of a 
peak at 25K, and a reduction of the number of cells in G1 and G2/M phases of the cell cycle. After 24 
h treatment, 40 % of PC9 cells were in sub-G1 at 3 and 10 μM gefitinib and 55 % of cells were in sub-
G1 at 20 μM gefitinib compared to 3% in untreated control cells. The percentage of cells in G1 and 
G2/M phase of the cell cycle were also decreased following treatment from 59 and 17% in control 
cells to 26 and 3 % at 20 µM gefitinib. After 48 h treatment, 0.001 and 0.01 μM of gefitinib did not 
lead to significant changes to the cell cycle distribution compared to 1 and 3 μM of gefitinib which 
led to significant changes to the percentage distribution of cells in the cell cycle. The percentage of 
cells in sub-G1 increased from 5 % in control cells to 78 % at 1 µM gefitinib, whilst the percentage of 
cells in G1 and G2/M phases decreased from 66 and 14 % in the control sample to 14 and 1 % at 
PC9 PC9ER
GI50 at 6 h >100 >100
GI50 at 24 h 42 (± 6) 62 (± 2)
GI50 at 48 h 0.060 (± 0.01) 6.7 (± 0.3)
GI50 at 72 h 0.036 (± 0.011) 5.8 (± 0.1)
   
 134 
1 µM gefitinib. The reduction of cells in G1, S and G2/M and the increase in cells in sub-G1 were 
indicative of cell death. 
As with the PC9 cells there was no change to the cell cycle profile of the PC9ER cells after 6 h 
gefitinib treatment, with over 40 and 30 % of the cells in G1 and G2M phase, respectively. After 24 h 
treatment, only the two highest concentrations of gefitinib led to a change in the cell cycle profile 
compared to the untreated cells. The percentage of cells in sub-G1 increased from 7 % in the 
untreated control cells to 25 % after 10 and 20 μM of gefitinib treatment (Figure 55B). After 48 h 
treatment, only the highest concentration of gefitinib of 3 μM led to any changes to the cell cycle 
profile of the PC9ER cells compared to the untreated control cells. Indeed, 12 % of cells were in sub-
G1 compared to 4 % in the untreated control cells (Figure 55B). 
In conclusion, the cell cycle profile analysis showed high levels of cell death in PC9 cells compared to 
PC9ER cells following gefitinib treatment for 24 and 48 h. The highest concentrations of gefitinib of 
10 and 20 µM also caused an increase in cell death in the resistant PC9ER cells. 
  




Figure 55: Cell cycle profile of PC9 or PC9ER cells following 6, 24 and 48 h gefitinib treatment. 
Cell cycle profile (top panels) and cell cycle phase distribution (bottom panels) indicating DNA content of PC9 (A) and 
PC9ER (B) cells following 6 h (left hand panel ), 24 h (middle panel) and 48 h (right hand panel) of gefitinib treatment. Data 
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5.1.1.2 Apoptosis levels following 6, 24 and 48 h gefitinib treatment 
Gefitinib treatment especially at concentrations above 10 μM and after 24 h treatment led to 
significant increases in the number of cells in sub-G1 phase of the cell cycle. An accumulation of cells 
in sub-G1 was characteristic of an increase in cell death. To further investigate whether cell death 
was due to caspase 3/7-induced apoptosis, a caspase glow 3/7 assay was carried out in both cell 
lines following gefitinib treatment (Figure 56). In PC9 cells, after 6 h treatment, there were no 
changes to levels of apoptosis at concentrations below 10 μM of gefitinib. A 1.8 and 2.4 fold increase 
in apoptosis were measured at 10 and 20 µM of gefitinib, respectively. After 24 h treatment, there 
was a 4, 8 and 17 fold increase in apoptosis in the PC9 cells treated with 3, 10 and 20 μM of gefitinib, 
respectively. After 48 h treatment, there were no changes to the levels of apoptosis at gefitinib 
concentrations below 0.1 μM. There was a 13 and 15 fold increase in apoptosis following 0.1 and 1 
and 3 μM gefitinib, respectively compared to untreated cells (Figure 56A). In PC9ER cells, levels of 
apoptosis were unchanged after 6 h gefitinib. After 24 h treatment, no apoptosis was measured at 
concentrations of gefitinib below 10 µM. However, there was a 6 and 20 fold increase in apoptosis 
levels after 10 and 20 μM gefitinib. After 48 h treatment, only 1 and 3 µM gefitinib led to an increase 
in levels of apoptosis. These increased by just under two-fold compared to control untreated cells 
(Figure 56B). 
In conclusion, the caspase glow3/7 assay showed high levels of apoptosis in PC9 cells at 10 and 
20 µM gefitinib after 6 and 24 h treatment and at 0.1, 1 and 3 µM gefitinib after 48 h treatment. 
High levels of apoptosis were only measured after 24 h treatment at 10 and 20 µM gefitinib in PC9ER 
cells. The high levels of apoptosis measured in the caspase glow 3/7 assay correlated with the high 
levels of cell death associated with high levels of sub-G1 measured in the cell cycle analysis of PC9 
and PC9ER cells following gefitinib treatment. 
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Figure 56: Apoptosis levels in PC9 and PC9ER cells following 6, 24 and 48 h gefitinib treatment. 
Fold change in apoptosis in PC9 (A) and PC9ER (B) cells following 6, 24 and 48 h gefitinib treatment assessed by carrying 
out a caspase 3/7 assay. Data show mean fold changes in apoptosis following protein normalisation of n = 4 samples ± SE 
from one representative experiment carried out two times. 
 
5.1.1.3 Changes to ChKα protein expression following 6, 24 and 48 h gefitinib treatment. 
The differential sensitivity of PC9 and PC9ER cells for gefitinib in particular after 48 h treatment were 
demonstrated above. The role of ChKα as a potential biomarker for the differential response to 
gefitinib treatment was then addressed. First, the protein expression profile of p-EGFR (Y1068), 
EGFR, p-ERK, ERK as well as ChKα following 6, 24 and 48 h gefitinib treatment of PC9 and PC9ER cells 
were investigated. p-EGFR (Y1068), EGFR, p-ERK and ERK showed similar patterns of expression after 
6, 24 and 48 h gefitinib treatment (Figure 57). In the gefitinib sensitive PC9 cells, p-EGFR (Y1068) and 
p-ERK were completely inhibited at all concentrations of gefitinib while EGFR and ERK were 
unchanged. In the resistant PC9ER cells, there was a dose dependant decrease in p-EGFR (Y1068) 
and p-ERK with increasing concentrations of gefitinib, only the highest concentration of 20 μM at 6 
and 24 h, and 3 μM at 48 h, of gefitinib led to complete inhibition of protein expression. EGFR and 
ERK protein levels were unchanged with treatment (Figure 57). ChKα expression was unchanged in 
both cell lines after 6 h gefitinib treatment. After 24 h treatment, the protein expression of ChKα 
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densitometry values for ChKα (Figure 57B right panel) whereas a concentration dependant increase 
in levels of ChKα were measured in PC9ER cells. After the longer incubation of 48 h, there was a 
concentration dependant decrease in the protein expression of ChKα in the PC9 cells. A decrease of 
over 40 % was measured at 1 and 3 μM gefitinib, whereas an increase in the protein expression of 
ChKα was measured in the PC9ER cells (Figure 57C right panel). 
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Figure 57: Changes in choline kinase alpha protein expression following 6, 24 and 48 h gefitinib 
treatment in PC9 and PC9ER cells. 
A-C- Protein expression of P-EGFR Y1068, EGFR, p-ERK, ERK and ChKα (left panel) of PC9 and PC9ER cells following gefitinib 
treatment for 6 h (A), 24 h (B) and 48 h (C). Right panel indicates densitometry values of ChKα expression corrected for β-
actin levels. Data show results from one representative experiment carried out three times.  
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To further investigate changes to ChKα expression, mRNA levels of ChKα were assessed following 
gefitinib treatment. 
5.1.1.4 Levels of ChKα mRNA following 6, 24 and 48 h gefitinib treatment. 
There was no significant change in the mRNA levels of ChKα in the PC9 cells at all three time points. 
In PC9ER cells, mRNA levels of ChKα increased following gefitinib treatment at 6, 24 and 48 h 
treatment. This increase was not always concentration dependant; after 6 h treatment, all three 
concentrations of the drug led to the same increase in expression of ChKα mRNA, just under 2 fold 
compared to control. There was a 2.8 and 3.1 fold increase in levels of ChKα mRNA after 1 and 3 μM 
gefitinib treatment, respectively (Figure 58B). 
 
 
Figure 58: Changes to ChKα mRNA levels following 6, 24 and 48 h gefitinib treatment. 
mRNA expression of ChKα of PC9 (A) and PC9ER (B) cells following 6, 24 and 48 h gefitinib treatment. Data represent mean 
levels of ChKα mRNA normalised to GAPDH and expressed relatively to control DMSO treated sample ± SE of duplicates 
from three separate experiments 
 
Despite a decrease in protein expression measured following 24 and 48 h gefitinib treatment in PC9 
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uncorrelated in PC9ER cells, in which an increase in mRNA levels of ChKα were measured at all three 
time points whereas an increase in the protein expression was only measured after 48 h treatment.  
Having measured differential expression levels of ChKα in PC9 and PC9ER cells following gefitinib 
treatment, the role of ChKα as a biomarker of response to gefitinib treatment was further assessed 
by measuring changes to the activity of ChKα. 
5.1.1.5 [3H]choline uptake following 6, 24 and 48 h gefitinib treatment. 
In order to assess the activity of ChKα following gefitinib treatment in the PC9 and PC9ER cells 
[3H]Choline uptake experiments were carried out. 
Choline kinase is responsible for the phosphorylation of choline to phosphocholine. Once choline is 
phosphorylated it is trapped within the cell. Therefore, the retention of [3H]phosphocholine in the 
cell can be used as a surrogate measure of the activity of ChKα (Nimmagadda et al., 2009). 
[3H]choline uptake experiments in which the retention of the radioactivity was measured in the 
whole cell lysate were first carried out (Figure 59). This uptake reflected both the transport and 
phosphorylation of [3H]choline. 
The basal levels of [3H]choline uptake, measured in untreated cells, were 2 to 3 fold higher in PC9 
than in PC9ER cells (Figure 59). In PC9 cells, the uptake of [3H]choline decreased by 50 % after both 6 
and 24 h treatment with gefitinib at 3 and 10µM. At the highest concentration of 20 µM the uptake 
of the radiotracer decreased by 70 % after 6 h and 84 % after 24 h treatment. (Figure 59A,B). After 
48 h treatment, both 1 and 3 µM of gefitinib led to a 74 % decrease in the uptake of [3H]choline 
(Figure 59C). 
In PCER cells, at 6 h, in contrast to the PC9 cells, only the highest concentration of 20 μM gefitinib led 
to a decrease in [3H]choline uptake, over 50 % compared to untreated cells (Figure 59A). After 24 h 
treatment, both 10 and 20 µM gefitinib led to a decrease in [3H]choline uptake (Figure 59B). Finally, 
following 48 h gefitinib treatment no change in the uptake of [3H]choline were measured in the 
PC9ER cells compared to control (Figure 59B,C). 
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Figure 59: Whole cell [3H]choline uptake in PC9 and PC9ER cells following 6, 24 and 48 h gefitinib 
treatment. 
Corrected counts per minute per µg of protein of [
3
H]choline in whole cell lysate of PC9 and PC9ER cells following 6 h (A), 
24 h (B) and 48 h (C) gefitinib treatment. Data show mean values ± SE of triplicates from one representative experiment 
carried out three times Stars indicate statistical difference between tested value and control of two-tailed unpaired t-test 
(* p ≤ 0.05 **p ≤ 0.01). 
 
 
Following [3H]choline incubation, cells were washed before being collected and lysed. Any 
untrapped [3H]choline should therefore have been removed during the washing step. Hence only the 
[3H]phosphocholine component which would have been trapped in the cell would be measured in 
the whole cell lysate. In order to further investigate that the radioactivity measured in the whole cell 
lysate reflected the formation of [3H]phosphocholine, a [3H]Choline uptake assay in which the 
[3H]phosphocholine component was isolated from the whole cell lysate was performed (Figure 60). 
As for the whole cell lysate uptake, the basal levels of [3H]phosphocholine were 2 to 3 fold higher in 
PC9 than in PC9ER cells (Figure 60A). In PC9 cells, there was a differential effect of gefitinib 
treatment at different time points. After 6h treatment, levels of [3H]phosphocholine decreased by 
20 % at 10 μM gefitinib and by 40 % at 20 μM gefitinib compared to untreated cells (Figure 60A). 
After 24 h treatment, 3 μM gefitinib caused a 60 % decrease in levels of [3H]phosphocholine whilst 
the highest concentration of 20 μM caused a 90 % decrease in [3H]phosphocholine (Figure 60B). At 
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48 h, there was a significant decrease in [3H]phosphocholine at all concentrations of gefitinib. Both 1 
and 3 μM of the drug led to a 67 % decrease in levels of [3H]phosphocholine compared to untreated 
cells.  
In PC9ER cells, after 6 h treatment, levels of [3H]phosphocholine decreased by 30 and 60 % at 10 and 
20 µM gefitinib, respectively. After 24 h treatment, only 20 μM gefitinib caused a significant 
decrease in [3H]phosphocholine levels (Figure 60A,B). At 48 h, in contrast to PC9 cells, levels of 
[3H]phosphocholine were unchanged following 48 h gefitinib treatment in PC9ER cells (Figure 60C). 
With the exception of 6 h treatment in the PC9 cell, the values of [3H]phosphocholine measured 
following phosphocholine isolation were in line with the uptake values obtained from whole cell 
lysate. Therefore, the radioactivity measured in the whole cell lysate corresponded to the 
phosphocholine component. The initial washes which were carried out to remove the excess 
[3H]choline at the end of the tracer incubation, removed any untrapped choline. Incomplete 
recovery of [3H] phosphocholine, during the extraction process, could account for some of the 
discrepancies between the uptake values measured using both methods. We therefore concluded 
that isolation of [3H]phosphocholine was not necessary and that measuring the uptake of [3H]choline 
in the whole cell was indicative of the levels of phosphocholine formed as a result of ChKα activity. 
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Figure 60: [3H]phosphocholine levels in PC9 and PC9ER cells following 6, 24 and 48 h gefitinib 
treatment. 
Counts per minute acquired per µg of protein of the [
3
H]phosphocholine fraction from PC9 and PC9ER cells following 
gefitinib treatment for 6 h (A), 24 h (B) and 48 h (C). Data show mean values ± SE of triplicates of one representative 
experiment carried out three times. Statistically significant changes compared to untreated control from two-tailed 
unpaired t-test are marked with star (* = P ≤ 0.05 and ** = p ≤ 0.01). 
 
In conclusion both [3H]phosphocholine isolation and whole cell lyaste [3H]choline uptake, indicated a 
differential effect of gefitinib on ChKα activity in the sensitive PC9 and resistant PC9ER cell line. At 
the earlier time points of 6 and 24 h, the activity of ChKα was decrease at all concentrations of 
gefitinib in the sensitive PC9 cells, whereas only the highest concentrations of 10 and 20 µM led to a 
decrease in ChKα activity in PC9ER cells. After 48 h treatment, there was a differential effect of 
gefitinib on ChKα activity as measured by a decrease in [3H]phosphocholine in PC9 cells but no 
change in PC9ER cells. 
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5.1.2 In vivo [18F]D4choline uptake in PC9 and PC9ER xenografts. 
As discussed in section 5.1.1 a differential effect of both ChKα protein expression and activity were 
measured in PC9 and PC9ER cells treated with gefitinib. After 48 h treatment there was a significant 
decrease in ChKα activity and protein expression in gefitinib sensitive PC9 cells whereas there was 
no change in PC9ER cells. Based on the findings, the aim was to investigate whether ChKα could be 
used as a biomarker of early response, failure of response to gefitinib treatment in vivo. 
Several radiotracers based on choline, including [11C]choline (Contractor et al., 2011a) and 
[18F]fluoromethylcholine (DeGrado et al., 2001a) discussed in chapter 1 have been developed for PET 
imaging of choline metabolism. In these studies, a deuterium derivative of [18F]fluoromethylcholine, 
[18F]D4choline(Leyton et al., 2009, Witney et al., 2012), was used to investigate changes to choline 
metabolism of PC9 and PC9ER xenografts, following 48 h oral treatment of either 50 mg/kg of 
gefitinib or vehicle. 
The merged CT/PET sagittal and transverse cross sections of PC9 xenografts (Figure 61A) indicated a 
low tumour uptake of [18F]D4choline. There was a high level of background uptake in the GI tract. 
Furthermore, there was a visibly lower uptake of the tracer at the very centre of the tumour. This 
was especially noticeable in the vehicle treated mouse (Figure 61A left panel) and could be caused 
by necrosis at the core of the tumour. The time activity curves (Figure 61B), indicated a higher 
uptake of [18F]D4choline in the gefitinib treated group compared to the vehicle treated group. The 
TACs were characterised by an initial phase from 0 to 3.5 minutes, in which the uptake of 
[18F]D4choline in the tumour increased in both groups. Following this initial perfusion of the tumour 
the uptake in the gefitinib treated group then decreased until 60 minutes, whereas the uptake in the 
vehicle treated group remained unchanged.  
The sagittal and transverse cross section of the PC9ER xenografts showed similar levels of uptake in 
the vehicle (Figure 61B, left panel) and gefitinib treated (Figure 61B, right panel) xenografts. The 
TACs for both the vehicle (n = 6) and gefitinib (n = 4) treated PC9ER xenografts indicated an initial 
increase in [18F]D4choline uptake from 0 to 3.5 min followed by a small decrease in radiotracer 
uptake in the tumour until 60 min (Figure 61D). The TAC of the gefitinib treated group highlighted a 
significant intragroup variability in the uptake of [18F]D4choline compared to the vehicle treated 
group. The lower n number of mice scanned in the gefitinib group could account for this variability 
compared to the vehicle treated mice.  
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Figure 61: [18F]D4choline PET imaging of PC9 and PC9ER xenografts following 48 h gefitinib 
treatment. 
A,C- Merged PET/CT image of representative sagittal (top) and frontal (bottom) cross section of PC9 (A) and PC9ER (C) 
xenograft mouse at baseline and following 48 h vehicle treatment or 48 h gefitinib treatment at 50 mg/Kg at 60 min post 
i.v. injection of 3.7 MBq of [
18
F]D4choline Tumours indicated by white arrow. B, D- Tumour time activity curves of PC9 (B) 
and PC9ER (D) xenografts. Values show mean ± SE of n = 4 mice per group. 
 
Other parameters were determined to compare the vehicle and gefitinib treatments in both tumour 
models. First, the normalised uptake value at t = 60 min, which indicated the uptake of the tracer in 
the tumour 1 h post radiotracer injection was calculated There were no differences in the average 
NUV60 of both vehicle and gefitinib treated PC9 and PC9ER xenografts (Figure 62A). The AUC value 
was significantly higher in the gefitinib treated group at 197 %ID/mL* min compared to 
138 %ID/mL* min in the vehicle treated group in the PC9 xenografts. This can be explained by a 
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significantly higher initial uptake of [18F]D4choline in the tumour of the gefitinib compared to the 
vehicle treated PC9 xenografts. In the PC9ER xenografts, there was no difference in the AUC of the 
gefitinib and vehicle treated groups. (Figure 62B). 
As described above the tumour models investigated were characterised by a tendency to develop 
necrotic cores, as illustrated in the H&E staining of sectioned tumours in Figure 63.  One way of 
addressing this confounding feature was to determine the uptake of the radiotracer that 
corresponded to the highest quartile of radiotracer uptake in the tumour. These values were plotted 
in Figure 62C. These values indicated higher uptake as illustrated by higher % ID/mL values 
compared to the NUV60. The uptake in the gefitinib treated group was no longer higher than that of 
the vehicle treated group for both the PC9 and PC9ER xenografts. This could indicate that potential 
higher levels of necrosis in the vehicle treated groups led to lower levels of uptake of [18F]D4choline 
than in the gefitinib treated groups. 
Finally another potential confound to the tumour uptake of [18F]D4choline was differential perfusion 
of the tumours. One way of expressing the retention of the radiotracer in the tumour whilst 
discarding the initial uptake phase was to calculate the fractional retention of the tracer (FRT). Here 
the FRT was measured between 3.5 and 60 min. In the PC9 xenografts the FRT decreased from 0.9 in 
the vehicle treated group to 0.7 in the gefitinib treated group, this represented a 20 % decrease in 
FRT (Figure 62D). There was no change in the fractional retention values measured in the PC9ER 
xenografts (Figure 62D). 
In conclusion, the confounds of tumour perfusion and necrosis may in part explain why no difference 
in tumour uptake were measured between the vehicle and gefitinib treated PC9 or PC9ER 
xennografts, when measuring the NUV60. The FRT value was significantly lower following gefitinib 
treatment than vehicle treatment in the PC9 xenografts and based on the FRT values [18F]D4choline 
could be used to assess early response to gefitinib treatment in NSCLC. 
 
  




Figure 62: Tumour uptake parameters from [18F]D4choline PET imaging of PC9 and PC9ER 
xenografts following 48 h gefitinib or vehicle treatment. 
Parameters determined after PET imaging of PC9 and PC9Er xenografts following 48 h gefitinib or vehicle treatment. A- 
Average tumour Uptake value of [
18
F]D4choline in PC9 and PC9ER tumours at t=60 min after tracer injection. B- Area under 
the curve values for PC9 and PC9ER tumours. C- Average highest quartile [
18
F]D4choline tumour uptake. D- Fractional 
retention of [
18
F]D4choline in PC9 and PC9ER tumours between 3.5 and 60 min post tracer injection. Data show mean ± SE 
of n = 4 mice per group. Statistically significant differences from two tailed unpaired t-test are marked with a star 
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Figure 63: Representative immunohistochemistry analysis of PC9 and PC9ER tumour samples from 
[18F]D4choline PET imaging. 
Tumours were extracted and fixed in formalin at the end of the PET scan. Tumours were then sectioned and stained for 
haematoxylin and eosin (H&E). Sample necrotic regions are indicated by yellow arrows. 
 
The tumours from the PET study were collected, processed and analysed by gel electrophoresis 
(Figure 64). In the PC9 tumours a complete inhibition of p-EGFR (Y1068) in the tumours obtained 
from the gefitinib treated xenografts was measured, compared to tumour lysates from the vehicle 
group. Gefitinib treatment also led to a decrease in p-SRC Y416, ChKα, p-AKT and p-ERK. Levels of 
total EGFR were also decrease compared to vehicle treated xenografts. Total levels of AKT and ERK 
were the same as in vehicle treated tumours. In the PC9ER tumour lysates there was a decrease in 
the expression of p-EGFR Y1068 following gefitinib treatment. However, this decrease was y less 
than that of the PC9 tumours. There was also a decrease in the levels of p-SRC Y416 in the gefitinib 
treated group. Levels of Chkα, p-AKT, AKT, p-ERK and ERK were unchanged between vehicle and 








48 h vehicle 48 h gefitinib
48 h vehicle 48 h gefitinib
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Figure 64: Protein expression analysis from PC9 and PC9ER tumour lysates following [18F]D4choline 
PET imaging. 
Protein expression of p-EGFR Y1068, EGFR, ChKα, p-SRC Y416, SRC, p-AKT, AKT, p-ERK, ERK in tumour lysates from PC9 and 
PC9ER xenograft from 48 h vehicle or 50 mg/kg gefitinib treated groups. Each column represents a lysate from one tumour. 
 
The changes to protein levels of ChKα that were measured from the analysis of the tumour lysates 
did not correlate with the values of [18F]D4choline which were measured in the different treatment 
groups of both the PC9 and PC9ER xenografts (when the measure was NUV60 or AUC). The western 
blots indicated a decrease in levels of ChKα in the PC9 gefitinib treated group, the same group that 
showed the highest uptake of radiotracer in the PET imaging.  
The FRT values for [18F]D4choline were the only parameters that appeared to correlate with the 
changes in ChKα expression. Indeed, no change in FRT values or ChKα expression were measured 
between the PC9ER groups and both the FRT and ChKα expression were decreased in the PC9 
gefitinib treated group compared to vehicle. 
5.1.3 Investigating the EGFR-ChKα-SRC complex. 
In order to understand if the changes seen could be attributed in part to EGFR–SRC-ChKα complex, 
the involvement of ChKα in this complex was further assessed. It has been reported in breast cancer 
PC9ER tumours PC9 tumours  
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models that SRC protein is involved in the interaction between EGFR and ChKα. Here, the interaction 
of EGFR, SRC and ChKα was studied in the sensitive and resistant lung cancer models used 
previously.  
The effect of inhibiting EGFR or SRC on ChKα expression and activity were assessed. Protein 
expression of p-EGFR Y1068, p-SRC Y416, SRC and ChKα were measured and [3H]choline uptake and 
changes in levels of apoptosis following both gefitinib and dasatinib were determined. 
Concentrations based on the GI50 of each drug in the cell line investigated were used. PC9 and PC9ER 
cells were therefore treated with different concentrations of drug. In order to focus mainly on the 
pharmacodynamic effect of the drugs on the complex changes, 1, 6 and 24 h treatment were 
assessed. 
5.1.3.1 Changes in protein expression, [3H]choline uptake and apoptosis following 1, 6 and 24 h 
gefitinib treatment. 
PC9 and PC9ER cells were treated with different concentrations of gefitinib based on the GI50 of this 
drug in each cell line. The concentrations used are summarised in Table 15. Hereafter the 
concentrations will be referred to as 0.5* GI50, GI50 and 5* GI50. 
Table 15: GI50 values of PC9 and PC9ER cells treated with gefitinib for 72 h. 
 
PC9 and PC9ER cells seeded in 96 well plates were treated with gefitinib for 72 h. After drug incubation, an SRB assay was 
carried out. GI50 values represents mean values ± SE from n = 6 replicates of three separate experiments.  
After 1, 6 and 24 h gefitinib treatment there was a concentration dependant decrease in p-EGFR 
(Y1068) but no changes to levels of total EGFR in both the PC9 and PC9ER cells. Expression of ChKα 
was unchanged at 1 and 6 h following gefitinib treatment but decreased at 5*GI50 concentration of 
gefitinib in both cell lines at 24 h. P-SRC Y416 was unchanged at 1 and 6 h treatment. However, there 
was a concentration dependant decrease in levels of P-SRC Y416 in the PC9 cells and a decrease at 
5* GI50 concentration of gefitinib in the PC9ER cells after 24 h gefitinib treatment (Figure 65). 
PC9 PC9ER
0.5*GI50 (μM) 0.018 2.9
GI50 (μM) 0.036(+-0.011) 5.8(+-0.1)
5*GI50 (μM) 0.18 29
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Figure 65: Effect of 1, 6 and 24 h gefitinib treatment on protein expression in PC9 and PC9ER cells. 
Protein expression of p-EGFR (Y1068), EGFR, ChKα p-SRC (Y416) and SRC in PC9 and PC9ER cells treated with gefitinib for 1 
h (A), 6 h (B),and 24 h (C). GI50, 0.5 and 5* GI50 concentration values are indicated in Table 15. Right panel represents the 
densitometry values of ChKα protein expression normalised for β-Actin. Data show results from one representative 
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After examining changes in the protein expression of EGFR, SRC and ChKα changes to the activity of 
ChKα were indirectly assessed by carrying out [3H]choline uptake experiments 
The values of [3H]choline uptake were expressed as percentage of untreated control cells for each 
cell line. After both 1 and 6 h gefitinib treatment there were no changes in levels of [3H]choline 
uptake in the PC9 cells. After 24 h treatment, the uptake of [3H]choline was decreased by 20 % at 
0.5* and 1* GI50 and by 45 % at 5* GI50 concentration of gefitinib (Figure 66). 
In the PC9ER cells at 1 h, only the 5* GI50 concentration of gefitinib led to a decrease in the uptake of 
[3H]choline compared to that in untreated control cells; the uptake was decreased by 40 % (Figure 
66A). After 6 h treatment, there was a dose dependant decrease in the uptake of [3H]choline in the 
PC9ER cells; there was a 25 % decrease in uptake at the GI50 concentration of gefitinib and a 75 % 
decrease in the uptake at the 5* GI50 concentration of gefitinib. Finally, after 24 h treatment, 0.5 and 
1* GI50 concentrations of gefitinib led to a 45 % decrease in [
3H]choline, whereas 5* GI50 led to 85 % 
decrease in [3H]choline uptake. The decrease in ChKα activity measured following 1 h treatment at 
5* GI50 concentration of gefitinib in the PC9ER cells could be caused by the direct inhibition of ChKα 
by gefitinib. 
  




Figure 66: Changes in ChKα activity following 1, 6 and 24 h treatment with gefitinib. 
Percentage of [
3
H]choline uptake compared to control in PC9 and PC9ER cells treated with gefitinib for 1 h (A), 6 h (B) and 
24 h (C). Data show mean values ± SE from three experiments each using triplicate samples per concentration. Statistically 
significant differences compared to control from two-tailed unpaired t-test are marked with a star (* = P ≤ 0.05 and ** = p 
≤ 0.01). 
 
Having treated cells with concentrations of up to 5* GI50 of gefitinib, levels of apoptosis were also 
accessed via caspase glow 3/7 assay. Changes to levels of cell death especially at the 24 h time point 
needed to be taken into consideration when drawing any conclusions from changes to expression 
and activity of ChKα.  
After 1 and 6 h drug treatment there was a small but insignificant increase in apoptosis in the PC9 
cells with the exception of the 6 h treatment at 5* GI50 concentration which was associated with a 
1.8 fold increase in apoptosis (Figure 67). No significant changes in apoptosis levels were measured 
in the PC9ER cells at both 1 and 6 h treatment with the exception of 5* GI50 concentration of 
gefitinib which led to a 1.6 fold increase in apoptosis (Figure 67). At 24 h treatment, levels of 
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than at control. In PC9ER cells there was a very high increase in levels of apoptosis at 5* GI50 value of 
gefitinib, increasing to over 11 fold from control (Figure 67C). 
 
Figure 67: Effect of 1, 6 and 24 h gefitinib treatment on apoptosis in PC9 and PC9ER cells. 
Fold increase in apoptosis in PC9 and PC9ER cells following 1 h (A), 6 h (B) and 24 h (C) gefitinib treatment assessed by 
carrying out a Caspase 3/7 assay. Data show mean values of fold increase in apoptosis normalised to protein levels ± SE of 
n = 4 samples per concentration from one representative experiment carried out twice. Statistically significant differences 
compared to control from two-tailed unpaired t-test are marked with a star (* = P ≤ 0.05 and ** = p ≤ 0.01). 
 
In summary, gefitinib dependant loss of EGFR activity occurred rapidly and in a dose dependant 
manner in both cell lines. However, after 1 and 6 h treatment, ChKα activity was not decreased in 
the PC9 cells and only the highest concentrations of gefitinib led to a decrease in ChKα in the PC9ER 
cells. As discussed above the decreased measured in ChKα at these concentrations of gefitinib could 
result from a direct inhibition of ChKα activity by gefitinib. The elevated levels of apoptosis at 24 h 
made understanding the regulation of ChKα activity by EGFR complicated. This suggested that EGFR 
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5.1.3.2 Changes in protein expression, [3H]choline uptake and apoptosis following 1, 6 and 24 h 
dasatinib treatment 
 
The second molecule in the EGFR-SRC-ChKα complex, which was investigated, was SRC. In order to 
determine whether active SRC was key to the activity of ChKα, PC9 and PC9ER cells were treated 
with SRC inhibitor dasatinib. Following dasatinib treatment, changes in protein expression 
[3H]choline uptake and apoptosis were measured. 
One, 6 and 24 h dasatinib treatment were assessed. The concentrations of drug were determined for 
each cell line based on the GI50 of dasatinib. These concentrations are summarised in Table 16. 
Hereafter the concentrations will be referred to as 0.5* GI50, GI50 and 5* GI50.  
Table 16: GI50 values of PC9 and PC9ER cells treated with dasatinib for 72 h 
 
PC9 and PC9ER cells seeded in 96 well plates were treated with dasatinib for 72 h. After drug incubation cytotoxicity was 
assessed via an SRB assay. GI50 represents mean values ± SE from n = 6 replicates of three separate experiments. 
 
After 1, 6 and 24 h of dasatinib treatment there was complete inhibition of p-SRC Y416 and an 
increase in total SRC protein expression in both cell lines at all three concentrations tested compared 
to untreated cells (Figure 68). Dasatinib also caused an inhibition of p-EGFR Y1068 expression; this 
occurred at the 5*GI50 concentration of dasatinib in the PC9 cells at 1 and 6 h treatment and at all 
three dasatinib concentration at 24 h treatment. There was a dose dependant decrease in p-EGFR 
Y1068 expression in the PC9ER cells at all-time points. Total EGFR levels were unchanged with drug 
treatment in both cell lines at all-time points. ChKα levels were unchanged in both cell lines after 1 h 
drug treatment. At 6 h, there was a dose dependant decrease in ChKα expression in the PC9ER cells 
following dasatinib treatment, whereas levels were unchanged in the PC9 cells (Figure 68B). At 24 h, 
there was a dose dependant decrease in ChKα in both cell lines (Figure 68C).  
PC9 PC9ER
0.5*GI50 (μM) 0.33 2.8
GI50 (μM) 0.66(±0.03) 5.69(±0.8)
5*GI50 (μM) 3.3 28
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Figure 68: Effect of 1, 6 and 24 h dasatinib treatment on protein expression in PC9 and PC9ER cells. 
Protein expression of p-EGFR (Y1068), EGFR, ChKα p-SRC (Y416), SRC in PC9 and PC9ER cells treated with dasatinib for 1 h 
(A), 6 h (B), and 24 h (C). GI50, 0.5 and 5*GI50 concentration values are indicated in Table 15. Right panel represents the 
densitometry values of ChKα protein expression normalised for β-Actin. Data show results from one representative 
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The effect of dasatinib on ChKα activity was then assessed. After 1 h dasatinib treatment, there was 
no change in the uptake of [3H]choline in PC9 cells. In PC9ER cells there was an 18 % decrease in 
[3H]choline uptake at 0.5*GI50 and GI50 concentrations of dasatinib and a 40 % decrease at 5*GI50 
concentration of dasatinib (Figure 68A). There was a significant decrease in [3H]choline uptake in 
both PC9 and PC9ER cells following dasatinib treatment for 6h. In PC9 cells at 0.5*GI50, GI50 and 
5*GI50 concentrations there was a 40 % decrease in uptake compared to control. In PC9ER cells, the 
uptake of [3H]choline decreased the most at 5*GI50, and was 56 % less than the uptake in the control 
untreated cells (Figure 69B). At 24 h there was a significant decrease in the uptake of [3H]choline, of 
over 50 %, in the PC9 cells at GI50 and 5*GI50 concentrations of dasatinib. In the PC9ER cells 0.5*GI50 
and GI50 concentrations of dasatinib led to a 35 and 25 % decrease in [
3H]choline uptake, 
respectively. The highest concentration of dasatinib led to a 72 % decrease in [3H]choline uptake. 
 




H]choline uptake compared to untreated control in PC9 and PC9ER cells treated with dasatinib for 1 h (A), 
6 h (B) and 24 h (C). Data show mean values ± SE from three experiments each using triplicate samples per concentration. 
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There were no marked changes in levels of apoptosis in PC9 and PC9ER cells after both 1 and 6 h 
treatment (Figure 70A,B). Levels of apoptosis were significantly higher after 24 h treatment. In PC9 
cells, there was a dose dependant increase in apoptosis. The highest concentration of dasatinib led 
to a 2.7 fold increase in apoptosis compared to control. In PC9ER cells, there was a slight increase in 
the levels of apoptosis at 0.5*GI50 and GI50 concentrations of dasatinib. However, at 5*GI50 
concentration of dasatinib there was an over 9.3 fold increase in apoptosis (Figure 70C). 
 
 
Figure 70: Apoptosis levels in PC9 and PC9ER cells following 1, 6 and 24 h dasatinib treatment. 
Fold increase in apoptosis relative to control in PC9 and PC9ER cells following 1 h (A), 6 h (B) and 24 h (C) dasatinib 
treatment assessed by carrying out a Caspase 3/7 assay. Data show mean values of fold increase in apoptosis normalised to 
protein levels ± SE of n = 4 samples per concentration from one representative experiment carried out twice. Statistically 
significant changes compared to control of an unpaired t-test are marked with a star (* = P ≤ 0.05 and ** = p ≤ 0.01). 
 
In summary, dasatinib dependant loss of SRC activity occurred rapidly and at all dose levels used. In 
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Increase levels of apoptosis at 24 h acted as a confound to the assessment of the effect of SCR 
activity of on the regulation of ChKα activity. 
5.1.3.3 siRNA knock down of EGFR or SRC. 
At the earlier time points of 1 and 6 h, only the highest concentration of gefitinib led to changes in 
[3H]choline uptake despite a decrease in p-EGFR Y1068, and thus activity of EGFR, at all 
concentrations of drug used. Similarly, dasatinib caused inhibition of p-SRC Y416, and thus activity of 
SRC, at all concentrations of drug used, but changes to ChKα activity were only measured following 
treatment with the highest concentrations of dasatinib. One possible explanation was that at the 
highest concentrations, both gefitinib and dasatinib were inhibiting other targets, these could 
include ChKα itself. Furthermore, after 24 h treatment there were high levels of apoptosis in cells 
treated at the highest concentrations of both drugs. Therefore, the changes in uptake of [3H]choline, 
ChKα activity, could be caused by the above rather than simple inhibition of either EGFR or SRC. 
In view of the above limitations, a more direct approach was employed to assess the roles of SRC 
and EGFR in the regulation of ChKα in lung cancer cells, appreciating that loss of protein will perhaps 
give a different outcome compared to drug induced loss of EGFR/SRC activity. 
Cells were transfected with either EGFR or SRC siRNA at 25 nM for 72 h. Following the siRNA 
transfection a [3H]choline uptake was carried out. In Both the PC9 and PC9ER cells only the EGFR 
siRNA treatment led to a decrease in [3H]choline uptake (Figure 71A). EGFR knock down was 
confirmed by western blot analysis (Figure 71BC). SRC knock down, was only achieved partially and 
this could explain the lack of change ChKα activity following SRC siRNA transfection (Figure 71A). 
Expression of ChKα was decreased in siRNA EGFR treated PC9 and PC9ER cells (Figure 71B). 
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Figure 71: [3H]choline uptake following SRC and EGFR siRNA transfection of PC9 and PC9ER cells. 
A- Percentage uptake of [
3
H]choline in PC9 and PC9ER cells following 72 h transfection with 25 nM of SRC, EGFR or 
scramble siRNA. Data show mean values ± SE of percentage [
3
H]choline uptake relative to control, from three experiments 
each using triplicate samples per concentration. Statistically significant differences compared to scramble treated cells are 
indicated by a star (** = p ≤ 0.01). B- Protein expression of EGFR, SRC and ChKα in PC9 (B) and PC9ER (C) cells following 72 
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5.2. Other clinically available tracers and their role for imaging early response to gefitinib 
treatment. 
Both [18F]FDG and [18F]FLT have been investigated for the monitoring of response to TKI treatment in 
lung cancer. These two radiotracers were used here, as means of comparison with the [18F]D4choline 
study. 
5.2.1 [18F]FDG 
5.2.1.1 In vitro assessment of the role of [18F]FDG as a biomarker of response to gefitinib treatment. 
In order to assess the potential role of [18F]FDG as a biomarker of response to gefitinib treatment, 
the uptake of [18F]FDG was measured in PC9 and PC9ER cells following 48 h gefitinib treatment 
(Figure 72). In untreated cells, the uptake of [18F]FDG was 2.5 times higher in PC9ER cells at 
25 CCPMA/μg of protein compared to 10.5 CCPMA/μg of protein in PC9 cells. There was up to 30 % 
decrease in the uptake of [18F]FDG in the PC9 cells treated with 0.01, 1 and 3 μM of gefitinib. There 
was no statistically significant difference in the uptake of [18F]FDG in PC9ER cells following drug 
treatment. The higher levels of uptake of [18F]FDG at baseline in PC9ER cells, compared to PC9 cells, 
could result from higher levels of expression of the GLUT1 transporter in the PC9ER cells (Figure 
72B). 
 
Figure 72: [18F]FDG uptake in PC9 and PC9ER cells following gefitinib treatment for 1, 6 and 24 h. 
A- Corrected counts per minute acquired per µg of protein of [
18
F]FDG uptake in PC9 and PC9ER cells following 1 h 
incubation with 0.37 MBq of [
18
F]FDG after 48 h gefitinib treatment. Data show mean values ± SE of triplicates from one 
representative experiment carried out three times. Statistically significant changes compared to untreated control are 
marked with a star (* = P ≤ 0.05 and ** = p ≤ 0.01). B- Membrane GLUT1 expression in PC9 and PC9ER cells. K+ ATPase: 
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5.2.1.2 In vivo uptake of [18F]FDG in PC9 and PC9ER xenograft 
[18F]FDG is currently the “gold standard” radiotracer in oncology and is used by clinicians for 
diagnosis but also monitoring of patients during a course of drug treatment. Here, [18F]FDG was used 
as a means of comparison to the previously performed [18F]D4choline PET imaging for the early 
prediction of response or failure of response to gefitinib treatment. 
CT/PET imaging of PC9 and PC9ER xenografts were investigated at baseline and following 48 h 
vehicle or 50 mg/Kg of gefitinib. The sagittal and transverse cross sections showed high levels of 
accumulation of [18F]FDG at baseline and following 48 h vehicle treatment in the PC9 xenografts 
(Figure 73A). There was a reduction in the accumulation of radiotracer in the tumour in the gefitinib 
treated group (Figure 73A). In the sagittal cross section of the vehicle treated mouse, the uptake was 
lower at the centre of the tumour. This could be a result of necrosis within the tumour tissue. The 
tumour time activity curves (TACs) at baseline and following vehicle treatment overlapped in the PC9 
xenografts, following the same pattern, with a gradual increase and accumulation in the tumour 
with time. The TAC of the gefitinib treated group showed initial delivery and accumulation of 
[18F]FDG in the tumour for the first 10 min post tracer injection, followed by a washout from 10 to 
60min (Figure 73B). In the PC9ER xenografts there was a high uptake of [18F]FDG at baseline and in 
both gefitinib and vehicle treated groups as shown by the sagittal and transverse cross sections 
(Figure 73C). The TAC’s obtained from the PC9ER xenografts showed a small decrease in the uptake 
of the radiotracer in the gefitinib group compared to baseline and vehicle treated groups (Figure 
73D). 
NUV60, AUC, highest quartile tumour uptake and FRT values were plotted in Figure 74. The NUV60 
was higher at baseline in the PC9ER tumours with a mean value of 5 %ID/mL of tissue compared to 
4.3 %ID/mL of tissue in the PC9 xenografts. This higher uptake is in line with the in vitro uptake in 
which PC9ER showed higher baseline uptake of [18F]FDG than PC9 cells. In the PC9 xenografts, all 
four parameters were unchanged between baseline and vehicle treated mice but decreased 
following 48 h treatment with 50 mg/kg of gefitinib. The NUV60 decreased from 4.3 %ID/mL of tissue 
at baseline to 2.9 %ID/mL of tissue after 48 h gefitinib treatment (Figure 53A). The AUC decreased 
from 250 at baseline to 190 %ID/ml *min following 48 h gefitinib treatment (Figure 53B). Finally, 
there was a 25 % decrease in the FRT in the gefitinib treated PC9 group (Figure 53D). 
In the PC9ER xenografts there was no statistically significant changes in the different parameters 
measured between all three groups, despite a decrease in the parameters following gefitinib 
treatment (Figure 74B). High intra variability could account for the lack of statistical significance. 
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In summary, following 48 h gefitinib treatment a decrease in [18F]FDG uptake in gefitinib sensitive 
PC9 xenografts but not in resistant PC9ER xenografts was measured. 
 
 
Figure 73: [18F]FDG PET imaging of PC9 and PC9ER xenografts following 48 h gefitinib treatment. 
A, C- Merged PET/CT image of representative sagittal (top) and transverse (bottom) cross section of PC9 (A) and PC9ER (C) 
xenograft mouse at baseline and following 48 h vehicle treatment or 48 h gefitinib treatment at 50 mg/Kg at 60 min post 
i.v. injection of 3.7 MBq of [
18
F]FDG. Tumours indicated by white arrow. B, D- Tumour time activity curves of PC9 (B) and 
PC9ER (D) xenografts. Values show mean ± SE of n = 4 mice per group.  
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Figure 74: Tumour uptake parameters from [18F]FDG PET imaging of PC9 and PC9ER xenografts 
following 48 h gefitinib treatment. 
A- Normalised uptake value of [
18
F]FDG in PC9and PC9ER tumours at t = 60 min after tracer injection. B-Area under the 
curve plot D- Average highest quartile tumour [
18
F]FDG uptake. C- Fractional retention of [
18
F]FDG in PC9 and PC9ER 
tumours between 3.5 and 60 min post tracer injection. Data show means ± SE of n = 4 mice per group. Statistically 
significant difference between data sets are indicated on the graphs (*= P ≤ 0.05 and **= P ≤ 0.01). 
 
Tumours from the mouse xenografts used in the [18F]FDG PET study were collected and protein 
levels assessed. The [18F]FDG study was carried out longitudinally, therefore only tumours 
corresponding to vehicle and gefitinib treated mice were available to carry out the protein 
expression analysis. In the PC9 tumours, there was complete knock down of levels of p-EGFR (Y1068) 
and a decrease in total EGFR following gefitinib treatment. p-ERK, p-AKT and p-SRC Y416 expression 
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ERK were unchanged. Levels of ChKα were decreased in 2 out of the 3 tumour samples from the 
gefitinib treated group. Finally there was also a small decrease in levels of GLUT1 (Figure 75 left 
column). 
In the PC9ER tumours, there was no decrease in p-EGFR (Y1068) in the gefitinib treated group. Levels 
of EGFR, SRC, p-SRC Y416, p-AKT, AKT, p-ERK, and ERK were the same in both vehicle and gefitinib 
treated groups. Levels of GLUT1 were decreased in two out of three of the gefitinib treated samples 
compared to the tumours from the vehicle treated group (Figure 75 right column). 
 
 
Figure 75: PC9 and PC9ER tumour lysate protein expression analysis from [18F]FDG PET imaging. 
Protein expression of p-EGFR (Y1068), EGFR, ChKα, p-SRC (Y416), SRC, p-AKT, AKT, p-ERK, ERK and total cellular GLUT1 in 
tumour lysates from PC9 and PC9ER xenograft from 48 h vehicle or 50 mg/kg gefitinib treated groups Each column 
represents a lysate from one tumour. 
 
PC9 tumours PC9ER tumours  


























   
 167 
 In summary, a decrease in [18F]FDG uptake at 48 h gefitinib treatment was measured in NSCLC 
sensitive but not resistant xenograft model, indicating the opportunity of assessing early response to 
treatment with this tracer. 
5.2.2 [18F]FLT 
5.2.2.1 In vitro assessment of the role of [18F]FLT as a biomarker of response to gefitinib treatment. 
In order to assess the potential role of [18F]FLT as a biomarker of response to gefitinib treatment, the 
uptake of [18F]FLT in PC9 and PC9ER cells was determined after 48 h treatment with gefitinib. The 
uptake of [18F]FLT at baseline was higher in PC9ER cells, 135 CCPMA/µg of protein, compared to the 
PC9 cells, 103 CCPMA/µg of protein. After 48 h gefitinib treatment, the uptake of [18F]FLT in PC9 
cells, decreased from 105 CCPMA/μg of protein in the untreated control cells to 5 CCPMA/μg of 
protein following 1 and 3 μM gefitinib treatment, corresponding to a 95 % decrease in [18F]FLT 
uptake (Figure 76). In PC9ER cells, only the highest concentration of gefitinib (3µM), led to a 
statistically significant decrease in the uptake of [18F]FLT from 135 in untreated cells to 110 










Figure 76: [18F]FLT uptake in PC9 and PC9ER cells following 48 h gefitinib treatment. 
Corrected counts per minute acquired per µg of [
18
F]FLT uptake in PC9 and PC9ER cells after 1 h incubation with 0.37 MBq 
of [
18
F]FLT following 48 h gefitinib treatment. Data show mean values ± SE of triplicates from one representative 
experiment carried out three times. Statistically significant changes compared to untreated control from an unpaired t-test 
are marked with a star (* = P ≤ 0.05 and ** = p ≤ 0.01). 
 
In conclusion, a differential effect of gefitinib treatment, on [18F]FLT uptake was measured in 
sensitive, PC9, and resistant, PC9ER, cells. There was a strong decrease in uptake of [18F]FLT in PC9 
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cells which was not measured in PC9ER cells following drug treatment. These results suggested 
[18F]FLT to be a good biomarker of response to gefitinib treatment in sensitive and resistant NSCLC. 
 
5.2.2.2 In vivo uptake of [18F]FLT in PC9 and PC9ER xenograft. 
Having demonstrated the differential uptake of [18F]FLT in PC9 and PC9ER cells following gefitinib 
treatment in vitro, [18F]FLT was investigated for the early prediction of response or failure of 
response to gefitinib treatment in vivo. [18F]FLT is currently a tracer used in the clinical trial setting 
and has shown efficacy in detection of tumour and monitoring patients during the course of 
treatment (Contractor et al., 2011c). 
As for [18F]FDG and [18F]D4choline, PET/CT scans of PC9 and PC9ER xenograft bearing mice were 
performed at baseline and following 48 h vehicle or 50 mg/Kg gefitinib treatment. The sagittal 
merged CT/PET images in Figure 77A showed a low uptake of the tracer in PC9 tumours in all three 
groups. In the baseline and gefitinib group there was a lack of accumulation of [18F]FLT at the very 
centre of the tumour, indicated by dark blue colour on the PET scan. This lack of uptake is due to 
central necrosis of the tumour. The TAC’s showed similar patterns of uptake of the radiotracer in 
both baseline and vehicle treated groups, characterised by a gradual increase in the uptake of 
[18F]FLT in the tumour from 0 to 10 min after which the uptake of [18F]FLT was unchanged until 60 
min. However, the uptake in the gefitinib treated group was different with an initial increase in the 
uptake up to 5 min followed by a decrease in the uptake of the tracer until 60 min (Figure 77B). 
In PC9ER xenografts (Figure 77C), a higher accumulation of [18F]FLT compared to PC9 xenografts was 
measured. The accumulation of tracer was highest in the gefitinib treated group. A high level of intra 
group [18F]FLT uptake variability was measured. The TAC’s showed that in all three groups there was 
a gradual increase in the uptake of the tracer throughout the scanning time frame. The TAC of the 
gefitinib group showed overall higher uptake of the tracer compared to baseline or vehicle groups 
(Figure 77D). 
By determining various tumour uptake parameters, further comparisons between the two xenograft 
models could be carried out. Both the NUV60 and AUC values were significantly higher in PC9ER, 5.8 
%ID/mL of tissue and 327 %ID/mL of tissue *min compared to 4.5 %ID/mL of tissue and 266 %ID/mL 
of tissue *min in PC9 tumours. 
The NUV60 and the AUC were the same in all three PC9 xenograft groups with values of 4.2 %ID/mL 
of tissue and 250 %ID/mL of tissue *min, respectively. The radiotracer uptake was therefore 
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unchanged with treatment when the imaging variable was NUV60 or AUC. The average highest 
quartile of [18F]FLT uptake in the tumour was similar in all three groups of PC9 xenografts. There was 
a statistically significant decrease (27 %) in the FRT of the gefitinib treated PC9 group compared to 
both baseline and vehicle groups. 
In PC9ER xenografts, the NUV60 was higher in the gefitinib treated group, at 7 %ID/mL of tissue, 
compared to 5.7 and 5 %ID/mL of tissue in baseline and vehicle groups, respectively. Due to high 
intra-group variability the differences in NUV60’s measured were not statistically significant There 
was a statistically significant increase In AUC from 275 %ID/mL of tissue * min in the vehicle treated 
group, to 400 %ID/mL of tissue * min in the gefitinib treated group. Both FRT values and highest 
quartile [18F]FLT uptake in the tumour were unchanged between all three groups (Figure 78). 
In conclusion, [18F]FLT showed no change in NUV60 or AUC in PC9 xenografts following 48 h gefitinib 
treatment. The gefitinib treated PC9 group did however show a decrease in the mean FRT value. 
These data highlighted the importance of the perfusion of tumours, and the influence perfusion has 
on differential uptake of the radiotracer in tumours. This was especially true as there was a low 
overall uptake of the tracer, along with necrosis of the central core of the tumours. The increase in 
uptake of [18F]FLT in PC9ER group following treatment was surprising and warrants further 
investigation. 
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Figure 77: [18F]FLT PET imaging of PC9 and PC9ER xenografts following 48h gefitinib treatment. 
A,C- Merged PET/CT image of representative sagittal (top) and frontal (bottom) cross section of PC9 (A) and PC9ER (C) 
xenograft mouse at baseline and following 48 h vehicle treatment or 48 h gefitinib treatment at 50 mg/Kg at 60 min post 
i.v. injection of 3.7 MBq of [
18
F]FLT. Tumours indicated by white arrow. B, D-Tumour time activity curves of PC9 (B) and 
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Figure 78: Tumour uptake parameters from [18F]FLT PET imaging of PC9 and PC9ER xenografts 
following 48 h gefitinib treatment. 
A- Normalised uptake value of [
18
F]FLT in PC9and PC9ER tumours at t = 60 min after tracer injection. B- Area under the 
curve plot. C- Average highest quartile [
18
F]FLT tumour uptake. D- Fractional retention of [
18
F]FLT in PC9 and PC9ER 
tumours between 3.5 and 60 min post tracer injection. Data show means ± SE of n = 4 mice per group. Statistically 
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The tumours from the PET study were collected, processed and analysed by gel electrophoresis 
(Figure 79). In PC9 tumours, there was a complete inhibition of p-EGFR (Y1068) in tumours that were 
treated with gefitinib compared to tumour lysates from the baseline and the vehicle groups. 
Gefitinib treatment also led to a decrease in p-SRC Y416, ChKα, p-AKT, p-ERK and levels of total 
EGFR. Total levels of AKT and ERK were the same as in baseline or vehicle treated tumours. 
In the PC9ER tumours, there was a decrease in the expression of p-EGFR (Y1068) in the gefitinib 
group. However, this decrease was significantly less than the gefitinib induced decrease in p-EGFR 
(Y1068) measured in the PC9 tumours. Levels of Chkα, p-AKT, AKT, p-ERK and ERK were unchanged 
between baseline, vehicle and gefitinib treated tumours. Levels of TK1, a key enzyme that 
phosphorylates [18F]FLT resulting in its trapping in the cell was measured in the tumour samples 
(Wagner et al., 2003). Levels of TK1 were decreased in two out of three of the tumour lysate samples 
from the gefitinib treated group compared to vehicle treated tumours in PC9 but not in the PC9ER 
tumours (Figure 79A, B) PC9ER tumours express higher levels of TK1 than PC9 tumours (Figure 79C). 
The colorectal cancer cell line, HCT116, which is characterised by high levels of proliferation 
associated with high levels of [18F]FLT uptake, was used as a reference. Levels of TK1, which play an 
important role in the tumour trapping of [18F]FLT, were measured in PC9 and PC9ER tumours and 
compared to levels in HCT116 tumour lysates (Figure 79C). This low level of TK1 would therefore 
explain the low levels of uptake of [18F]FLT in both tumour models and the higher baseline uptake of 
[18F]FLT in PC9ER compared to PC9 xenografts. 
  




Figure 79: PC9 and PC9ER tumour lysate protein expression analysis from [18F]FLT PET imaging. 
A-B- Protein expression of p-EGFR (Y1068), EGFR, ChKα, p-SRC (Y416), SRC, p-AKT, AKT, p-ERK, ERK and TK1 in tumour 
lysates from PC9 (A) and PC9ER (B) xenograft from baseline, 48 h vehicle or 50 mg/kg gefitinib treated groups. C- Protein 
expression of Tk1 in HCT116, PC9 and PC9ER tumour lysates. Each column represents a lysate from one tumour. 
 
In conclusion, the strong in vitro decrease in [18F]FLT uptake following gefitinib treatment in PC9 
compared to PC9ER cells was not replicated in our in vivo studies, when assessing NUV60 or AUC. 
However, a significantly lower measure of FRT in the gefitinib treated compared to baseline or 
vehicle treated PC9 group, indicated possible detection of response to gefitinib treatment via 
[18F]FLT. The confounds of tumour perfusion and necrosis could explain why only FRT but not NUV60 
PC9ER tumours PC9 tumours  
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or AUC were changed. The increased uptake of [18F]FLT following gefitinib treatment in PC9ER 
xenografts, when NUV60 and AUC variables were used, was not accompanied by any changes in 
levels of TK1 expression and remains to be explained. 
  





Chapter 6: Discussion   
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6.1 Imaging mutant EGFR 
The epidermal growth factor receptor is overexpressed in several cancers including, breast, ovarian, 
brain and colorectal (Sebastian et al., 2006). The overexpression of EGFR and its role in cancer 
progression led to the development of specific TKI’s directed against EGFR. However, the efficacy of 
gefitinib and erlotinib against wild type EGFR in patients was disappointing, with only a small fraction 
of unselected patients responding to TKI treatment (Thatcher et al., 2005). It was instead found that 
a sub group of patients, shown to express active mutant EGFR had significantly higher response rates 
to TKI treatment (Mok et al., 2009). Identifying patients that express mutant EGFR, non-invasively via 
PET imaging could assist in therapeutic selection. To date no PET tracers have been approved for the 
imaging of either WT or mutant EGFR in the clinic. The discovery of an L858R mutant EGFR specific 
[18F] PET radiotracer that showed a 7.6 fold higher uptake in H3255 (L858REGFR) compared to H1975 
(L858R/T790M EGFR) xenografts was an important breakthrough in the imaging of mutant EGFR 
(Yeh et al., 2011). However, this radiotracer was only studied in L858R mutant EGFR and further 
investigation of this tracer to the other common active mutant EGFR, del 746-750 EGFR, would be 
important. 
A series of cyanoquinoline compounds had previously been developed, in our group, for the imaging 
of EGFR. These molecules were structurally based on the TKI, EKB-579, and showed strong affinity, in 
nanomolar range, for EGFR. One compound from the series, [18F]FED6, demonstrated higher uptake 
in high EGFR vs low EGFR expressing xenografts as well as a favourable metabolic profile. The first 
part of this thesis, investigated [18F]FED6 for the imaging of mutant EGFR (Pisaneschi et al., 2010). 
The specificity of FED6 for EGFR was initially reaffirmed, by measuring a lower uptake of [18F]FED6 in 
low EGFR expressing cells, MCF7, vs high EGFR expressing cells, A431. A431 cells transfected with 
EGFR siRNA also had a reduced uptake of [18F]FED6 compared to untransfected cells, confirming 
selectivity of [18F]FED6 for EGFR.  
To investigate FED6 for the imaging of mutant EGFR, del 746-750 mutant EGFR expressing H1650 
NSCLC cells, were compared to WT EGFR expressing A549 and H358 cells. When probe inhibitory 
activity, against EGFR phosphorylation at pharmacological concentrations, was used as a surrogate 
for potential tracer affinity for imaging, western blot analysis showed that FED6 had a significantly 
higher inhibition potential against del 746-750 mutant EGFR expressing cells compared to WT EGFR 
expressing cells. This differential affinity of FED6 for active mutant vs wild type did not however 
translate into higher in vitro uptake of [18F]FED6 in the H1650 cells. Instead, WT EGFR expressing 
A549 and H358 cells showed higher levels of [18F]FED6 uptake. Furthermore the difference in 
[18F]FED6 uptake was not linked to differentially EGFR expression, as A549 and H1650 cells expressed 
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higher levels of EGFR than H358 cells. The in vivo PET imaging, of H1650 and A549 xenografts with 
[18F]FED6, showed no statistical difference in the tumour uptake of [18F]FED6 in both A549 and 
H1650 xenografts. The levels of tracer uptake in the tumour were low in comparison to the high 
uptake in the GI tract. Furthermore, the time activity curve of [18F]FED6 showed a gradual wash out 
of the tracer from the tumour over time. The high non-specific binding of [18F]FED6 and the lack of 
accumulation in the tumour could explain why no differential uptake of [18F]FED6 was measured 
between both tumour models. 
Other mutant EGFR expressing NSCLC cell lines were investigated to further evaluate a possible 
correlation between the affinity of FED6 for mutant EGFR and [18F]FED6 uptake. As in del 746-750 
EGFR expressing H1650 cells, FED6 showed a higher affinity against active mutant EGFR in PC9 (del 
746-750 EGFR) and H3255 (L858R EGFR) cells compared to resistant mutant EGFR expressing PC9ER 
(del 746-750/ T790M EGFR) and H1975 (L858R/T790M EGFR) cells.  
The uptake of [18F]FED6 was greater in the H3255 and the PC9 cells and lowest in H1975 cells. The 
higher uptake of [18F]FED6 in H3255 cells as opposed to the low uptake in H1975 cells correlated 
with the differential potency (affinity) of FED6 in these two cells lines, assessed by western blot. 
However, it is important to note that both expression levels of EGFR and mutant status will impact 
on the uptake of [18F]FED6. H3255 cells had the highest expression of EGFR compared to the other 
NSCLC cell lines investigated. It is not possible to confirm that the higher uptake of [18F]FED6, in the 
H3255 cells, is a consequence of the higher affinity of FED6 for L858R mutant EGFR, higher 
expression of EGFR or a combination of both. To address this problem and to be able to characterise 
the uptake of [18F]FED6 based on the mutational status of EGFR rather than levels of expression of 
EGFR, cell lines that have the same levels of expression of EGFR but differ in mutational status 
should be used for comparison. The PC9 and PC9ER cell lines are isogenic with similar expression 
levels of EGFR but different mutational status. When comparing these two cell lines, no statistical 
difference in the uptake of [18F]FED6 was measured. This could be explained by the fact that IC50 
values of FED6 obtained from the % inhibition of p-EGFR were in the same order of magnitude for 
both PC9 and PC9ER cells. Another confounding effect, which will be discussed further in the 
subsequent parts of this discussion, and impacted on the uptake of [18F]FED6 in the NSCLC was the 
expression of ABC transporter molecules. In order to image mutant EGFR preferentially over WT 
EGFR, irrespective of the total levels of EGFR, the tracer needs to have high specificity for mutant 
EGFR. In imaging L858R EGFR, Yeh et al. screened a series of compounds and selected the compound 
that showed the highest affinity for active mutant vs wild type EGFR. They showed a higher affinity 
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of their tracer in L858R EGFR expressing cells compared to cells that overexpressed WT EGFR (Yeh et 
al., 2011).  
Different levels of expression of EGFR will result in different levels of uptake of the radiotracer. 
Unless, the radiotracer  is designed in such a way that the affinity for WT EGFR is so low that even in 
cases where the expression levels of  WT EGFR are ten folds greater than that of  mutant EGF, it 
would not lead to higher levels of uptake of the tracer. This aspect needs to be carefully considered 
before stating the sensitive and selective imaging of mutant Vs WT EGFR. 
Although FED6 showed higher levels of binding to high vs low EGFR cells in vivo, there was a lack of 
accumulation over time of the radiotracer in the tumour with TACs indicative of a washout of the 
radiotracer.  
To support the design of an optimal imaging cyanoquinoline radiotracer, it was imperative to further 
elucidate additional properties of FED6 that contributed to its non-specific actions. 
Non radiolabelled FED6 blocking studies led to an increase rather than a decrease in [18F]FED6 
uptake. One hypothesis was the involvement of an interaction between FED6 and members of the 
ABC transporters. By hypothesizing that FED6 is both a substrate and an inhibitor of the ABC 
transporters, non-radiolabelled FED6 would act as an inhibitor of the ABC transporters leading to an 
increased uptake of [18F]FED6 which would no longer be effluxed from the cells. This is in line with 
work carried out by Mishani et al. who developed the quinoline containing EGFR radiotracer, ML04, 
similar in structure to FED6. Mishani et al. demonstrated the involvement of the ABCB1 ABC 
transporter in the active efflux of ML04 from cells (Abourbeh et al., 2007). Based on the similarity of 
structure of FED6 to ML04 and on the findings above, the possible substrate specificity of FED6 for 
the ABC transporters was investigated. In addition, it has been reported that compounds that exhibit 
substrate specificity for the ABC transporters can also act as inhibitors (Wang and Fu, 2010). We 
therefore hypothesized that FED6 could be both a substrate and an inhibitor of the ABC 
transporters. 
6.2 FED6 substrate specificity for the ABC transporters. 
Multi-drug resistance phenotype is a common feature in cancer patients. Indeed, prolonged 
treatment, with chemotherapeutic or target specific therapies, commonly leads to acquired 
resistance. One of the key components of MDR is the increase in expression of ABC transporters on 
the surface of tumours (Szakacs et al., 2006, Fletcher et al., 2010). The increased expression of ABC 
transporters will result in tumour efflux of cancer therapies, thus reducing their efficacy. In the 
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context of PET imaging, ABC transporter substrate specificity also plays its part. As only tracer 
amounts of the radiolabelled probe are injected into the patients, efflux via such transporters will 
significantly decrease the potential accumulation of the radioligand in the tumour. Several TKIs, 
including EKB-569 from which the FED series of compounds were synthesised, have been shown to 
be substrates for members of the ABC transporter family (Hegedus et al., 2012). As discussed above, 
we hypothesized that FED6 interacts with one or several of the ABC transporters. A series of 
experiments were performed in order to find out if this was the case and if so, which ABC 
transporters were involved. 
6.2.1 FED6 is a substrate for ABCB1 and ABCG2. 
 
We focused on the three main ABC transporters reported to be involved in MDR, ABCB1, ABCG2 and 
ABCC1 (Mizuno et al., 2003). The initial in silico characterisation of the FED series of compounds, 
indicated that these compounds had several characteristics which made them potential substrates 
for both ABCB1 and ABCG2 transporters including MW > 400, log P > 3 (ABCB1 substrate) and PSA > 
85 Å2 (ABCG2 substrate) (Varma et al., 2005, Dellinger et al., 1992, Didziapetris et al., 2003). We 
therefore predicted that FED6, FED2, and FED9 would be substrates for ABCB1 and ABCG2, whereas 
FED14, that had a reduced molecular weight, would not. The cell viability - SRB - assays performed in 
the paired cell lines that expressed or not the specific ABC transporters, allowed us to indirectly 
assess the substrate specificity of the series of compounds for the transporters, by exploiting their 
cytotoxicity. The higher GI50 values of FED6 in both the ABCB1 expressing 3T3-MDR1 cells and the 
ABCG2 expressing MCF7MX cells compared to the paired cells that expressed no transporters were 
indicative of the substrate specificity of FED6 for both transporters. The substrate specificity of FED6 
for both transporters was further confirmed by a decrease in the GI50 values following inhibition of 
the transporters with specific inhibitors, zosuquidar or FTC. Other molecules in the cyanoquinoline 
series were also found to be substrates for these two transporters. As predicted from its structure, 
FED14, which corresponds to the cyanoquinoline core, showed no substrate specificity for the ABC 
transporters tested. For further expansion of the cyanoquinoline library of compounds, in the view 
of designing out any ABC transporter substrate specificity, knowing that the cyanoquinoline core was 
non-substrate was an important finding. The substrate specificity of FED6 and any of the other 
tested compounds for ABCC1 was ruled out as the ratio of the GI50 values was less than 2. However, 
it is important to note that the A549 cells also express low levels of ABCG2 and this will have 
affected the GI50 values measured. 
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The low uptake of radiolabelled [18F]FED6 in the MCF7MX and 3T3-MDR1 cells, which was increased 
with FTC and zosuquidar pre-treatment, respectively, compared to the higher uptake in the MCF7 
and 3T3 cells further confirmed the substrate specificity of [18F]FED6 for both the ABCB1 and ABCG2 
transporters. 
The Caco2 model permitted investigation of the interaction between members of the 
cyanoquinoline family and the ABC transporters, ABCB1 and ABCG2, expressed at physiological 
levels. By measuring the efflux ratios corresponding to the ratio between the rate of secretion over 
the rate of absorption of a compound, the active extrusion of a compound from the cell could be 
determined. Efflux ratios above 1 were indicative of active ABC transporter efflux (Szakacs et al., 
2006). EKB-569, FED2 and FED6 all had efflux ratios indicative of active efflux. The efflux of FED6 was 
partially reduced in the presence of FTC but not in the presence of zosuquidar. The largest decrease 
in the efflux of FED6 was measured following pre-treatment with Verapamil. Verapamil is a non-
specific drug that has higher potency against ABCB1 but also inhibits other members of the ABC 
transporters including ABCG2 (Liu et al., 2012). These results would indicate that FED6 is a substrate 
for both ABCB1 and ABCG2. Verapamil led to the highest decrease in the efflux ratio due to 
inhibition of both ABCB1 and ABCG2. Zosuquidar alone did not lead to a significant decrease in the 
efflux ratio as FED6 was still being effluxed via the ABCG2 transporter. 
6.2.2 Overcoming ABCG2 efflux of FED6 
 
Having shown that FED6 is a substrate for ABCB1 and ABCG2, the goal was to determine which if any 
of these two transporters were expressed in the cell lines previously selected to study [18F]FED6. No 
ABCB1 was detected in any of the cell lines studied. ABCG2 was expressed in all the cell lines studied 
with the exception of the H3255 and H358 cells. The levels of ABCG2 were moderate to low in 
comparison to that in MCF7MX cells, which overexpressed ABCG2. The rest of our work focused on 
the role of the ABCG2 transporter in the efflux of FED6 and how this efflux could be overcome. To 
investigate the inhibition of efflux via ABCG2, FTC, a well-characterised inhibitor of ABCG2 and 
gefitinib, was investigated. The role of gefitinib as an ABCG2 inhibitor has been demonstrated in 
several studies (Lopez et al., 2007, Nakamura et al., 2005, Yanase et al., 2004, Chen et al., 2011). 
The ABCG2 substrate specificity of the fluorescence dye Hoechst 33324 (Scharenberg et al., 2002) 
was used to assess the effect of knocking down ABCG2 via siRNA or inhibiting ABCG2 with FTC, 
gefitinib or FED6. In the MCF7MX, ABCG2 overexpressing cells, the increase in fluorescence 
measured with increasing concentration of FTC and gefitinib was indicative of a reduction in the 
efflux of Hoechst by ABCG2 following its inhibition. The lack of increase in Hoechst 33324 following 
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pre-treatment with FED6 indicated that unlike previously hypothesized, FED6 was not an inhibitor of 
ABCG2. The decrease in efflux and increase in fluorescence of Hoechst 33324 was also measured 
following ABCG2 siRNA transfection. The trends seen in the Hoechst assay were replicated in the 
uptake of [18F]FED6 in MCF7MX cells. There was a significant decrease in radiotracer efflux, and 
conversely, an increase in uptake of [18F]FED6 following ABCG2 siRNA transfection or pre-treatment 
with FTC or gefitinib. Western blot analysis showed that ABCG2 siRNA transfection did not lead to a 
complete knock down of the expression of ABCG2; this could explain why both the levels of 
fluorescence in the Hoechst experiment and the uptake of [18F]FED6 following siRNA treatment, did 
not reach the levels of those measured following FTC and gefitinib pre-treatment. 
Having shown the inhibitory role of gefitinib and FTC on the efflux of [18F]FED6 in the ABCG2 
overexpressing cellular model, both drugs were investigated as inhibitors of [18F]FED6 efflux in A431 
cells that express moderate levels of ABCG2. The fluorescence of Hoechst 33324 at baseline was 
significantly higher in the A431 cells compared to the MCF7MX cells, indicating an accumulation of 
Hoechst dye and little efflux by ABCG2. The moderate levels of expression of ABCG2 in the A431 did 
not appear to impact on the retention of the Hoechst 33324 dye, present in excess concentrations. 
This could explain why ABCG2 siRNA transfection did not cause an increase in fluorescence in the 
A431 cells. On the other hand, the uptake of [18F]FED6 was increased in A431 cells treated with 
ABCG2 siRNA. In contrast to the Hoechst assay, [18F]FED6 was added in tracer amounts. We 
hypothesized that in tracer amounts the accumulation of [18F]FED6 would be more sensitive to 
events such as ABC transporter efflux. Pre-treatment with both FTC and gefitinib led to an increase 
in fluorescence in the Hoechst assay and [18F]FED6 uptake. The uptake of [18F]FED6 following 
gefitinib pre-treatment was over 2 fold higher than the uptake following ABCG2 siRNA transfected 
cells. We hypothesized that the increase in [18F]FED6 uptake following gefitinib pre-treatment was 
only partly caused by an inhibition of ABCG2, and that gefitinib may also have caused an increase in 
membrane interactions. This would have lead to an increased affinity of [18F]FED6 for proteins of the 
cellular membrane. Compared to Hegedus et al. the concentration of gefitinib selected for the 
inhibition of ABCG2 in this study where 10 fold higher (Hegedus et al., 2012). At a concentration of 
100 μM, gefitinib could be involved in non-specific binding, that could modify the permeability of the 
cells to Hoechst 33324 and [18F]FED6. Alongside the inhibitory role of gefitinib for ABCG2, it is 
important to highlight that gefitinib will ultimately be binding to EGFR, the same target probed by 
[18F]FED6. Owing to the increase in uptake following gefitinib treatment, it was suggested that the 
inhibition of ABCG2 and subsequent decrease in efflux of [18F]FED6 played a dominant role over 
changes in [18F]FED6 uptake caused by blocking of EGFR receptor by gefitinib. However, further 
investigation into other potential actions of gefitinib in this context is needed. The increase in 
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[18F]FED6 uptake following pre-treatment with gefitinib measured in vitro was replicated in vivo in 
A431 xenograft. The uptake of [18F]FED6 in the A431 xenografts that were not pre-treated with 
gefitinib was low with values under 1 % ID/mL tissue. Pre-treatment with an i.p. injection of 100 
mg/Kg of gefitinib led to a doubling of the tracer uptake in the tumour.  
In conclusion, having demonstrated the substrate specificity of FED6 for both ABCB1 and ABCG2, 
ABCG2 was the transporter which was expressed in the majority of the cellular models investigated. 
The uptake of [18F]FED6 could be increased both in vitro and in vivo following gefitinib pre-
treatment. However, the effects of gefitinib pre-treatment were not solely caused by the inhibition 
of ABCG2. Future work could involve the investigation of novel inhibitors of ABCG2, which don’t 
interact with EGFR, and their role in modulating the uptake of [18F]FED6 both in vitro and in vivo. 
One such example could be sorafenib, which has recently been shown to act as an inhibitor of 
ABCG2 (Wei et al., 2012). In addition, FED6 did not appear to act as an inhibitor of ABCG2. Therefore, 
further work needs to be carried out, to understand why pre-treatment with non radiolabelled FED6 
lead to an increase in [18F]FED6 in A431 cells.  
Rather than having to block the effect of the ABC transporters to which our radiotracer is a 
substrate, designing a radiotracer that lacks the ABC transporter substrate specificity is preferred 
The potential substrate specificity of a radiotracer for the ABC transporters, involved in MDR, should 
be investigated early in the development stages of the radiotracer. Indeed, structure activity 
relationship studies could be implemented during the design of the radiotracers. Furthermore, the 
substrate specificity could be probed through a series of in vitro assays once lead compounds have 
been selected. Carrying out these investigations, an selecting radiotracers that are not substrates of 
the ABC transporters, would insure that efflux of the radiotracer, due to MDR, would not impede on 
the uptake and accumulation of the radiotracer in the tumour. 
. 
6.2.3 Investigation of an alternative cyanoquinoline molecule: FED20 
 
The main goal in the design of a “second“generation cyanoquinoline compound was to eliminate the 
substrate specificity of these compounds to the ABC transporters, whilst maintaining high affinity 
against EGFR. The addition of a glucose moiety to form FED20, led to a decrease in Log P (2.1) 
compared to 3.9 for FED6. The affinity of FED20 for EGFR was shown to be in the low nanomolar 
range, and the higher uptake of [18F]FED20 in the A431 vs MCF7 cells was indicative of the specificity 
of the tracer for EGFR. The lack of significant decrease in the uptake of [18F]FED20 following blocking 
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with cold FED20, would indicate a degree of non-specific binding, which has been reported for other 
EGFR tracers (Abourbeh et al., 2007). Furthermore, compared to FED6 the uptake values of FED20 
were significantly lower with values of under 2 CCPMA/μg of protein compared to values of 10 to 
100 CCPMA/μg of protein for [18F]FED6. It was hypothesized that the higher lipophilicity of FED6 
could cause a high level of non-specific binding in the cell membrane leading to the much higher 
values of uptake of [18F]FED6. One of the main drawbacks of FED6, which was discussed above, was 
the substrate specificity for the ABC transporters, and the confounding effect this had on PET 
imaging of WT and mutant EGFR. It was therefore important that this characteristic be designed out 
of any new molecules in the series. Caco2 and [18F]FED20 uptake experiments in paired cells that 
expressed or not ABCB1 and ABCG2 showed no substrate specificity of FED20 for either transporter. 
The lower Log P of FED20 could explain the lack of substrate specificity for the transporters, as this is 
a feature known to contribute to the substrate specificity of a compound (Dellinger et al., 1992). 
The second goal with [18F]FED20 was to investigate this tracer for the imaging of mutant vs WT EGFR. 
NSCLC cell lines expressing active mutant EGFR showed the highest affinity for FED20. However, 
there was not a clear correlation between this data and the uptake values of [18F]FED20. There was a 
strong correlation between high affinity with high uptake and low affinity with low uptake, in some 
cell lines (H3255, PC9, and H1975) but not in others (H1650 and A549). One of the main explanations 
for this lack of clear correlation, which was discussed above for FED6, was the differential expression 
of p-EGFR (Y1068) and EGFR in the NSCLC studied. Indeed, this will impact on the uptake of 
[18F]FED20 and make it difficult to specifically attribute[18F]FED20 uptake values to the affinity 
(correlating to mutational status of EGFR) of FED20 in the NSCLC cell lines. However, the higher 
uptake of [18F]FED20 in the active mutant PC9 vs resistant mutant PC9ER cells, which both express 
similar levels of EGFR, was promising for the further investigation of [18F]FED20 in the context of 
selective imaging of active vs resistant mutant EGFR expressing cells. 
The assessment of the uptake, metabolism and biodistribution of [18F]FED20 in vivo, which was not 
completed due to lack of time, will be necessary for further investigation of this molecule for the 
imaging of WT and mutant EGFR. 
PET imaging of EGFR and particularly mutant EGFR could be used for several application: in vivo 
EGFR mutational status determination, treatment response monitoring and identification of the 
development of drug resistance (Bahce et al., 2013, Yeh et al., 2011). The current recommendation 
are that, NSCLC patients undergo screening for mutations to EGFR before the start of therapy 
(Lindeman et al., 2013). This allows the selection of patients with active mutant to be given TKI 
gefitinib or erlotinib. In fact, gefitinib was approved by NICE in 2009 for first line treatment for 
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advanced metastatic NSCLC, with active mutant EGFR (NICE, 2010). PET imaging of active mutant 
EGFR could complement this screening. Biopsies are not always possible and different nodules may 
present different mutational expression that would not be picked up if one site was biopsied. 
The area in which PET imaging of EGFR could be indispensable is in the early detection of resistance 
to therapy. Following prolonged TKI treatment, patients inevitably acquire drug resistance (Oxnard 
et al., 2011). Clinical signs of resistance to therapy may occur a long time after the initial molecular 
changes have arisen. This means that patients may remain on non-effective treatment until the 
clinical signs of resistance are measured. Being able to detect acquired resistance at an early stage 
would significantly reduce the time a patient remains on drugs that are no longer effective and 
would allow new therapy options to be given to the patient. In NSCLC patients, treated with TKI 
therapies such as gefitinib or erlotinib, 50 % of cases of acquired resistance are the result of T790M 
mutation to EGFR (Kobayashi et al., 2005, Balak et al., 2006). PET imaging could allow early detection 
of acquired resistance caused by T790M mutant EGFR, as well as the potential to detect 
subpopulations of tumour cells that have been shown to express T790M before the start of 
treatment (Inukai et al., 2006). In 2009, a drug that is selective for T790M mutant EGFR was 
discovered (Zhou et al., 2009, Zhou et al., 2011b). Using a similar approach, one could design a PET 
tracer that binds selectively to T790M mutant EGFR, allowing for early detection of resistance to TKI 
therapy in NSCLC patients. It is important to note that such approaches are however limited. Indeed, 
the T790M mutation only accounts for 50 % of cases of resistance to gefitinib or erlotinib therapy. 
Acquired resistance caused by other pathways including MET amplification (Engelman et al., 2007) 
and K-RAS mutations (Massarelli et al., 2007) would not be detected. 
6.3 Chkα as a biomarker of response to gefitinib treatment. 
Novel radiotracers for the imaging of EGFR, such as the cyanoquinoline compounds discussed above, 
could be used to measure pharmacodynamic effects of EGFR directed therapies, by giving a read out 
of the activity of the receptor. These radiotracers may also be used to monitor response to 
treatment by measuring a cell viability response. Yeh et al demonstrated such effect with [18F]-
PEG(6)-IPQA, whereby a decrease in EGFR activity following gefitinib treatment was associated with 
a decrease in radiotracer uptake (Yeh et al., 2011). 
Another approach is to monitor response to EGFR treatment by measuring changes in other 
molecules. In this regard, the roles of both Chkα and SRC as key components in the regulation of the 
activity of EGFR have been elucidated in breast cancer. The mechanistic involvement of ChKα as part 
of this complex makes it an important molecule to investigate in the assessment of response to 
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therapies directed against EGFR. As well as the mechanistic link between ChKα and EGFR, the 
biological relevance of studying ChKα in the context of lung cancer is also significant. In fact, ChKα 
expression and activity have been shown to be upregulated in several cancers, including lung cancer 
(Lenkinski et al., 2008, Iorio et al., 2010, Ramirez de Molina et al., 2002a). Furthermore, higher levels 
of expression of ChKα were also shown to be linked to poorer prognostic of survival in NSCLC 
patients (Ramirez de Molina et al., 2007). Finally, ChKα has previously been examined as a novel 
pharmacodynamic or response to treatment biomarker following both TKI and antibody treatment. 
Preclinical work from our group by Leyton et al showed a decrease in uptake of [18F]D4Choline in 
mouse xenografts following MAPK inhibitor treatment (Leyton et al., 2009). A clinical study 
investigated [11C]Choline imaging in the context of measuring response to antibody therapy in breast 
cancer patients. Kenny et al showed a decrease in tumour uptake of [11C]Choline following 
trastuzumab treatment (Kenny et al., 2010). 
The mechanistic, biological relevance and previous investigation of ChKα as a biomarker of response 
to treatment led us to investigate ChKα as a biomarker of response to gefitinib treatment in NSCLC. 
For this, the effect of gefitinib treatment on ChKα in a gefitinib sensitive NSCLC cell line, PC9, and its 
isogenic gefitinib resistant PC9ER cell line was determined. 
6.3.1 In vitro assessment of ChKα as a biomarker of response to gefitinib treatment in PC9 and 
PC9ER cells. 
 
PC9 and PC9ER cells showed differential response to gefitinib treatment, with cell viability assays 
indicating a 160 fold higher sensitivity to gefitinib in PC9 vs PC9ER cells. The aim of this in vitro work 
was to determine the potential role of ChKα as a biomarker of the differential response to gefitinib 
treatment. [3H]Choline uptake was used as a surrogate of ChKα activity assessment. The extraction 
of [3H]phosphocholine and the uptake values measured from the whole cell lysate, indicated that 
[3H]choline uptake, measured in the whole cell lysate, was representative of the phosphocholine 
component. Levels of phosphocholine are linked to the activity of ChKα which catalyses the 
phosphorylation of choline to phosphocholine (Gibellini and Smith, 2010). At baseline a higher 
uptake of [3H]choline was measured in PC9 than in PC9ER cells. This could be a result of increased 
basal levels of ChKα activity and, or, increased protein expression which was measured in the PC9 
cells. Gefitinib treatment, led to a greater decrease in [3H]choline uptake in the PC9 cells compared 
to the PC9ER cells at both 6 and 24 h treatment. The highest concentrations of gefitinib which were 
used also caused high levels of apoptosis in both cell lines at the 24 h time point, and this cell death 
could be a confounding effect on the changes measured in [3H]choline uptake. Furthermore, at these 
concentrations, gefitinib could be directly inhibiting ChKα, leading to a decrease in phosphocholine 
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formation and hence a decrease in the radioactivity uptake measured. Indeed, at concentrations of 
10 and 20 μM gefitinib is also binding to many off targets. This has been reported in a kinase screen 
carried out on over 113 kinase (Fabian et al., 2005). The lower concentrations of gefitinib used for 48 
h treatment, reduced the likelihood of direct inhibitory role of gefitinib on the activity of ChKα. The 
absence of change in [3H]choline uptake in the PC9ER cells following 48 h treatment was opposed by 
a marked decrease in [3H]choline uptake in the PC9 cells. Decrease in Chkα protein expression in PC9 
and increase in ChKα protein and mRNA expression in PC9ER cells may also contribute to this distinct 
profile of response to gefitinib treatment. This differential uptake of [3H]choline in the sensitive PC9 
and resistant PC9ER cells after 48 h gefitinib was indicative of the potential usefulness of ChKα as a 
biomarker of response vs resistance to gefitinib treatment in NSCLC. One aspect that warrants 
further investigation is the role of choline transporter molecules in the uptake of [3H]choline. 
Possible changes to expression or activity of these transporters following gefitinib treatment, 
especially after the 48 h time point, would be necessary to rule out their involvement in the changes 
measured in [3H]choline uptake, and to confirm that the changes measured were a surrogate of 
ChKα activity.  
In this present study we focused on one model of resistance. It will be important to further 
characterise the role of ChKα, in other sensitive and resistant NSCLC cell lines, to affirm it’s use as a 
biomarker of response, failure of response to TKIs such as gefitinib. 
6.3.2 Role of SRC and EGFR activity on ChKα activity. 
 
Miyake et al investigated the interaction between EGFR, ChKα and c-SRC. In a breast cancer model 
they showed that ChKα interacted with EGFR in a c-SRC dependant manner. C-SRC but not EGFR 
kinase activity was necessary for the EGFR-ChKα interaction to occur (Miyake and Parsons, 2012). To 
investigate whether EGFR and c-SRC activity were required for ChKα activity in the PC9 and PC9ER 
NSCLC the effect of inhibiting either EGFR or SRC activity, or protein expression were assessed. 
Gefitinib dependant loss of EGFR activity occurred rapidly and in a dose dependant manner in both 
cell lines. However, after 1 and 6 h treatment, ChKα activity was not decreased in the PC9 cells and 
only the highest concentrations of gefitinib led to a decrease in ChKα in the PC9ER cells. As discussed 
above, the decrease in ChKα activity, measured at these concentrations of gefitinib could result from 
a direct inhibition of ChKα activity by gefitinib. After 24 h, significant levels of apoptosis rendered the 
use of this model to understand regulation of ChKα activity by EGFR complicated. These results 
indicated that EGFR activity would not be necessary for ChKα activity. 
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Dasatinib dependant loss of SRC activity occurred rapidly and at all dose levels used. In contrast, 
ChKα activity had a longer latency and changes were measured at 6 h. After 24 h, significant levels of 
apoptosis rendered the use of this model to understand regulation of ChKα activity by SRC 
complicated. The lack of complete knock down of SRC protein expression following siRNA treatment 
made it difficult to assign SRC protein expression rather than SRC activity to the regulation of ChKα 
activity. EGFR knock down was indicative of the importance of EGFR protein expression for the 
activity of ChKα but its knock down alone did not cause complete loss of ChKα activity.  
In conclusion, it would appear that SRC but not EGFR activity may play a part in the regulation of 
ChKα in NSCLC and further experiments should be carried out to confirm this. 
The investigation of the interaction of EGFR, ChKα and SRC was investigated at the cellular level. This 
was deemed important in order to ensure that all the possible co factors required for their 
interaction where present. However, investigating the interaction of these proteins in isolation 
would allow further elucidation of specific sites of binding and this should be carried out with 
mutant forms of EGFR, to measure how these mutations would impact on the interaction of EGFR 
with SRC and ChKα. 
6.3.3 In vivo [18F]D4 choline uptake in PC9 and PC9ER xenografts 
 
In vivo imaging of choline kinase metabolism has been carried out in a number of cancers including 
lung, prostate and breast cancer; both [11C] and [18F] analogues of Choline have been used (DeGrado 
et al., 2001a, DeGrado et al., 2001b, Hara et al., 2002, Contractor et al., 2011b). Imaging of choline 
metabolism has been used for tumour detection but also for assessment of response to treatment 
(Leyton et al., 2009, Kenny et al., 2010) with this in mind and following the positive in vitro results 
the investigation of [18F]D4choline as an early biomarker of response or failure of response to 
gefitinib treatment in NSCLC was performed. 
The difference in ChKα activity, which was measured, between PC9 and PC9ER cells in vitro was not 
reproduced in vivo. In fact, the NUV60 and AUC measures of [
18F]D4choline tumour uptake were 
similar in both tumour models. In addition, there were no changes to NUV60 or AUC values following 
48 h gefitinib treatment compared to vehicle in the PC9 and PC9ER xenografts. Western blot analysis 
of tumour lysates indicated that gefitinib treatment induced a marked decrease in ChKα protein 
expression in PC9 but not PC9ER tumours. ChKα activity is not directly correlated to expression of 
ChKα and this could explain why a decrease in protein expression did not cause a decrease in 
[18F]D4choline uptake in the PC9 xenograft, as assessed by NUV60 or AUC measurements. 
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The lack of decrease in [18F]D4choline uptake following 48 h gefitinib treatment in the PC9 
xenografts could be caused by confounding factors. The two main confounding factors were tumour 
necrosis and differential tumour perfusion. The presence of possible necrotic core at the centre of 
the tumours was characterised on the PET images by low uptake of the radiotracer, at the very 
centre of the tumour. Measuring the values that corresponded to the highest quartile of tumour 
radiotracer uptake, should allow for only the uptake in viable tissue to be measured. The highest 
quartile NUV data did not indicate any statistical difference following gefitinib compared to vehicle 
treatment in the PC9 tumours. The values of tumour uptake of [18F]D4choline were however closer 
between both groups. This could indicate that necrosis played a more significant role in confounding 
the uptake of the radiotracer in the vehicle treated group compared to the gefitinib treated group. 
One explanation could be that gefitinib treatment halted the growth of the tumours decreasing the 
development of necrosis, which can be associated with larger tumours. The second confound was 
tumour perfusion. The uptake of any radiotracer within a tumour is dependent on the perfusion of 
this tumour (Huang et al., 2012). Tumours that display different degrees of perfusion will show 
different levels of uptake of the radiotracer, regardless of the expression levels of the specific target 
imaged by the tracer. FRT values have been previously reported as a means of comparing the 
tumour uptake of a radiotracer in models where perfusion may play an important role (Leyton et al., 
2008). The FRT value decreased in PC9 xenografts following gefitinib treatment compared to the 
vehicle treated group. In the PC9ER xenografts there were no changes in FRT values between both 
groups. These results indicated that measuring FRT was a better read out for the response to 
gefitinib treatment compared to NUV60 or AUC and this was due to the role of perfusion in the initial 
tumour uptake of [18F]D4choline.  
Based on the reported impact of necrosis and perfusion on the uptake of [18F]D4choline, it will be 
important to screen other TKI sensitive and resistant tumour models. Although necrosis is an 
inherent characteristic of tumours, using models in which the impact of necrosis isn’t so great will 
allow a more thorough investigation of the impact of the uptake of [18F]D4choline in sensitive VS 
resistant tumours. 
 
6.4 [18F]FDG and[18F]FLT PET imaging of response to gefitinib treatment in comparison to 
[18F]D4choline. 
[18F]FDG and [18F]FLT have both been studied as biomarkers of response to TKI treatment in NSCLC. 
Several NSCLC xenograft studies showed a decrease in the uptake of [18F]FLT following TKI treatment 
(Ullrich et al., 2008, Zannetti et al., 2012), others showed a decrease in [18F]FDG uptake following TKI 
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treatment (Su et al., 2006). Having investigated [18F]D4choline as a biomarker of early response to 
gefitinib treatment, [18F]FDG and [18F]FLT were used in the same models as means of comparison. 
The tumour uptake of [18F]FDG as measured by NUV60, AUC, highest quartile NUV and FRT all 
indicated a decrease in uptake of the radiotracer following gefitinib compared to vehicle treatment 
in the PC9 but not PC9ER xenografts. This is in line with the finding of Su et al., that demonstrated a 
decrease in [18F]FDG uptake following TKI treatment in sensitive NSCLC tumours (Su et al., 2006). In 
comparison to [18F]D4choline, the decrease in uptake of [18F]FDG following gefitinib treatment 
compared to vehicle treatment, as measured by FRT, was greater. This could be explained by higher 
overall values of tumour uptake with [18F]FDG than with [18F]D4choline, allowing for a larger 
decrease in signal following treatment. Further ex vivo analysis of gefitinib and vehicle tumours from 
both models, to determine hexokinase activity but also immunohistochemistry staining for GLUT1, 
could elucidate the molecular mechanisms behind the differential uptake of [18F]FDG following 
gefitinib treatment in PC9 but not PC9ER tumours (Phelps, 2000, Jadvar et al., 2009). 
The uptake of [18F]FLT was significantly higher in the PC9ER than the PC9 tumours. This could in part 
be a result of higher expression of TK1 in the PC9ER tumours. TK1 phosphorylates [18F]FLT resulting 
in its trapping in the cell and the expression of TK1 has been correlated to [18F]FLT uptake (Barthel et 
al., 2005). However, TK1 activity may correlate better with changes to [18F]FLT uptake, and 
differential activity of TK1 in both models may account for the difference in basal levels of [18F]FLT 
uptake. As for [18F]D4choline only the FRT values were decreased following gefitinib treatment in the 
PC9 cells, with no change measured in the NUV60 or AUC. This was indicative that again tumour 
perfusion influenced the initial uptake of the radiotracer in the tumour. 
In conclusion, a decrease in FRT following gefitinib treatment was measured using all three 
radiotracers in the PC9 but not the PC9ER tumours, indicating that all three probes could be used for 
the detection of sensitivity and or resistance to gefitinib therapy. Further work should include the 
comparison of all three radiotracers in other NSCLC models to potentially reduce the confound of 
necrosis and perfusion of the PC9 and PC9ER models. In addition, immunohistochemistry analysis of 
the tumour sections would allow further confirmation of the PET imaging data. 
The different results published in the literature highlight the need for better standardisation of 
studies and parameters which are measured. This would allow robust comparison of different 
investigations in order to select the most appropriate tracer for monitoring response to gefitinib 
treatment in NSCLC. 
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 Poster presentation at ACCR/SNMMI San Diego, CA, February 2013. 
Cyanoquinoline based tracers and their interaction with the ABC transporters for the imaging of 
EGFR in cancer 
Slade R.; Pisaneschi F ;Kaliszczak M.; Smith G.; Nguyen Q.D.; Aboagye EO. 
 
The epidermal growth factor receptor (EGFR) plays a key role in biological processes including 
proliferation and cell cycle regulation through the activation of downstream signal transduction 
pathways. Furthermore, this tyrosine kinase receptor is overexpressed in many cancers including 
ovarian, breast, head and neck and Brain. Imaging EGFR using positron emission tomography (PET) 
linked to EGFR mutational status could help select patients who are more likely to respond to small 
molecule tyrosine kinase inhibitors such as Gefitinib. We previously showed by PET that 18F-FED6, a 
radiolabeled cyanoquinoline EGFR antagonist, had higher uptake in A431 xenograft tumors (high 
EGFR; high ABCG2, no ABCB1) compared to HCT116 xenograft tumors (low EGFR; low ABCG2, no 
ABCB1). However the overall tumor radiotracer uptake is low possibly due to the ATP binding 
cassette transporters, frequently overexpressed in tumor cells and actively extruding drugs from the 
cytosol.  
 
The aim of this study is to further characterise cyanoquinoline tracers for 18F PET imaging of EGFR, 
investigating the role of the ABC transporters. Following exposure of isogenic wild-type and ABC 
transporter over-expressing cells to the cyanoquinoline series (FED1-9) several of the compounds 
were found to be potential substrates of ABCB1 (P-glycoprotein) and ABCG2 transporters. Transwell 
caco2 cell permeability assays confirmed compound efflux and hence ABC transporter substrate 
specificity. Efflux of the cyanoquinolines was significantly decreased in the presence of inhibitors of 
both ABCB1 and ABCG2 transporters, further confirming specificity. Radiolabeled 18F-FED6, was 
shown to have a four-fold lower in vitro uptake in ABCB1 or ABCG2 overexpressing cell lines 
compared to the isogenic counterpart. Finally, in vivo PET imaging in A431 xenografts with 18F-FED6, 
showed over a two-fold increase in the tumor uptake of the radiolabeled cyanoquinoline, when mice 
were pre-treated with gefitinib. In vitro studies confirmed gefitinib’s role as an ABCG2 inhibitor. 
We confirm that ABC transporter expression can confound PET imaging of EGFR using 18F-FED6. 
Further development and investigation into a second generation of compounds, devoid of ABC 
transporters interaction and improved tumor uptake are required. Initial studies have commenced 
on one such second generation cyanoquinoline. 
 
Poster presentation at CRUK imaging conference, London, April 2012. 
 
Cyanoquinoline based tracers for the imaging of mutant EGFR in cancer. 
Rozanna Slade; Pisaneschi F.; Aboagye E. 
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The epidermal growth factor receptor (EGFR) plays a key role in biological processes including 
proliferation and cell cycle regulation through the activation of downstream signal transduction 
pathways [1]. Furthermore, this tyrosine kinase receptor is overexpressed in many cancers including 
ovarian, breast, head and neck and Brain .[2] In NSCLC the presence of so called activation mutations  
to EGFR such as del747-750 have been shown to lead to improved response to small molecular TKI 
(TKI) such as gefitinib. Imaging EGFR using positron emission tomography, PET, could be used to 
select, monitor and assess therapeutic response to inhibitors such as gefitinib. A series of  18-F 
radiolabeled EGFR specific cyanoquinoline based compounds,   have been previously 
characterised  showing higher radiotracer uptake in A431 xenograft tumours ( High EGFR) 
compared to HCT116 xenograft tumours ( low EGFR).[3]  
 
The aim of this study is to further characterise the cyanoquinoline tracers for 18F PET 
imaging of EGFR, investigating their specificity and selectivity for different mutant forms of 
EGFR. First, a series of western blots were carried out to assess the inhibition of p-EGFR in a 
series of cell lines expressing different mutant forms of EGFR. P-EGFR was more strongly 
inhibited by the cyanoquinoline compounds in cell lines containing active mutant forms of 
EGFR compared to wild type EGFR expressing cell lines. 
Second, both cell uptake and in vivo imaging were performed with a selected 18F labelled 
cyanoquinoline. These studies showed no difference in tracer uptake between mutant and 
wild type EGFR expressing NSCLC cell lines. 
However the overall tumour radiotracer uptake is low possibly due to the ATP binding cassette 
transporters, actively extruding substrates from the cytosol. [4] 
A second generation of compounds are needed that have little or no interaction with the ABC 
transporters and thus improve the tumour uptake of the tracer. 
 
(1) Sebastian, S., J. Settleman, et al. (2006). Biochim Biophys Acta 1766(1): 120-39. 
(2) Wells, A. (1999). "EGF receptor." Int J Biochem Cell Biol 31(6): 637-43. 
(3) Pisaneschi,F., Q.D.Nguyen, et al.(2010) Bioorg MED Chem 18(18)66343-45 





ABC transporter interaction of cyanoquinoline PET imaging molecule. 
Rozanna Slade, Federica Pisaneschi, and Eric O. Aboagye. 
 Comprehensive Cancer Imaging Centre, Imperial College London, Faculty of Medicine, Hammersmith 
Hospital Campus, Du Cane Road, London W12 0NN, United Kingdom 
 
